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Lysine acetylation regulates thousands of proteins and nearly every cellular process from 
cell replication to cell death. Dysregulated acetylation has been implicated in diseases including 
cancer, neurodegenerative disorders, and infectious diseases. For this reason, the enzymes that 
regulate acetylation, including the histone deacetylases (HDACs), are targeted for drug 
development, and understanding their biological function is of the utmost importance. 
Unfortunately, few HDAC-specific substrates have been identified, and how HDACs recognize 
and select for their substrates, a key aspect of their biological function, is poorly understood. 
HDAC8, a unique member of class I, is phosphorylated at S39, which affects HDAC8 substrate 
selectivity in vitro and may be used by the cell to regulate HDAC8 biological function. 
Measuring HDAC8 phosphomimetic mutant S39E-catalyzed deacetylation of various peptides 
demonstrates altered HDAC8 activity and importantly substrate selectivity. Structural analyses 
indicate this alteration is due to changes in the substrate binding pocket and active-site 
architecture. Moreover, wild-type HDAC8 substrate selectivity is influenced by both substrate 
sequence and structure in vitro. Comparing HDAC8-catalyzed deacetylation of histone H3 K9ac, 
K14ac, and K56ac peptides and proteins reveals that protein structure enhances activity from 40- 
to over 300-fold, and local sequence determines substrate selectivity, particularly in less 
structured regions. These data support the use of peptide substrates to determine relative activity 
and to identify HDAC substrates. To expand on these results, HDAC6-catalyzed deacetylation of 
a library of peptides was tested to develop a structure-based model of HDAC6 activity. The 
results reveal HDAC6 distinguishes between sequences, catalyzing deacetylation of peptides 
with kcat/KM values from 10 to 106 M-1s-1. These data demonstrate the usefulness of a prediction 
model based on peptides. Together, these investigations reveal that phosphorylation, local 
sequence, and protein structure affect HDAC substrate selectivity and activity in vitro and likely 
play key roles in the biological function and dysfunction of HDACs in the cell. Finally, 
development of structure-based models combined with peptide-based experiments can be used to 
identify HDAC substrate candidates for study in vivo.  
ABSTRACT 
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Post-Translational Modifications, Epigenetics, and Protein Acetylation 
Post-Translational Modifications Diversify the Proteome 
The central dogma of molecular biology dictates that DNA is transcribed to RNA which 
is then translated to protein. Out of approximately 20,000 genes in the human genome1-2 
consisting of four deoxyribonucleic acids that code for 20 amino acids, arise all of the building 
blocks to create life. The fascinating complexity of the human species boils down to a mere 
20,000 coding segments of genetic information. Even more perplexing than this is the fact that 
humans share 96% of their genetic information with chimpanzees3 and over 40% with fruit flies.4 
It only takes a casual observation to note that there are major differences between fruit flies, 
chimpanzees, and humans. Even within the human species, where 99.9% of genetic information 
is shared, there is incredible diversity.5 In a 2016 TED talk, physicist and entrepreneur Riccardo 
Sabatini explained that if your entire genetic code was written down, it would fill around 
262,000 pages or 175 large books, and that out of all of those pages, only about 500 would be 
unique to you.6 The key to this incredible diversity, the differences seen among humans and 
between humans and other species, lies, in part, with post-translational modifications (PTMs), 
chemical additions to proteins that alter their functionality. 
Currently, over 400 different types of post-translational modifications have been 
observed, the most abundant and famous of these being phosphorylation.7 Phosphorylation 
occurs on serine, threonine, and tyrosine residues within proteins and alters the size, charge, and 
therefore function of the amino acids. Phosphorylation was first described in the 1950s by Edwin 
Krebs and Edmond Fischer, who were awarded the Nobel prize in 1992 for their work.8 Since 
that time, phosphorylation research has grown to become the most studied PTM. 
Phosphorylation was found as an integral regulator of countless biological pathways, most 
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notably metabolism and signal transduction, and a special class of proteins known as kinases 
were identified as the enzymes responsible for the addition of this PTM.9-10  
The History of Acetylation and the Birth of Epigenetics 
Only a few years after the discovery of phosphorylation, a less conspicuous post-
translational modification, and the central topic of this dissertation, was discovered on the tails of 
histone proteins: acetylation (Figure I.1).11-12 In comparison to phosphorylation with its unique 
phosphorous atom and charged oxygens, the acetyl moiety consisting of two carbons, four 
hydrogens, and an oxygen garnered less attention. However, in the 1960s, researchers started to 
investigate acetylation more deeply and began to suspect this modest PTM was an important 
modulator of cellular processes. Although little was known about histones, it was hypothesized 
that these complex proteins may somehow be responsible for controlling RNA synthesis, and 
that the chemical groups, including acetylation, peppering the long, unstructured tails of the 
histones were a key aspect to this regulation. In 1963, following the discoveries of coenzyme A 
and acetyl CoA in the 1940s and 1950s by Fritz Lipmann, Konrad Bloch, and Feodor Lynen,13-15 
who also received Nobel Prizes for their research (Lipmann together with Hans Kreb for acetyl-
CoA and the citric acid cycle in 1954 and Bloch and Lynen for fatty acid metabolism in 1964), 
Phillips reported the presence of acetyl groups on histones isolated from calf thymus.11 A year 
later, in 1964, Allfrey, Faulkner, and Mirsky described the process of acetylation, along with 
methylation, as a reversible, post-translational mechanism for regulating RNA synthesis.16 
Fast forward thirty years, and the field of phosphorylation has expanded dramatically as 
researchers took advantage of methods to visualize and study the PTM’s unique phosphorous 
atom. Without similar strategies available to study acetate, the field of acetylation moved more 
slowly. However, several important discoveries were made during that time including 
identification of n-butyrate as an inhibitor of deacetylation in the 1970s17-20 and acetylation of a-
tubulin on residue K40 and the development of residue-specific antibodies in the 1980s.21-24 
Eventually, in the mid-1990s and early 2000s, enzymes were identified and isolated that added, 
removed, and read acetylation PTMs, and as more information was uncovered about the histone 
proteins, research in the field of epigenetics rapidly expanded.12, 25-26 With new advancements in 
information and protein science, the hypotheses purported by the scientists in the 1960s were 
confirmed. Histone tail modifications do indeed regulate transcription, and they do so by 
promoting chromatin condensation (heterochromatin) or relaxation (euchromatin) through direct 
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alterations of the DNA-protein interactions and/or through the recruitment of chromatin-binding 
factors and transcriptional remodeling machinery.27 This selective gene activation and silencing 
allows cells, which all contain the same genetic information, to differentiate themselves and 
carry out their discrete and necessary functions.26 The complex combinations of multiple histone 
tail modifications have been referred to as the histone code, and is currently under heavy 
investigation.28-29 It was soon discovered that the histone code is essential for cellular processes 
and physiological homeostasis, and when these finely tuned systems go awry, the cells quickly 
degrade, or worse, quickly divide.26 Numerous diseases are linked to aberrant epigenetics, the 
most notable of which is cancer.26 Aberrant acetylation, in particular, is linked to a plethora of 
diseases, including various types of cancer, neurodegenerative and autoimmune disorders, and 
infectious disease, among others.12, 30-34 The enzymes regulating acetylation, the writers known 
as histone acetytransferases (HATs) and the erasers known as histone deacetylases (HDACs), 
and the proteins containing acetylation reader bromodomains became targets of interest in drug 
discovery research.12, 26 Acetylation was observed, predominantly by means of site-specific 
antibodies, on several dozen additional proteins, including human transcriptional factors p5335, 
YY136, HMG37, STAT338, GATA39, EKLF40, MyoD41, nuclear androgen42 and estrogen 
receptors43, and NF-kB44, as well as molecular chaperone Hsp9045 and viral HIV-Tat,46 among 
others, alluding to a broader role for acetylation in the cell.47  
 
Figure I.1 Timeline of Key Events in Acetylation Research 
Summary timeline of acetylation research indicating major discoveries that have occurred over 
the past 50 years.  
















































Fast forward another 10 years to the last decade, during which new and improved 
techniques paved the way for the field of research called proteomics and opened the door to 
study this unobtrusive PTM in miniscule detail. Mass spectrometry advancements allowed 
researchers to sort through thousands of proteins and differentiate, identify, and measure specific 
acetylated residues within proteins from other acetylated or non-acetylated residues.29, 48 In 
proteome-wide searches, acetylation was observed on significantly greater numbers of proteins 
than previously identified, thus revealing the broad impact acetylation has in biological pathways 
ranging from metabolism to cell signaling, a role second only to phosphorylation in significance 
(Figure I.2).49-50 Today, using a wide variety of in silico, in vitro, and in vivo tools, researchers 
are uncovering more information each day about protein acetylation, including the proteins and 
pathways that are regulating and regulated by acetylation and the ways misacetylation is linked 
to disease.  
 
 
Figure I.2 Acetylation Versus Phosphorylation Publication Growth 
Comparison of phosphorylation and acetylation publication growth. Values indicate the number 
of citations on PubMed referencing the terms ‘phosphorylation’ or ‘acetylation’. Acetylation 
citation number is plotted on the right-hand y-axis and phosphorylation citation number is 
plotted on the left-hand y-axis. Data presented in previous review.51  















































Bromodomains, Histone Acetyltransferases, and Histone Deacetylases 
Acetylation Readers and Writers 
Canonical acetylation occurs on the e-amino group of lysine residues within proteins. The 
PTM is enzymatically added and removed. Although spontaneous (chemical) acetylation has 
been observed under certain circumstances, namely in the mitochondria where high acetyl-CoA 
concentrations and pH conditions favor the reaction, acetylation is irreversible without enzymatic 
intervention.52 Acetylation also occurs on the N-termini of nascent proteins where it is important 
for protein stability, folding, and binding.53 Acetylation can occur on proteins in the nuclear, 
cytoplasmic, and mitochondrial compartments of the cell leading to a wide variety of 
outcomes.48 On histones, acetylation is generally associated with euchromatin and active 
transcription, whereas deacetylation is associated with heterochromatin and lack of transcription 
(Figure I.3). This phenomenon was originally attributed to the neutralization of lysine’s positive 
charge and consequently the interruption of electrostatic interactions between the histones and 
negatively charged DNA. However, the process has proved to be significantly more complicated, 
involving recruitment of transcription factors and chromatin remodeling complexes, and this 
mechanism is not fully understood.  
 
Figure I.3 Histone Acetylation and Transcriptional Regulation1 
Lysine acetylation by histone acetyltransferases (HAT) on the N-terminal tails of histones 
regulates transcription through altering the charge state of lysine and recruiting chromatin 
remodeling machinery that allow for chromatin relaxation and transcription activation. 
Acetylation PTMs are read by bromodomains (BROMO) and deacetylated by histone 
deacetylases (HDAC) returning chromatin to its condensed state and silencing transcription.  
                                               
1 Figure created using media from the Library of Science and Medical Illustrations provided by somersault 



















Shortly before the discovery of acetylation writers and erasers, a reader domain was 
reported.54 Bromodomains recognize and bind to acetylated lysine residues and are generally 
structurally conserved with four a-helices forming a hydrophobic cavity and a few conserved 
residues including an asparagine residue that facilitates acetyl-lysine recognition.55 
Bromodomains have very little sequence homology due to a wide range of acetyl-lysine residue-
specific selectivity for acetyl-lysine.55 Currently, over 40 proteins have been identified with over 
60 putative bromodomains, and only half of those have been verified to bind specific acetyl-
lysine residues.55 These proteins have varying functions serving as scaffolds, transcription 
factors, transcriptional co-regulators, and biological catalysts, and due to their dysregulation in a 
number of diseases, are targeted with small molecule inhibitors.55 
The enzymes responsible for adding acetylation to lysine residues within proteins are 
known as histone acetyltransferases (HATs), named for their first, and at the time presumed 
only, substrate or more appropriately lysine acetyltransferases (KATs). In 1996, a protozoan 
enzyme was isolated and shown to be homologous to yeast Gcn5 and capable of catalyzing 
lysine acetylation.56 Since then, the number of histone acetyltransferases (HATs or KATs) has 
grown to over 20 widely varied proteins identified from different species.57 This family of 
enzymes is currently divided into five sub-families: HAT1, Gcn5/PCAF, MYST, CBP/p300 and 
Rtt109.58 Like kinases, this divergent family of enzymes share a structurally homologous core 
made up of three b-sheets flanked by an acetyl-CoA binding a-helix.59 Interestingly, these 
enzymes share very little sequence homology within this catalytic domain as well as within their 
N- and C-terminal domains.60 Furthermore, although these enzymes catalyze the same 
acetylation reaction, they do so by using multiple mechanisms.60 This diversity has led 
researchers to suggest that more structurally and mechanistically diverse HATs remain to be 
discovered, as currently known enzymes were identified through having at least some homology 
to other known acetyltransferases.58 Although HAT substrates are far from being fully 
characterized, some HATs recognize specific lysine residues, particularly on histones, and small 
molecule modulators are of clinical interest due to aberrant HAT activity in cancer, autoimmune 
disorders, diabetes, and infectious disease.58 
Acetylation Erasers and Disease 
The histone deacetylase (HDAC) family of enzymes is responsible for removing acetyl-lysine 
post translational modifications. This family of enzymes, also known as lysine deacetylases 
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(KDACs) or more appropriately acetyl-lysine deacetylases (AcKDACs), consists of 18 enzymes 
divided into four classes, based on phylogenetic similarities (Figure I.4).61-62 Class I, II, and IV 
are mechanistically similar relying on a catalytic divalent ion to perform deacetylation. Class III, 
the sirtuins, are mechanistically dissimilar from the other classes, relying on an NAD+ co-
substrate to carry out deacetylation. HDACs have been linked to human disease, and HDAC 
inhibition has proven to be promising in indications ranging from neurogenerative disorders to 
cancer.63 Although genetic deletions of all class I HDACs as well as HDAC4, HDAC7, and both 
HDAC5 and HDAC9 are lethal in mice, conditional deletions after development are non-fatal, 
underscoring the importance of HDACs in development and explaining the surprising efficacy of 
global inhibition of metal-dependent HDACs in certain indications.63  
 
Figure I.4 Family of Histone Deacetylases 
Structural representation of histone deacetylase classes I-IV indicating amino acid length, 
















































To date, there are four FDA-approved inhibitors targeting HDACs (Figure I.5): Merck’s 
Zolinza (vorinostat/suberoylanilide hydroxamic acid or SAHA),65-67 Celgene’s Istodax 
(romidepsin),68-69 and Onxeo’s Beleodaq (belinostat)70-71 for T-cell lymphoma and Novartis’s 
Farydak (panobinostat) for multiple myeloma.72-73 Unfortunately, since these compounds are 
non-selective and target most of the metal-dependent deacetylases to some extent, they are often 
treated as the drug of last resort due to toxicity and adverse side effects including fatigue, weight 
loss, nausea, diarrhea, and low blood cell count.74 Additional compounds are currently 
undergoing clinical trials with many more inhibitors in development.75 A recent survey reported 
patents filed for over 70 HDAC inhibitors between 2013-2017.76 Most of these compounds were 
isozyme-specific, and while over 100 clinical trials were currently underway, less than 5% have 
reached stage III, emphasizing an ongoing need for the development of more effective 
therapeutics.76 
 
Figure I.5 FDA-approved pan-HDAC inhibitors  
Chemical structures of the four FDA-approved histone deacetylase inhibitors, hydroxamic acids 
vorinostat, belinostat, and panobinostat and depsipeptide romidepsin, for treatment of t-cell 






Class I HDACs 
Class I HDACs (HDAC177, HDAC278, HDAC379-80, and HDAC881-82) share similarities 
with the yeast deacetylase Rpd3 (reduced potassium dependency 3). In 1996, the first human 
HDAC was purified (aptly named HDAC1), and whose sequence similarity with Rpd3, a known 
gene regulator, quickly spurred the search and subsequent identification of other isozymes.12, 77 
Class I HDACs are predominantly nuclear, although HDAC8 and HDAC3 have been observed in 
both the nucleus and the cytoplasm and contain nuclear localization and export signals.83 
HDAC1 and HDAC2 are nearly identical sharing 82% sequence identity and often displaying 
functional redundancy.84 HDAC1 and HDAC2 are components of large chromosomal 
remodeling complexes including Sin3, NuRD, and CoREST. Additionally, HDAC1 and HDAC2 
are post-translationally phosphorylated, which regulates their activity and facilitates protein-
protein interactions. The functions of HDAC3 and HDAC8, sharing 34% sequence identity with 
each other, are more varied and less well defined.84 HDAC3, in association with class II HDACs 
-4, -5, and -7, was found to be linked to two co-repressor complexes N-CoR (nuclear receptor 
co-repressor) and SMRT (silencing mediator of retinoic acid and thyroid hormone receptors).85-87 
HDAC8 is not observed to associate with any known complexes in cells, and activity is retained 
in the absence of any cofactors when recombinantly expressed and purified.88 Class I HDACs are 
ubiquitously expressed, however, expression levels change depending on cell type and disease.89 
All four isozymes have been linked to a variety of diseases including cancer, neurodegeneration, 
and autoimmunity.31 
Class II HDACs 
Class II HDACs (HDAC485, HDAC585, HDAC685, HDAC786, HDAC990, and 
HDAC1091-92) share homology with the yeast deacetylase Hda1. Larger than class I isozymes 
with molecular weights ranging from 80-131 kDa, these enzymes are divided into sub-classes IIa 
and IIb. Class IIa HDACs (HDAC4, HDAC5, HDAC7, and HDAC9) contain one deacetylase 
domain, while Class IIb HDACs, HDAC6 and HDAC10, contain two fully intact deacetylase 
domains and one intact and one partial deacetylase domain, respectively.64 Generally speaking, 
class IIa HDACs shuttle between the nucleus and cytoplasm and have low deacetylase activity 
when purified and have been proposed to have predominantly non-deacetylation roles in the 
cell.64, 84-85 In contrast, class IIb HDACs catalyze deacetylation and are predominantly 
cytoplasmic, although HDAC6 has been observed in the nucleus in complex with HDAC11.84, 93 
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The activity of class II HDACs can be regulated through post-translational modifications and 
protein-protein interactions. For example, HDAC4, HDAC5, and HDAC7 are phosphorylated 
which regulates their interaction with 14-3-3 proteins that anchor the HDACs in the cytoplasm.94 
Complex disassociation allows for these enzymes to translocate to the nucleus where they 
interact with HDAC3.85, 94  Additionally, HDAC4 and other class II HDACs have been shown to 
interact with MEF2 proteins.95 HDAC4, HDAC5, and HDAC7 have divergent N and C-terminal 
extensions that presumably facilitate isozyme-specific functions.62 The N-terminal domains of 
these isozymes share homology, except HDAC7 lacks a nuclear export signal.84 HDAC10 is one 
of the least studied deacetylases and its function is not well understood.64 Recently, however, 
HDAC10 was shown to function as a polyamine deacetylase.96 In contrast, HDAC6 has become 
one of the most studied isozymes due to its predominantly cytoplasmic role and involvement in a 
separate set of cellular functions and disease.84  
Class III HDACs 
Class III HDACs, the sirtuins SIRT1-7, unlike their metalloenzyme cousins, use NAD+ as 
a cosubstrate.97 The sirtuins, like the classic HDACs, bind a zinc(II) ion, however, the ion serves 
a structural rather than catalytic role.98 The sirtuins are named for their homology to yeast Sir2 
(silent information regulator 2), a transcriptional regulator first described in the 1970s and 
heavily investigated for its apparent role in starvation and longevity.97, 99 Human sirtuins were 
identified as deacetylases due to their homology to Sir2 and their ability to catalyze deacetylation 
of core histones, transcription factors, and other acetylated proteins.97, 100-101 Sirtuins have a 
conserved catalytic core with varying N- and C-terminal sequences and use NAD+ as a 
cosubstrate to form nicotinamide, adenine diphosphate ribose, acetate, and the deacetylated 
protein product.100, 102-103 Although there is some functional redundancy, the sirtuins vary in 
subcellular localization, substrate selectivity, and cellular function.97 SIRT1, the closest 
homologue to Sir2, is primarily nuclear, although it shuttles between the nucleus and 
cytoplasm.97 SIRT1 deacetylates core histones and various transcription factors.64 SIRT2, shares 
similar functions to SIRT1, although it resides primarily in the cytoplasm.97 Additionally, SIRT2 
has been shown to have demyristoylase and mono-ADP-ribosyltransferase activity in addition to 
deacetylation.64, 104 SIRT3 is localized to the mitochondria and catalyzes deacetylation and other 
deacylation reactions.97 Mitochondrial SIRT4 and SIRT5 display lower activity and also catalyze 
alternative deacylation reactions.97 Finally, SIRT6 and SIRT7 are localized to the nucleus with 
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activity similar to that of SIRT4 and SIRT5.97, 103 The sirtuins are also implicated in various 
human diseases including cancer and metabolic and neurodegenerative disorders, among others 
and are targeted for inhibitor and activator development in drug discovery research.97 
Class IV HDACs 
Class IV contains the remaining human isozyme HDAC11, which is classified separately 
despite sharing sequence homology with class I HDACs, including 28% sequence homology 
with HDAC8.105 Phylogenetic analysis supports three separate sub-families of metal-dependent 
HDACs with human HDAC11 and other HDAC11-type enzymes falling into the third 
category.61 This evidence supports the existence of non-redundant functions for each class in 
basic cellular processes. Notably, while class I and II are found in all fully-sequenced eukaryotic 
organisms, there are no class IV enzymes in fungi.61 Described in 2002, HDAC11 is the most 
recently identified, and at only 347 residues and 39 kDa, is the smallest classical HDAC.105 
HDAC11 is ubiquitously expressed with increased expression levels in the brain, kidney, heart, 
skeletal muscle, and testis, suggesting HDAC11 may have tissue-specific roles.105 Relatively 
little is known about HDAC11 function in comparison with its class I and II brothers, however 
abnormally overexpressed HDAC11 has been implicated in breast, kidney, and liver cancers, 
where inhibition was shown to decrease cancer cell viability, although with some apparent 
overlap with HDAC1 and HDAC2.106 An additional role for HDAC11 in the adaptive immune 
response has been proposed due to its regulation of interleukin-10 expression.107 Moreover, 
inhibition of HDAC11 led to enhanced Foxp3+ Treg cell function and Treg-dependent 
suppression of allograft rejection in a model of organ reperfusion, presumably due to 
deacetylation of Foxp3.108 HDAC11 has relatively low deacetylase activity in vitro, however, 
recently HDAC11 has been proposed to have myristoyl-lysine hydrolase functionality.109 The 
next section focuses on HDAC8 and HDAC6 as model enzymes from class I and II and the foci 
of this dissertation. 
HDAC8 Function, Regulation, and Physiological Role 
HDAC8 Discovery and Structure 
HDAC8 was first described in 2000 when three groups published separate analyses of a 
new class I deacetylase capable of in vitro deacetylation of histones.81-82, 110 Shortly thereafter, in 
2004, the crystal structure of human HDAC8 was solved,111-112 the first reported human 
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deacetylase structure and the first of many HDAC8 structures. At 377 amino acid residues and 
42 kDa and containing little more than a deacetylase domain, HDAC8 is the smallest class I 
isozyme and the second smallest HDAC (next to HDAC11) (Figure I.7). Since its discovery, 
HDAC8 has become arguably the best mechanistically and structurally characterized HDAC.113 
HDAC8 displays an arginase-like fold consisting of a single a/b domain arranged with a central 
eight-stranded b-sheet flanked by eleven a-helices.68, 111-112, 114-123 The substrate binding surface 
is characterized by 9 flexible loops and an 11 Å substrate binding tunnel terminating in the active 
site divalent metal coordinated by a His/Asp/Asp triad.118, 124 In addition to its catalytic divalent 
ion, HDAC8 also binds two monovalent ions (K+ or Na+) with an activating binding site distal to 
the active site and an inhibitory site near the active site.125 These ions allow for regulation of the 
enzyme depending on cellular conditions and explain the sensitivity of HDAC8 activity to salt 




Figure I.6. HDAC8 Structure 
HDAC8 crystal structure bound to a hydroxamic acid inhibitor (PDB ID 1W22) and graphical 
representation highlighting the catalytic domain (CD), nuclear localization signal (L), and amino 
acid length. Potassium ions are shown in red, the zinc(II) ion is shown in purple, and the 
inhibitor molecule is shown in green. 
HDAC8 Catalytic Mechanism and Metal Activation 
The proposed mechanism for HDACs is general acid-base catalysis (GABC), where the 
active site metal ion coordinates the substrate and a water molecule, and two conserved histidine 
residues serve as the general acid and/or general base (Figure I.7).118 In HDAC8, the divalent 
metal ion is bound to the protein by interactions with D178, D267, and H180, and coordinates 
the substrate carbonyl and a water molecule. Structural and biochemical data support one 
catalytic histidine residue, H143, acting as both general acid and general base. This side chain 
initiates catalysis by deprotonating and activating a water molecule for attack on the carbonyl 
oxygen of the acetyl moiety to form a tetrahedral intermediate. The second histidine residue 
H143 is proposed to remain protonated throughout the catalytic cycle, serving as an electrostatic 
catalyst.118 Another conserved residue, Y306, enhances catalytic activity, and is proposed to 
stabilize the oxyanion of the transition state through hydrogen-bonding with the tetrahedral 
intermediate.118 Breakdown of the tetrahedral intermediate occurs simultaneously with donation 
of a proton from protonated H143, now serving as the general acid, to the product amine 
resulting in free acetate and deacetylated lysine.118   
E CD L 377 aa 
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Figure I.7. HDAC8 Mechanism 
Proposed catalytic cycle and mechanism of HDAC8 whereby Tyr306 and a zinc(II) ion, 
coordinated by His180, Asp276, and Asp178, orient the carbonyl oxygen of the acetyl-lysine 
substrate in the active site to be acted on by catalytic acid/base H143, while protonated H142 
serves as an electrostatic catalyst. Figure adapted from Gantt et al. 2016.118 
 
HDAC8 is activated by multiple catalytic divalent ions including zinc(II), the canonical 
active site metal, cobalt(II), iron(II), nickel(II), and manganese(II).88 HDAC8 is most active 
when bound to cobalt with a kcat/KM = 7500 ± 300 M-1s-1 for deacetylation of the coumarin-
tagged test substrate, a p53-derived tetrapeptide.88 However, cellular levels of cobalt(II) preclude 
this ion from being the physiologically relevant catalytic metal ion.88 The next most activating 
ion is iron(II) at 2300 ± 160 M-1s-1 followed by zinc(II) at 800 ± 50 M-1s-1.88 HDAC8 metal 
affinities (KD) for these two ions compare to their putative readily exchangeable cellular 
concentrations, with Zn(II) binding more tightly than the more abundant Fe(II); therefore, both 
zinc and iron have the potential to be physiologically relevant.126 Although HDAC8 is bound to 











































































































has yet to be determined. Interestingly, HDAC8 is maximally activated by zinc at 1:1 
stoichiometry, and excess zinc(II) is inhibitory likely due to a secondary metal binding site.88 In 
certain cases, HDAC8 has displayed oxygen sensitivity suggesting HDAC8, or a portion of 
HDAC8, may be bound to iron(II) in vivo.88 Since HDAC8 is inactive with iron(III), allowing for 
oxidative regulation of activity, and inhibited by excess zinc(II), the cellular metal ion 
concentrations may play a crucial role in regulating HDAC8 activity.88 Additionally, HDAC8 
has been shown to have different substrate selectivity depending on the identity of the active site 
metal ion.127 HDAC8 may potentially bind either metal ion in cells and be regulated by a metal-
switching mechanism, as seen with other metalloenzymes such as the E. coli deacetylase 
LpxC.128 
HDAC8 Regulation by Localization and Post-Translational Modifications 
Unlike nuclear class I HDACs 1-3, HDAC8 has been observed in the nucleus and 
cytoplasm of cells. In HEK293 cells, HDAC8 is localized in the nucleus, but in smooth muscle 
cells, skin fibroblasts, and NIH3T3 cells, HDAC8 has been observed in both the nucleus and 
cytoplasm.129-130 HDAC8 contains a putative nuclear localization sequence suggesting that 
HDAC8 may shuttle between the nucleus and cytoplasm. HDAC8 is post-translationally 
phosphorylated at residue Ser39 by protein kinase A (PKA), which effects enzyme structure and 
function (see Chapter II). Although other HDACs are post-translationally acetylated, 
ubiquitinated, and sumoylated, the only PTM reported for HDAC8 is phosphorylation of S39.  
HDAC8 Protein-Protein Interactions  
While other class I and class II isozymes have known functions in protein complexes that 
regulate their activity and function, HDAC8 has not been observed in any known functional 
protein complexes. Furthermore, HDAC8 is purified and is catalytically active in vitro in the 
absence of binding partners, suggesting HDAC8 acts predominantly as a monomer in vivo. If 
protein-protein interactions are weak or short-lived, regardless of their importance, such 
complexes may escape detection by current methods. However, HDAC8 does interact with other 
proteins that may regulate HDAC8 activity and selectivity.  
For example, in HEK293 cells, overexpressed HDAC8 co-immunoprecipitates with 
nuclear cAMP responsive element-binding protein (CREB) and its phosphatase PP1, resulting in 
CREB dephosphorylation and inactivation.131 Additionally, HDAC8 colocalizes with a-actin in 
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the cytoskeleton of human smooth muscle NIH-3T3 fibroblast cells, and HDAC8 RNAi 
decreased cell spreading thus suggesting a role for HDAC8 in smooth muscle cytoskeleton 
regulation and contraction.129-130 Moreover, HDAC8 co-immunoprecipitates with Hsp20, cofilin, 
a-actin, and myosin heavy chain in myometrial smooth muscle cells and impacts Hsp20 
acetylation and muscle contraction.132 Another study demonstrated that overexpressed HDAC8 
in HeLa cells coimmunoprecipitates with overexpressed human Ever-Shorter Telomeres 1B 
(hEST1B) and HOP1 and endogenous levels of HOP1 interacting partners Hsp70 and Hsp90.133 
As Hsp90 is a known modulator of a-actin and a-tubulin, this provides further evidence of 
HDAC8 regulation of cytoskeletal dynamics.133 
In a comprehensive study to elucidate and characterize the interaction network or 
‘interactome’ of histone deacetylases, over a dozen protein interactions, including SMC1A and 
SMC3, were identified for HDAC8 by immunoprecipitation in CEM T-cells stably expressing 
HDAC8.134 Over half of the proteins identified had a non-canonical or unknown role in 
biological processes, while the other half was split between cell-cycle and transportation 
processes.134 This study was limited to identifying the most stable complexes under one set of 
experimental conditions and was unable to measure the stoichiometry and composition of the 
complexes. Although there is strong evidence that SMC3 is an HDAC8 substrate,135-136 little 
information exists to implicate the remaining proteins as HDAC8 substrates, some of which have 
not been identified as acetylated. The role of HDAC8 in these protein-protein interactions is 
difficult to identify. HDAC8 may provide scaffolding or other activity-independent functions in 
these interactions, or HDAC8 may directly deacetylate or initiate a cascade that results in 
deacetylation of its interacting partner(s). As HDAC8 substrate disassociation is proposed to be 
rapid to facilitate turnover, interactions that survive pull-downs or are long lasting enough to be 
visualized in another manner are likely not HDAC8 substrates. Interestingly, the proteins that 
immunoprecipitated with HDAC8 were predominantly specific for this isozyme, unlike the 
complex network of overlapping protein-protein interactions between HDAC1 and HDAC2.134 
This study underscores the significance of protein complexes for HDAC1 and HDAC2 and 
suggests lower significance of protein complexes for the cellular function of HDAC8, further 
emphasizing the functional differences between isozymes. 
In efforts to capture transient interactions and identify potential HDAC8 substrates, non-
natural amino acid incorporation was used to insert a photocrosslinker into specific sites within 
 17 
HDAC8, including one near the active site, to covalently link HDAC8 with any interactors in 
HEK293 cell lysates.137 The study reported the identification of numerous protein interactors by 
mass spectrometry. Hits from photocrosslinkers distal to the active site were identified as binding 
partners, while hits from the active site photocrosslinker, including Hsp90 and a-tubulin, were 
identified as putative substrates.137 Furthermore, acetylated peptide substrates corresponding to 
those proteins showed reactivity with HDAC8 in vitro.137 Other substrate-enzyme interactions 
were proposed by an acetylome-wide survey of proteins affected by treatment with an HDAC8-
specific inhibitor, PCI-34051, in MCF-7 cells. Using stable isotope labeling in cell culture 
coupled with mass spectrometry (SILAC-MS), about a dozen proteins, including previously 
reported SMC3 as well as novel proteins such as ARID1A, RAI1, NCOA3, and KAT14, were 
identified with differentially increased acetylation upon HDAC8i compared to controls.138 
Although the study could only provide evidence of HDAC8-mediated hyperacetylation and not 
direct deacetylation of these proteins by HDAC8, acetylated peptides corresponding to the 
putative substrates demonstrated reactivity with HDAC8 in vitro.138 
HDAC8 in Development and Cornelia de Lange Syndrome 
The physiological role of HDAC8 is poorly understood, however HDAC8 has been 
connected to a number of cellular processes. First, HDAC8 appears to be integral to 
development. Embryonic knockout of HDAC8 leads to perinatal death in mice due to skull 
defects leading to brain hemorrhage.139 The skull defects result from improper neural crest 
patterning, a phenomenon seen upon overexpression of transcription factors Otx2 and Lhx1, 
suggesting HDAC8 may be involved either directly or indirectly in regulation of these 
proteins.139 Conditional deletions of HDAC8 are non-lethal; however, mutations to HDAC8 have 
been linked to a rare genetic disorder called Cornelia de Lange syndrome (CdLS) caused by 
defects in the cohesin complex.121-122, 135, 139-142 The cohesin complex regulates the separation of 
sister chromatids during cell division, and errors in this process lead to the developmental 
disorder characterized by physical and intellectual impairments. While the majority of CdLS 
cases arise due to mutations in proteins within this complex, including SMC3 (structural 
maintenance of chromosomes 3), a number of HDAC8 loss-of-function mutations led to the 
same phenotype.135, 142 As SMC3 is post-translationally acetylated and assists in complex 
formation, it is hypothesized that HDAC8-catalyzed deacetylation of SMC3 promotes complex 
disassociation leading to separation of sister chromatids under normal conditions, and impaired 
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HDAC8 leads to hyperacetylated SMC3 and prolonged complex association.135 Moreover, 
HDAC8 is implicated in neural-crest derived childhood neuroblastoma (described in the next 
section), which also indicates a prominent role for HDAC8 in development and developmental-
related disorders.143 
HDAC8 in cancer 
HDAC8 has been implicated in numerous types of cancer including lymphoma/leukemia, 
childhood neuroblastoma, and breast cancers, among others, although HDAC8 function in 
pathology is not fully understood. 144 For this reason, HDAC8 is an attractive target for drug 
development. Higher expression levels of HDAC8 mRNA are reported in numerous cancer cell 
lines and tissues including leukemia, neuroblastoma, and female reproductive system cancers, 
compared to normal cells and tissues.89 Analysis of protein expression levels of class I HDACs 
by immunoblot and immunostaining reported that while the enzymes, including HDAC8, were 
expressed in the selected cancerous cell types, they were only slightly overexpressed in 
comparison with the corresponding normal cell types and tissues.145 However, in a study 
focusing on liver cancer, HDAC8 mRNA and protein expression were elevated in several 
hepatocellular carcinoma (HCC) tissues and cell lines compared to paired normal tissues and 
cells, and RNAi knockdown of HDAC8 decreased cell growth and proliferation.146 Moreover, 
HDAC8 dysregulation may play a predominant role in disease progression, despite normal 
expression levels,  
Vannini et al. reported HDAC8 RNAi-mediated growth inhibition of lung (A549), colon 
(HCT-116), and cervical (HeLa) cancer cell lines.111 In contrast, a study reporting on the activity 
of HDAC8-specific inhibitor PCI-34051 demonstrated poor growth inhibition and no apoptosis 
of these cells and other solid tumor lines at the dosage tested.147 The difference could be due to 
the difference between RNAi- and PCI-34051-mediated inhibition the analysis used. However, 
PCI-34051 effectively inhibited growth and induced apoptosis of T-cell derived cell lines 
(Jurkat, HuT78, HSB-2, and Molt-4).147 This is in agreement with another study that placed 
HDAC8, along with transcription factors SOX4 and FRA-2/JUND, in an oncogenic cascade 
implicated in promoting cell growth of acute t-cell leukemia/lymphoma (ATL).148 SOX4, 
activated by FRA-2/JUND, in turn upregulates HDAC8 expression by activation of the HDAC8 
promoter.148 RNAi knockdown of members of this cascade, including HDAC8, suppresses ATL 
cell growth.148  
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In acute myeloid leukemia (AML), approximately 8% of cases harbor the inversion(16) 
chromosomal translocation and resulting chimera protein inv(16). The fusion protein interacts 
with HDAC8 and mSin3a (and mSin3a-associated HDACs) separately to promote the inv(16)-
mediated transcriptional repression linked to AML pathology.149 HDAC8 is further implicated in 
inv(16)+ AML through regulation of p53 acetylation, where hypoacetylated p53 promotes 
leukemia stem cell transformation and maintenance.150 HDAC8i treatment with compound 
22d151 led to apoptosis in inv(16)+ CD34+ cells and decreased AML tumorigenesis and 
propagation. Furthermore, HDAC8 regulates mRNA and protein expression of p53 in colon and 
pancreatic cancer cell lines, suggesting HDAC8i may be a therapeutic approach to treatment of 
mutant p53-directed cancers.152 Since the p53 gene is the most frequently mutated gene in 
cancer, these findings underscore the clinical significance and potential for HDAC8 inhibition.153 
In triple negative breast cancer (TNBC), HDAC8 mRNA overexpression was observed in 
24% of tested clinical tissues samples compared to controls, and HDAC8 overexpression 
correlated with late stage disease and poor prognosis in early-stage.154 Breast cancer is the 2nd 
leading cause of cancer-related mortality in the United States, and TNBC, a highly malignant 
form, is often metastatic and difficult to treat due to the lack of targetable hormone receptors. 
Inhibition of HDAC8 by RNAi or PCI-34051 treatment yielded impaired TNBC cell migration, 
and altered the expression of numerous cell-movement- and cancer-related genes. In a similar 
study, RNAi of HDAC1, HDAC8, and HDAC6 repressed TNBC cell migration and invasion, 
and induced cell-cycle arrest and apoptosis.155  
HDAC8 also appears to play a prominent role in childhood neuroblastoma, a solid tumor 
cancer that accounts for 10% of childhood cancers, 15% of childhood mortality from cancer, and 
50% of infant cancers.156 Neuroblastoma, a cancer arising from neural crest-derived cells, most 
often affects infants (<18 months) where it generally results in good outcomes, even in late 
stages (>90% survival).139 However, in older children (>18 months), neuroblastoma tumors are 
particularly malignant and metastatic resulting in poor prognosis (<30% survival).74 As 
mentioned in the previous section, global deletion of HDAC8 in mice results in perinatal 
lethality due to morphological errors in skull development attributed aberrant HDAC8 in cranial 
neural crest cells.139 HDAC8 was identified as the only classical HDAC whose expression 
correlated significantly with late stage disease and metastasis.143 Interestingly, downregulation of 
HDAC8 correlated with stage 4S neuroblastoma, which is associated with spontaneous 
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regression.143 Moreover, HDAC8-specific inhibition in neuroblastoma cell lines and xenograft 
mouse neuroblastoma models led to cell cycle arrest and differentiation without the toxicity 
associated with pan-HDAC inhibitor SAHA.157 In addition to HDAC inhibitors and 
combinatorial treatments, micro RNAs, short non-coding suppressive RNA elements, may prove 
to be therapeutic approaches for downregulating HDAC8 mRNA expression along with other 
oncogenes in neuroblastoma.158-159 Together, these results suggest HDAC8 inhibition is a 
promising strategy for treatment of these highly malignant and devastating cancers. 
HDAC8 in Infectious Disease 
HDAC8 is also implicated as a target to treat infectious disease. In the neglected tropical 
disease schistosomiasis, the HDAC8 orthologue in the parasitic flatworm Schistosoma mansoni 
is an ongoing target for drug discovery.160 Schistosomiasis affects over 200 million people 
resulting in up to 200,000 deaths per year worldwide. Currently, praziquantel is the primary drug 
for treatment of schistosomaisis. While effective, praziquantel is at risk for resistance 
development due to lack of alternative treatments and praziquantel’s widespread use, as it is 
often administered as a preventive measure in at-risk communities. The HDAC pan-inhibitor 
TSA leads to larvae and adult flatworm death. HDAC8 is the least conserved and most abundant 
HDAC orthologue in S. mansoni. Therefore HDAC8-specific inhibitors may prove to be 
effective treatment options without the side-effects caused by TSA.161-163 HDAC8 has also been 
implicated in influenza A infection, where cellular HDAC8 promotes viral mechanisms 
including endocytosis, acidification, and penetration, and HDAC8 RNAi resulted in reduced 
viral infection rates.164 
HDAC6 structure and physiological role 
HDAC6 Discovery, Structure, and Mechanism 
Histone deacetylase 6 (HDAC6), first described in 1999 by Grozinger and colleagues, is 
unique among the family of HDACs.85 HDAC6 is the largest of the HDACs at 1,215 amino acid 
residues and contains two active catalytic domains (CD1 and CD2) with different substrate 
specificity and selectivity.62, 85, 165-166 Along with HDAC10, which contains one active and one 
partial, inactive catalytic domain, HDAC6 belongs to class IIb.91 While class I HDACs 
(HDAC1-3, 8) are primarily localized in the nucleus and are ubiquitously expressed to differing 
levels depending on tissue type, class II HDACs (HDAC4-7,9-10) are predominantly 
 21 
cytoplasmic and appear to have more tissue-specific roles.79, 82, 84, 167 Class IIa HDACs have 
modest to no activity, and it is proposed that these enzymes may perform other functions within 
the cell.62 On the other hand, HDAC6 is robustly active in vitro.165 HDAC6 contains other 
important and unique structural features (Figure I.8). An N-terminal nuclear localization signal 
(L) and N- and C-terminal nuclear export signals (E) allow HDAC6 to travel between the 
nucleus and cytoplasm, and a C-terminal serine glutamate tetradecapeptide repeat (SE14) 
facilitates cytoplasmic retention.165, 167 Interestingly, HDAC6 also contains a C-terminal zinc 
finger ubiquitin binding domain (BUZ) which may participate in both deacetylase dependent and 
independent functions.165, 168-169 Several physiological roles have been proposed for HDAC6 
mainly in the cytosol, including cytoskeleton dynamics, protein degradation and cellular stress. 
 
Figure I.8 Diagram of HDAC6 structural features  
Human HDAC6 (blue) is composed of 1,215 amino acid residues organized into several key 
domains: N-terminal nuclear localization signal and C-terminal serine-glutamate 
tetradecapeptide repeat cytoplasmic retention domain (L and SE14, respectively in yellow), N- 
and C-terminal nuclear export signals (E in teal), catalytic domains 1 and 2 (CD1 and CD2 in 
orange), and finally the dynein motor binding domain and ubiquitin binding zinc finger domain 
(DM and BUZ, respectively in red).  
HDAC6 and Cytoskeleton Dynamics 
HDAC6 plays an important role in cell function through interaction with the 
cytoskeleton.170 Alpha- and beta- tubulin polymerize to form microtubules, which along with 
actin polymers (microfilaments) and fibrillary proteins, form the eukaryotic cytoskeleton.171 The 
cytoskeleton is a crucial element of the cell, providing cell structure and flexibility, aiding in 
tissue organization, and regulating cell cycle through maintenance of cytoskeletal dynamics 
involved in cell growth, movement, and division.172 The cytoskeleton is also important in cell 
signaling where signal uptake and intracellular transport are key components of signal 
cascades.173-175 Acetylation of a-tubulin, most notably at K40 within the actin binding domain of 
cortactin, aids in microtubule and microfilament polymerization. In contrast, deacetylation, 
catalyzed at least in part by HDAC6, is associated with microtubule depolymerization and 
consequently cytoskeletal reorganization.170, 176-179 
CD2EL CD1 SE14 BUZEDM
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HDAC6 in Protein Degradation and Cellular Stress 
HDAC6 plays an integral role in protein degradation, where the balance between two 
protein degradation pathways, the proteasome-ubiquitin system and autophagy, is dependent on 
HDAC6.180 Under normal, non-stressed cellular conditions, the proteasome-ubiquitin system 
clears mis-folded proteins.181 Under these conditions, HDAC6 is complexed with heat shock 
protein 90 (Hsp90) and heat shock factor 1 (HSF1), as shown by Hsp90 pull-downs from mouse 
fibroblasts.182 When the proteasome is inhibited, or accumulation of mis-folded proteins occurs 
faster than the proteasome can clear them, proteasome-independent autophagy is triggered.183 
Under these conditions, the complex dissociates as HDAC6 binds to excess ubiquitinated 
proteins and associates with dynein motor proteins to transport the cargo along the microtubule 
to undergo autophagy.184-186 Additionally, release of HSF1 and deacetylation of Hsp90 catalyzed 
by HDAC6 is proposed to activate chaperone activity aiding in cellular stress response.45, 182, 187-
188 
HDAC6 as a drug target 
Over the past 20 years, HDAC6 has risen to be one of the most studied deacetylases as 
seen in the increase in publications mentioning HDAC6 (Figure I.9). Indeed, many drug 
discovery efforts have focused on the development of HDAC6-specific inhibitors. Recently, the 
crystal structures of HDAC6 catalytic domains 1 & 2 were reported.165, 189 Before the HDAC6 
structure was known, rational inhibitor design depended on homology models.190 The crystal 
structure of HDAC6 now allows for rationale inhibitor design and the development of more 
effective compounds. In a recent HDAC inhibitor patent survey, over two thirds of the patents 
for isozyme-specific inhibitors targeted HDAC6.76 While class I HDACs, in particular HDAC1 
and HDAC2, have been targeted due to an apparent role in chromatin remodeling and 
overexpression in various cancer subtypes,191 the role of HDAC6 in disease remains mysterious, 
as aberrant increased and decreased activity is observed in cancer,180 neurodegenerative 
diseases,169 and autoimmune disorders.192 Although HDAC6i appears to be antagonistic in 





Figure I.9. Publication growth of HDAC6 has drastically increased over the past decade 
compared to most cited deacetylase: HDAC1 
Graph represents fold change in the HDAC1 (blue bars) and HDAC6 (red bars) percentage of 
total yearly HDAC publications compared to the first year mentioned (1996 for HDAC1, 1999 
for HDAC6). Pubmed search input for total HDAC Publications: “HDAC” OR “Histone 
Deacetylase”; HDAC6 publications: “HDAC6” OR “Histone Deacetylase 6”; HDAC1 
publications: “HDAC1” OR “Histone deacetylase 1”.  
HDAC6 in cancer 
HDAC6 is an attractive target in cancer therapeutics since its role in cell cycle regulation, 
cellular stress response, and cell signaling is often a contributing factor in oncogenic 
transformation and tumor cell survival (reviewed by Aldana-Masangkay and Sakamoto 2011).180 
HDAC6 misregulation of cortactin, a-tubulin, and cytoskeletal dynamics aids in tumor 
metastasis,177, 194 and HDAC6 clearance of misfolded proteins and activation of the heat shock 
response promotes cell survival.182, 195 HDAC6 also appears to play a role in Ras/MAPK 
signaling regulation where it aids in oncogenic transformation through an unknown mechanism. 
195-196 In addition, HDAC6 overexpression has been implicated in a variety of cancer types 
including breast,155, 197-201 ovarian,202-204 oral squamous,205 cutaneous T-cell lymphoma,206 and 
acute myloid and lymphoblastic leukemia cancers,207 among others, underscoring the diverse 
role of HDAC6 in oncogenic pathologies, the necessity of better understanding those roles, and 



































































HDAC6 in neurodegenerative disease 
Accumulation of misfolded proteins is the hallmark of many neurodegenerative disease, 
as seen in the tau neurofibrillary tangles and b-amyloid plaques of Alzheimer’s disease, 
aggregated a-synuclein Lewy bodies of Parkinson’s disease, and accumulation of huntingtin in 
Huntington’s disease.169, 208 While HDAC6 aids in misfolded protein clearance, misregulated 
HDAC6 can also lead to accumulation of misfolded proteins under certain circumstances.169 For 
example, in Alzheimer’s disease, HDAC6 activation of Hsp90 by deacetylation leads to 
increased levels of tau protein, an Hsp90 client, as activated Hsp90 inhibits tau degradation due 
to increased association with hypoacetylated Hsp90 and decreased tau polyubiquitination leading 
to proteasomal degradation.209 Additionally, microtubule degradation is exacerbated by HDAC6 
deacetylation of a-tubulin promoting microtubule de-polymerization and cytoskeleton 
disorganization.210-211 This in turn leads to impairment of intracellular transport, loss of synapse 
integrity, and eventually cell death by way of b-amyloid accumulation and tau 
hyperphosphorylation. 
HDAC6 in autoimmune disorders 
The adaptive immune response is powered by an army of cells called lymphocytes, also 
known as B and T cells. While B cells carry the information needed to rapidly produce 
antibodies against previously encountered pathogens, T cells are responsible for identifying and 
attacking novel threats, such as a new pathogen.81 Regulatory T cells, or Tregs, control the 
activation of T cells in response to an antigen. Tregs are critical in preventing excessive and 
harmful immune response, as seen in autoimmune disorders.212 Treg activation and consequently 
immune response suppression is controlled by the transcription factor Foxp3, which is in turn 
regulated by HDAC6, potentially through deacetylation of Foxp3 and/or Hsp90.213 HDAC6 
genetic knockout and treatment with HDAC6-specific inhibitors tubacin and tubastatin A in 
mice, leads to enhanced Treg activation and immune system suppression and is therefore a 
potential therapeutic avenue in autoimmune disorders and other immune response-related issues 
such as transplant rejection. It is also possible that HDAC6 inhibition could be used in 
immunotherapies for cancer. 
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Challenges and the Future of HDAC Research 
The family of HDACs represents a promising avenue for targeting therapeutics and drug 
discovery due to their widespread impact on physiological processes and disease pathology. 
Modern technological advancements have equipped researchers with tools to characterize these 
enzymes in order to better understand their function. Recent studies have uncovered a rich 
complexity to HDACs including divergent structures, intricate mechanisms, and widely varied 
substrate selectivity, protein-protein interactions, subcellular localization, and tissue distribution. 
This research is ongoing, as many questions remain, and the individual roles for these enzymes is 
not fully understood. This insight is essential for developing the best targeting approaches for 
HDACs in disease and for providing the most effective treatment options for these diseases. An 
important task regarding HDAC-specific function is deciphering their individual targets. Thus 
far, numerous HDAC-specific substrates have been proposed, underscoring the diverse and 
individual functions for the different members of this family of enzymes. However, with 
thousands of acetyl-lysine residues reported in the human acetylome, there are still many 
residues left to characterize and identify the HDAC(s) responsible for their regulation.  
HDAC research is both exciting and challenging. Challenges include designing 
increasingly more sensitive tools to analyze low acetylation levels, developing methods to parse 
individual and overlapping HDAC activity, and collaborating to create systematic, streamlined, 
and rapid approaches to compiling and connecting the most relevant and robust information. One 
thing is evident, there is no one tool, method, or approach that can provide all the answers. For 
this reason, a barrage of techniques, or a so-called ‘toolbox’ of methodologies, must be 
implemented to assign substrates, identify biological pathways, detect overlapping function 
between isozymes, and make relevant connections between studies. Developing robust, well-
designed, and high-throughput methods for quickly surveying a continuously expanding pool of 
targets will be critical for future success in the field.  
In the following pages, I describe a set of such experiments used to characterize the 
impact of post-translational modifications, structure, protein-protein interactions, and substrate 
specificity and selectivity on the regulation and function of representative class I HDAC8 and 
class II HDAC6. In chapter 2, the role of HDAC8 phosphorylation in regulating HDAC8 activity 
and substrate selectivity is investigated. A phosphomimetic S39E HDAC8 mutant catalyzes 
deacetylation of a library of singly-acetylated peptides more slowly and with altered substrate 
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selectivity than wild type. For a peptide corresponding to SMC3, the best validated HDAC8 
substrate, the glutamate substitution nearly abolishes activity suggesting that phosphorylation 
could be a mechanism used in the cell to regulate HDAC8-catalyzed deacetylation of this 
protein. Crystallographic analysis suggests that the altered enzyme activity and substrate 
selectivity are due to minor structural changes at the site of phosphorylation (S39) that are 
translated through the protein to affect active site architecture. Molecular dynamics simulations 
of S39E, wild-type, and pS39 HDAC8 recapitulate the structural observations and suggest 
additional changes at the substrate binding interface that lead to altered molecular recognition of 
peptides.  
The data in chapter 3 demonstrate the impact of interactions between substrate and 
HDAC8 distal to the active site. HDAC8-catalyzed deacetylation of full-length histone H3/H4 
complexes containing modifications at H3 K9ac, K14ac, or K56ac were measured and compared  
to reactivity of the corresponding peptides. The results demonstrate that contacts distal to the 
active site made between substrate and enzyme increase deacetylation rates at least 30-fold. 
However, when comparing the activities, the protein and peptide substrates showed similar 
trends in reactivity. For both peptides and proteins, HDAC8 deacetylated histone H3 K9ac more 
rapidly than H3 K14ac, despite their close proximity and similar structure and sequence 
environment. This indicates that local sequence impacts substrate selectivity and supports the 
continued use of peptides as substrate surrogates in future studies. 
In chapter 4, a structure-based computational method for determining the substrate 
specificity and selectivity of HDAC6 is developed. HDAC6-catalyzed deacetylation of a library 
of over 30 peptides was measured, demonstrating a wide range of activities varying up to 
20,000-fold. These data indicate HDAC6 has significant substrate sequence preferences and may 
be modeled to develop a computational algorithm capable of predicting HDAC6 activity. Using 
the Rosetta FlexPepBind platform, our collaborators in the lab of Dr. Ora Schueler-Furman have 
developed a structure capable to predicting good HDAC6 substrates. This computational model 
will be useful in identifying cellular HDAC6 substrates and enhancing our understanding of the 
function of this enzyme.  
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Histone deacetylase (HDAC) enzymes that catalyze removal of acetyl-lysine post 
translational modifications are also frequently post-translationally modified. HDAC8 is 
phosphorylated within the deacetylase domain at conserved residue serine 39 which leads to 
decreased catalytic activity. HDAC8 phosphorylation at S39 is unique in its location and 
function and may represent a novel mode of deacetylation regulation. To better understand the 
impact of phosphorylation of HDAC8 on enzyme structure and function, we performed 
crystallographic, kinetic, and molecular dynamics studies of the S39E HDAC8 phosphomimetic 
mutant. This mutation decreases deacetylation of peptides taken from acetylated nuclear and 
cytoplasmic proteins. However, the magnitude of the effect depends on the peptide sequence and 
the identity of the active site metal ion (Zn(II) vs Fe(II)) with the value of kcat/KM for the mutant 
decreasing 9- to >200-fold compared to wild-type HDAC8. Furthermore, the dissociation rate 
constant of the active site metal ion increases by ~15-fold.  S39E HDAC8 was crystallized in 
complex with the inhibitor Droxinostat revealing that phosphorylation of S39, as mimicked by 
the glutamate side chain, perturbs local structure through distortion of the L1 loop. Molecular 
dynamics simulations of both S39E and phosphorylated S39 HDAC8 demonstrate that the 
perturbation of the L1 loop most likely occurs because of the loss of the hydrogen bond between 
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CHAPTER II                                                                                                        
Phosphorylation of Histone Deacetylase 8: Structural and Mechanistic Analysis of 





D29 and S39. Furthermore, the S39 perturbation causes structural changes that propagate 
through the protein scaffolding to influence function in the active site. These data demonstrate 
that phosphorylation likely plays an important regulatory role for HDAC8 by affecting ligand 
binding, catalytic efficiency and substrate selectivity. 
Introduction 
Addition of post translational modifications (PTMs) is a well-known mechanism used by 
cells to reversibly regulate protein structure and function. The family of histone deacetylases 
(HDACs), enzymes responsible for the removal of acetylation PTMs on proteins, are frequently 
modified themselves by various PTMs, including phosphorylation. HDACs 1-9 are 
phosphorylated at one or more sites, and the PTM regulates their protein-protein interactions, 
protein complex formation, and subcellular localization.1-2 Of these, only HDAC5, HDAC6, and 
HDAC8 have a phosphorylation site within the deacetylase domain of their protein structure, 
which is more likely to impact enzyme activity.2  
The location of phosphorylation on HDAC8 within the deacetylase domain is unique 
among HDACs. HDAC8 is phosphorylated by protein kinase A at serine 39 (S39), a residue not 
conserved among the closely related class I HDACs (arginine in HDAC1 and HDAC2, alanine in 
HDAC3).3-4 HDAC4, 5, 7, and 9 have a nearby serine based on sequence alignment, though the 
local sequence environment is different.5 S39 is conserved in homologues from many species 
including Mus musculus (Mouse), Bos taurus (Bovine), Xenopus laevis (African clawed frog) 
and Danio rerio (Zebrafish),6 suggesting that the residue is important for HDAC8 function. 
However, S39 is not conserved in the orthologue of Schistosoma mansoni. This blood fluke is 
the most common parasite infecting humans and is responsible for intestinal schistosomiasis, a 
neglected tropical disease inflicting over 200 million people whose main treatment option is 
widely used and at risk for development of resistance. Since S. mansoni HDAC8 is targeted for 
antiparasitic drug development, clarification of S39 phosphorylation structure and function could 
illuminate novel targeting approaches.7-9 HDAC8 phosphorylation is also unique among HDACs 
in function. While phosphorylation has been suggested to activate the catalytic activity of 
HDAC1 and HDAC2,3, 10-13 phosphorylation decreases HDAC8 activity.4 Moreover, despite 
conflicting results, phosphorylation appears to play an important role in HDAC1 and HDAC2 





complex formation in cells, HDAC8 activity in vitro is not dependent on complex formation as 
in the case of HDAC1 and HDAC2.  
The purpose of HDAC8 S39 phosphorylation remains a mystery. However, S39 
phosphorylation clearly impacts HDAC8 structure and function by means of several proposed 
mechanisms. First, HDAC8 phosphorylation appears to alter subcellular localization in certain 
cell types.14 Unlike other class I isozymes, HDAC8 has been observed in both the nucleus and 
the cytoplasm.14-16 In myometrial cells, unmodified HDAC8 is observed in the cytoplasmic, 
cytoskeletal, and nuclear fractions.14 In contrast, phosphorylated HDAC8 co-localizes almost 
entirely with the cytoskeleton.14 Intriguingly, phosphorylated HDAC8 levels are increased in the 
myometrial cells of pregnant women while overall HDAC8 expression remains unchanged.14 
Phosphorylation may be used as a way to direct all or a portion of HDAC8 to specific 
compartments within the cell, potentially dependent on cell status, type, or location. 
Phosphorylation-dependent mechanisms of translocation have been observed in other HDACs as 
well. Providing a precedent for this behavior, phosphorylation regulates class II HDACs 
movement between nucleus and cytosol.17-22  
In addition to regulating subcellular localization, HDAC8 phosphorylation also impacts 
acetylation levels in cells. Although within the deacetylase domain, S39 is located over 20 Å 
from the catalytic metal ion.23-29 Despite this distance, S39 phosphorylation leads to inhibition of 
catalytic activity by an unknown mechanism.4 Increased acetylation was observed on histones 
isolated from PKA-activated HeLa cells expressing Flag-tagged HDAC8 and treated with the 
adenylyl cyclase PKA activator forskolin, compared with untreated, non-overexpressed, and 
S39A-HDAC8 expressed control cells, indicative of PKA-mediated HDAC8 inhibition.4 
Moreover, phosphorylated Flag-HDAC8, immunopurified from the PKA-activated cells, 
exhibited slower rates of deacetylation of core histones H3 and H4 compared to the non-
phosphorylated HDAC8 control.4  
One hypothesis suggests S39 phosphorylation impacts catalytic activity through altering 
protein-protein interactions. Phosphorylation increases HDAC8 association with Human Est1p-
like protein B (hEST1B) and Hsp70 in co-immunoprecipitation experiments, demonstrating 
selectivity for binding phosphorylated HDAC8.30 Alternatively, S39 phosphorylation may have  
a direct impact on the active site and surrounding areas by leading to structural changes. R37 





gatekeeper to the internal channel of HDAC8 by regulating hydrogen bond interactions between 
conserved ‘gate’ residues G303 and G305.31 Presumably, a conformational change of R37 due to 
nearby S39 phosphorylation could lead to a similar outcome. Moreover, as shown in crystal 
structures of HDAC8, S39 is located at the base of loop L1 (Figure II.1) and is poised to 
modulate interactions with binding partners, substrates, and/or inhibitors distal to the active 
site.23-24, 28-29 The L1 and L2 loops flank the active site of HDAC8 and their high flexibility 
accommodate binding of different ligands, as shown by crystallographic and molecular dynamics 
studies.23-24, 28-29, 32-33 Indeed, the L1 and L2 loops are critical for ligand recognition and binding 
in part through the interaction between K33 (L1 loop) and D101 (L2 loop),32-33 and in 
comparison with other isozymes, such as HDAC1 whose loops are more rigid, likely govern 
binding selectivity.34 Perturbing the size and charge of S39 would lead to distortions in the α2 
helix, which could impact K33 positioning and possibly the K33-D101 interaction and thereby 
substrate binding affinity and selectivity.  
 
Figure II.1 Structure of HDAC8 
Crystal structure of human, wild-type HDAC8 (grey, PDB ID 2V5W) bound to a peptide 
substrate derived from p53 (cyan)26. Loops L1 and L2 are shown in green and the active site 
zinc(II) ion is shown in red. Indicated are helices a1 and a2 and residues S39, R37, K33, D101, 
G303 and G305.  
 
Since HDAC8 is involved in a variety of diseases, this isozyme is a target for drug 
development.8 However, to date, no HDAC8-specific inhibitor has been approved for drug use. 
















regulation, and therefore is an important subject for further investigation to identify and develop 
isozyme-specific drug targeting routes. Here we combine structural and biochemical data of the 
S39E phosphomimetic mutant to demonstrate that phosphorylation modulates conformational 
changes, which alter the reactivity and substrate selectivity of HDAC8. 
Materials and Methods 
Reagents 
The HDAC inhibitor 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide (Droxinostat) 
was obtained from Sigma Aldrich and was used without further purification. Tris(2-
carboxyethyl)phosphine (TCEP) was purchased from GoldBio. All other reagents were 
purchased from Fisher unless otherwise specified. 
Expression and purification of S39E HDAC8 for crystallization 
The S39E mutation was introduced into the HDAC8-His6-pET20b construct24 using 
Quickchange site directed-mutagenesis kit protocols (Agilent Technologies, Inc.). Primers used 
for PCR mutagenesis are as follows: forward, 5’-GCT AAA ATC CCG AAA CGT GCA gag 
ATG GTG CAT TCT TTG ATT GAA G-3’; and reverse, 5’-C TTC AAT CAA AGA ATG CAC 
CAT ctc TGC ACG TTT CGG GAT TTT AGC-3’. Incorporation of the desired mutations was 
confirmed by DNA sequencing at the University of Pennsylvania Perelman School of Medicine. 
Recombinant S39E HDAC8 was expressed in BL21(DE3) Escherichia coli cells and purified 
according to a previously published procedure.35 
Expression and purification of wild-type and S39E HDAC8 for assays 
The S39E mutation was introduced into the pHD4 (HDAC8-TEV-His6) plasmid36 using 
custom primers (Integrated DNA Technologies) and Quickchange site directed-mutagenesis kit 
protocols (Agilent Technologies, Inc.). Primers used for PCR mutagenesis are as follows: 
forward, 5’-CCC GAA ACG TGC Aga GAT GGT GCA TTC TTT GAT TGA AGC ATA TG-
3’; and reverse, 5’-CAT ATG CTT CAA TCA AAG AAT GCA CCA TCt cTG CAC GTT TCG 
GG-3’. Incorporation of desired mutations was confirmed by DNA sequencing performed by the 
University of Michigan DNA Sequencing Core, and the corresponding mass of the purified S39E 
HDAC8 was confirmed by Q-TOF HPLC-MS (Agilent) analysis. Wild-type (WT) and S39E 





previously published procedures with modifications.36-37 Briefly, BL21(DE3) cells were grown 
in 2x-YT media at 34°C. Once the OD600 reached at least 0.4, the temperature was decreased to 
18°C for 45 min followed by zinc supplementation with 0.2 mM ZnSO4, and expression 
induction with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). At 16 h post-induction, 
the cells were harvested by centrifugation at 6,238 x g for 15 min at 4°C.  
The pelleted cells were resuspended in nickel buffer A (30 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) pH 8, 150 mM NaCl, 1 mM imidazole, 1 mM TCEP, 5 
mM KCl) supplemented with a cocktail of protease inhibitors and lysed using a microfluidizer 
(Microfluidics). Nucleic acids were precipitated using 0.1% PEI, pH 7.9, added dropwise with 
stirring on ice for 10-15 min. The lysate was cleared by centrifugation for 45 min at 26,900 x g 
and 4°C. The cleared lysate was loaded onto a 15-mL pre-charged HisPur Ni-NTA resin 
(Thermo Scientific) column, and HDAC8 was eluted using a 1-200 mM linear imidazole 
gradient. For His6x-tag cleavage, the fractions from the nickel column containing HDAC8, as 
determined by SDS-PAGE, were pooled, combined with 0.5 mg 6His-TEV protease per 1 L 
culture, and dialyzed overnight at 4°C against 30 mM HEPES, pH 8, 150 mM NaCl, 1 mM 
TCEP, and 5 mM KCl. After overnight dialysis, HDAC8 was separated from the protease using a 
3-mL Ni-NTA column, concentrated in 30K MWCO Amicon centrifuge filters at 1700 x g to <2 
mL.  
Apo enzyme was prepared by dialyzing the concentrated enzyme against 200-fold metal-
chelation buffer (25 mM MOPS pH 7.5, 5 mM KCl, 1 mM EDTA, 1 mM TCEP) containing 1 
mM ethylenediaminetetraacetic acid (EDTA) twice at 4°C with one incubation occurring 
overnight. To remove EDTA, the enzyme was dialyzed in the same way against 200-fold metal-
free buffer, omitting the EDTA. Residual EDTA was removed using a PD-10 column (GE 
Healthcare) in metal-free assay buffer (25 mM HEPES, pH 8, 137 mM NaCl, and 3 mM KCl) 
plus 1 mM TCEP. Apo enzyme was verified to contain less than 10% metal contamination using 
inductively coupled plasma mass spectrometry (ICP-MS). Metal-free enzyme was aliquoted, 
flash frozen with liquid N2, and stored at -80°C. 
Fluor-de-Lys assay 
The Fluor-de-Lys assay38-39 (Enzo Life Sciences) was performed as described.36 Metal-
free HDAC8 was reconstituted for 1 h on ice with stoichiometric Zn(II) (Fluka Zinc Atomic 





30°C using the Fluor-de-Lys HDAC8 or Sirt1 p53-based commercial fluorophore-conjugated 
peptide substrate (Enzo Life Sciences). Enzyme was used to initiate reactions in HDAC8 assay 
buffer with substrate. Enzyme and substrate were equilibrated for at least 5 min at 30°C prior to 
initiation. For iron assays, solid iron(II)chloride (Sigma), solid ascorbic acid (Fluka), and 
HDAC8 assay buffer were equilibrated overnight in an anaerobic chamber (Coy Laboratory 
Products). The enzyme was equilibrated in the anaerobic chamber for 1 h prior to reconstitution, 
and substrate was equilibrated 1 h prior to the assay. Iron assays performed outside the anaerobic 
chamber were completed within 2 h, the effective working timespan for ascorbic acid to maintain 
Fe(II) (data not shown). Enzyme concentrations were 0.5 to 1 µM and substrate concentrations 
were 10 to 1000 µM. Time points were quenched using a combination of trypsin developer and 
trichostatin A (TSA) solution. After at least a 15 min incubation at room temperature, the 
fluorescence of product (ex. 340 nm, em. 450 nm) and substrate (ex. 340 nm, em. 380 nm) was 
measured using a PolarStar fluorescence plate reader. The ratio of product to substrate 
fluorescence was used to calculate HDAC8 activity using a standard curve derived from the 
completed reaction of HDAC8 with known amounts of substrate. kcat/KM values were generated 
by fitting the Michaelis-Menten equation (Equation II.1) to the v0/[E] data at varying [S]. 








Enzyme-coupled deacetylation assay 
Non-fluorophore conjugated peptides were assayed by coupling deacetylation of acetyl-
lysine residues to the formation of NADH as described.40-41 Briefly, hydrolysis of acetyl-lysine 
forms acetate, which is converted to NADH via acetyl-CoA synthetase, citrate synthase, and 
malate dehydrogenase, and NADH is measured by fluorescence. Peptides (Peptide 2.0 or 
Synthetic Biomolecules) were N-terminally acetylated (N-terminal acetylation is not 
hydrolyzable by HDAC8) with C-terminal amides. The enzyme-coupled acetate-detection assay, 
referred to simply as the ‘acetate assay’, was performed as described.40 As in the Fluor de Lys 
assay, metal-free HDAC8 was reconstituted for 1 h on ice with stoichiometric Zn(II) (Fluka Zinc 
Atomic Spectroscopy standard #96457). HDAC8 concentration ranged from 1-5 µM and 
substrate concentration varied from 10-1200 µM. Reaction time points (60 µL) were quenched 
into 5 µL 10% hydrochloric acid. Coupled enzyme solution reagents were purchased from 





described.40 Time points neutralized with 15 µL 6% sodium bicarbonate (60 µL) were loaded 
into wells of a black 96-well plate containing coupled enzyme solution (10 µL) and allowed to 
equilibrate protected from light. The fluorescence of the resulting NADH was measured (ex. = 
340 nm, em. = 460 nm) and converted to product concentration using an acetate standard curve. 
An NADH standard curve was prepared to verify coupled solution activity. kcat/KM values were 
generated by fitting the Michaelis-Menten equation (Equation II.1) to the v0/[E] data at varying 
[S]. 
Molecular dynamics (MD) simulations 
The coordinates for the HDAC8-substrate complex for the simulations were taken from 
PDB ID: 2V5W.26 The spatial positions of K+ and Zn2+ ions were retained in the simulation from 
the original PDB. Three sets of simulations were completed: wild-type HDAC8, HDAC8 with 
phosphorylated S39 and HDAC8 with S39E mutation. 
The modified phosphorylated protein simulation was made using the Forcefield PTM 
server (www.selene.princeton.edu/FFPTM). The AMBER forcefield parameters for post-
translational modifications were taken from Khoury et al.42-43 The S39E mutant structure was 
obtained from the crystal structure reported in this manuscript. Disordered loops were 
reconstructed using 2V5W structure as the template. The substrate was introduced in the HDAC8 
enzyme after superimposition with 2V5W structure. A total of six simulations were carried out, 
with and without substrate.  
The parameters for substrate were generated via the Antechamber module of the AMBER 
software using Generalized AMBER force field.44-45 The charges were assigned to the substrate 
using the AM1-BCC method.46 The systems were set up using xleap module of AMBER14.47 K+ 
ions were used for neutralization and TIP3P water molecules were used for solvation. AMBER-
adapted Joung and Cheatham parameters specific for TIP3P waters and K+ ions (radius 1.593 Å 
and well depth 0.4297054 kcal mol-1) were used.48 The system was solvated in a periodic box 
whose boundaries extended at least 10 Å from any solute atom. The periodic boundary 
conditions were defined by the PME algorithm and non-bonded cut-off was set to 10 Å.49 All 
chemical bonds involving hydrogen atoms were restrained using SHAKE, allowing for stable 
simulations with a 2 fs time step.50 Simulations were carried out using an NPT ensemble, using 
the Berendsen algorithm to control temperature and pressure.51 Standard equilibration protocols 





for 400 ns using ACEMD and the frames were collected every 10 ps using a timestep of 4 fs.53 
Analyses of the trajectory were performed using the GROMACS 4.5 tools.54-55 The programs 
ICM, VMD and PyMOL were used for visualization.56-58  
Crystallization and data collection  
Crystals of the S39E HDAC8-Droxinostat complex were grown in sitting drops at 21°C 
using the vapor diffusion method. A 500 nL drop containing 5.0 mg/mL S39E HDAC8, 50 mM 
Tris (pH 8.0), 150 mM KCl, 5% glycerol, 1 mM dithiothreitol, 2 mM Droxinostat, and 0.03 M 
glycylglycylglycine was added to a 500 nL drop of precipitant solution and equilibrated against a 
100 µL reservoir of precipitant solution. The precipitant solution consisted of 100 mM BisTris 
(pH 6.5), 6% (w/v) PEG 8,000 (Hampton Research), and 4 mM TCEP.  
Crystals appeared within 1 day. Crystals were flash-cooled in liquid nitrogen after 
transfer to a cryoprotectant solution consisting of precipitant solution supplemented with 25% 
glycerol. X-ray diffraction data were collected on beamline X29 at the National Synchrotron 
Light Source (NSLS, Brookhaven National Laboratory, New York). Data collection statistics are 
recorded in Table II.1. Data were indexed, integrated and scaled using HKL2000.59 
Phasing, model building, and structure refinement  
Crystals belonged to space group P21, with 2 molecules in the asymmetric unit. The 
crystal structure was solved by molecular replacement using PHENIX60 with the atomic 
coordinates of the H143A HDAC8–tetrapeptide substrate complex (PDB accession code 
3EWF)24 less substrate, metal ions, and solvent molecules used as a search probe. The model was 
refined with iterative cycles of refinement in PHENIX60 and manual model rebuilding in 
COOT.61 Solvent molecules and inhibitors were added after initial rounds of refinement. 
Translation Libration Screw (TLS) refinement was performed in the late stages of refinement. 
TLS groups were automatically determined using PHENIX. Final refinement statistics are 
recorded in Table II.1. 
Portions of the N-terminus, the C-terminus, and the L1 and L2 loops were characterized 
by missing or broken electron density. These segments appeared to be disordered and were 
excluded from the final model as follows: M1-S13 (monomers A and B), A32-I34 (monomer B), 
G86-D89 (monomer A) G86-E95 (monomer B), I378-H389 (monomer B), and E379-H389 





were excluded from the model as follows: L14 (monomers A and B), K33 (monomer A), I34 
(monomer A), K52 (monomer B), K58 (monomer B), K60 (monomers A and B), K81 
(monomers A and B), Q84 (monomer A), E85 (monomer A), I94 (monomer A), E95 (monomer 
A), Y100 (monomer B), E106 (monomer B), K132 (monomers A and B), K221 (monomer B), 
E238 (monomer B), Q253 (monomers A and B), E358 (monomer B), K370 (monomer A), V377 
(monomer A), and I378 (monomer A). 
Occasional ambiguous electron density peaks were observed in the structure. These peaks 
were usually elongated and potentially correspond to disordered PEG fragments or other 
molecules present in the crystallization buffer. However, since these electron density peaks were 
not confidently interpretable, they were left unmodeled. Similarly, ambiguous electron density 
was observed around W141 in monomer A, possibly corresponding to alternative conformations. 
However, since such conformations were not confidently interpretable, the W141 side chain was 
modeled in only one primary conformation. 
Results 
Crystal structure of S39E HDAC8  
Because the phosphorylated enzyme is difficult to obtain in the large quantities and purity 
needed for crystallization, we used the S39E-HDAC8 phosphomimetic mutant, which mimics 
phosphorylation at this site. The mutant was crystallized in an inhibitor-bound state. This is the 
first crystal structure of an HDAC isozyme complexed with Droxinostat, a selective HDAC3, 
HDAC6, and HDAC8 inhibitor with IC50s of 16.9 ± 5.0, 2.47 ± 1.09, and 1.46 ± 0.11 µM, 
respectively and >20 µM for HDACs 1, 2, 4, 5, 7, 9 and 10.62 The structure of the S39E HDAC8-
Droxinostat complex shows how phosphorylation of S39, as mimicked by the glutamate 
substitution, might influence inhibitor binding in the enzyme active site. Residue S39 is located 
in the α2 helix, approximately 20 Å away from the catalytic Zn2+ ion. The structure of the S39E 
HDAC8–Droxinostat complex is similar to that of the wild-type HDAC8–M344 complex (PDB 
accession code 1T67)23 with a root mean square (r.m.s.) deviation of 0.49 Å for 356 Ca atoms 
and 0.47 Å for 350 Ca atoms, for monomers A and B, respectively. Although the S39E 
substitution does not cause any large-scale change in the HDAC8 structure (Figure II.2A), local 





structural changes in Loop L1. Presumably, these structural changes would be similarly triggered 
by phosphorylation of S39 in the wild-type enzyme.  
In the wild-type HDAC8 structure, the hydroxyl group of S39 donates a hydrogen bond 
to the carboxylate group of D29, which is located in the adjacent α1 helix. In S39E HDAC8, the 
E39 side chain is oriented toward solvent and does not interact with any surrounding residues, 
including positively charged K36. Similarly, E39 does not perturb the nearby residue R37, the 
“gatekeeper” for the internal channel.31 However, the S39E mutation induces a slight shift of 
D29 (0.6 Å for the Ca atom). The carboxylate side chain of D29 undergoes a conformational 
change away from E39, presumably to minimize electrostatic repulsion (Figure II.2A). A similar 
conformational change likely results from phosphorylation of S39 in wild-type HDAC8. The 
conformational change of D29 causes the L1 loop to reorganize. The L1 loop (L31-P35) 
connects helices α1 and α2 and is adjacent to the active site. Alternative conformations for the 
L1 and L2 loops are often observed in HDAC8 structures as they accommodate the binding of 
different ligands. Interestingly, the L1 loop in S39E HDAC8 appears to be more disordered than 
usually observed in HDAC8 complexes. This loop is characterized by higher thermal B factors, 
along with missing electron density for the side chains of K33 and I34 in monomer A, and weak 
electron density in monomer B that did not allow modeling of the A32-I34 segment.  
This disorder appears to propagate through to the active site; the 4-chloro-2-
methylphenoxyl capping group of the hydroxamate inhibitor Droxinostat is characterized by 
somewhat weaker electron density (Figure II.2B) and higher thermal B factors. The hydroxamate 
moiety of Droxinostat coordinates to the active site Zn2+ ion, forming a five-membered ring 
chelate, as typically observed in HDAC8-hydroxamate crystal structures.23-26, 29, 35 The 
coordination distances to the Zn2+ ion are 2.0 Å and 2.2 Å for the hydroxamate hydroxyl and 
carbonyl groups, respectively. The Zn2+-bound hydroxamate is also stabilized by hydrogen bond 
interactions with Y306, H142, and H143 (Figure II.2B). The capping group of Droxinostat does 
not make significant interactions with residues at the mouth of the active site. A contact is made 
between the chlorine atom of Droxinostat and the hydroxyl group of Y100 in the L2 loop (the 
Cl--O distance in monomer A is 3.2 Å; the side chain of Y100 is disordered in monomer B). 
However, Y100 is poorly oriented to consider this interaction as a hydrogen bond. The 





A           B 
                     
Figure II.2 Structural comparison of S39E and wild type HDAC8 
A. Stereo view superimposition of the S39E HDAC8-Droxinostat complex (monomer A: C = 
wheat, N = blue, O = red, Zn2+ = magenta sphere) and the wild-type HDAC8-M344 complex 
(PDB 1T67, color-coded as above except C = light blue). In the wild-type structure, S39 donates 
a hydrogen bond (black dashed line) to D29. Upon substitution to a glutamate (simulated omit 
map contoured at 4.0s showing the E39 side chain), this interaction is not conserved and causes 
local rearrangement. The L1 loop adopts a different conformation as highlighted in red and blue 
for the S39E HDAC8-Droxinostat complex and the wild-type HDAC8-M344 complex, 
respectively. B. Simulated annealing omit map of Droxinostat bound in the active site of S39E 
HDAC8 (monomer A, contoured at 3.0s). Atomic color codes are as follows: C = wheat 
(protein, monomer A), or green (inhibitor), N = blue, O = red, Zn2+ = magenta sphere. Metal 
coordination and selected hydrogen bond interactions are shown as solid black or dashed black 





Table II.1 Data collection and refinement statistics for S39E-HDAC8-Droxinostat Complex 
Unit cell  
   Space group symmetry P21 
   a, b, c (Å) 53.4, 84.4, 94.6 
   α, β, γ (deg) 90, 99.4, 90 
  
Data collection  
   Wavelength (Å) 1.075 
   Resolution limits (Å) 43.0-1.59 
   Total/unique reflections 819616/110604 
   Rmergea,b 0.080 (0.605) 
   I/σ(I)a 19.3 (4.7) 
   Redundancya 7.4 (7.1) 
   Completeness (%)a 100 (100) 
  
Refinement  
   Reflections used in refinement/test set 110567/5539 
   Rcrystc 0.142 
   Rfreed 0.160 
   Protein atomse 5648 
   Water moleculese 777 
   Ligand moleculese 2 
   Zn2+ ionse 2 
   K+ ionse 4 
   Glycerol moleculese 2 
  
R.m.s. deviations from ideal geometry  
   Bond lengths (Å) 0.010 
   Bond angles (°) 1.3 
   Dihedral angles (°) 12 
  
Ramachandran plot (%)f  
   allowed 91.1 
   additionally allowed 8.9 
  
PDB accession code 5BWZ 
                                               
a Values in parentheses refer to the highest shell of data. 
b Rmerge = åïIh - áIñhï/åIh, where áIñh is the average intensity for reflection h calculated from replicate reflections. 
c Rcryst = åï|Fo| - |Fc|ï/å|Fo| for reflections contained in the working set. êFoê and êFcê are the observed and 
calculated structure factor amplitudes, respectively. 
d Rfree = åï|Fo| - |Fc|ï/å|Fo| for reflections contained in the test set held aside during refinement. 
e Per asymmetric unit. f Calculated with PROCHECK version 3.4.4 





S39E decreases HDAC8 activity and changes substrate selectivity with peptides in vitro 
While inhibition of HDAC8 activity by phosphorylation had been observed for core 
histone deacetylation in cell-based experiments,4 detailed kinetic parameters for the 
phosphorylated enzyme or the phosphomimetic S39E mutant had not been determined. We 
hypothesized that perturbation of the L1 loop by S39 phosphorylation or mutation to glutamate 
could affect the substrate recognition by the enzyme. To investigate whether S39 alteration 
affects substrate selectivity or simply dampens activity globally towards all substrates, we 
measured the catalytic efficiency of Zn(II)-constituted S39E HDAC8 and wild-type HDAC8 
toward deacetylation of a library of peptide substrates in vitro. Since the methylcoumarin 
fluorophore on the widely used Fluor-de-Lys peptide substrates enhances activity and substrate 
affinity with HDAC8, we selected additional un-labeled peptide substrates to test using the 
acetate assay, an assay that couples the formation of acetate to a fluorescent NADH readout.40, 63 
This selection of peptide substrates is taken from acetylated nuclear and cytoplasmic proteins 
that encompass a diverse range of cellular functions (Table II.2). Additionally, the list includes 
peptides from putative and novel HDAC8 substrates determined from computational modeling 
and cell-based proteomics screens including a peptide from SMC3, the best validated putative in 
vivo HDAC8 substrate to date.64 65-67 Consistent with previous reports, S39E HDAC8 activity 
was decreased compared to wild-type HDAC8 in all cases tested (Table II.2). 
Notably, the deacetylase activity of S39E HDAC8 was reduced to differing extents, 
depending on the substrate (Table II.2, Figure II.4) with values ranging from a 9-fold to 220-fold 
decrease in activity for the S39E mutant compared to wild-type HDAC8. For the peptide 
corresponding to SMC3, the mutation nearly abolished activity. However, for the peptide 
corresponding to LARP1, the mutation caused a modest 9-fold reduction in activity compared to 
wild type (Figure II.3). Furthermore, while the wild-type catalytic efficiencies for the CAD and 
LARP1 peptides (660 ± 27 versus 653 ± 99 M-1s-1, respectively) were comparable, the S39E 
phosphomimetic displayed a 60-fold decrease in activity for the CAD peptide. Similarly, the 
value of kcat/KM for wild-type HDAC8 catalyzed deacetylation of the fluorogenic p53 HDAC8 
peptide is comparable to the values for CAD and LARP1, yet S39E HDAC8 exhibited a 37-fold 
decreased catalytic efficiency for the labeled p53 HDAC8 peptide. These data indicate that the 
S39E mutation not only decreases activity but also has an impact on peptide substrate selectivity. 





phosphorylation. Since the sequences for the CAD and LARP1 peptides are similar, we 
wondered whether swapping the C- and N-terminal sequences would impact selectivity. 
Unexpectedly, these sequence changes increased the reactivity of wild-type HDAC8 with both 
peptides by 4-5-fold while decreasing the reactivity with S39E HDAC8 by 4-7-fold. Therefore, 
the WT/S39E selectivity ratio increased significantly (Table II.2). This surprising result suggests 
alternate contacts between the peptide and the binding interface of the two enzymes caused by 
the shift in loop L1 due to changes in S39.  
 
Table II.2 Kinetics of deacetylation of acetylated peptides catalyzed by S39E and wild-type 
HDAC8a 





H3K9 Chromatin TKQTARK(ac)STGGKA 51 ± 3b 1.7 ± 0.2 30 ± 4 
SMC3 Cell cycle RVIGAKK(ac)DQY 58 ± 2 <0.5 >120 
CSRP2BP Acetyltransferase STPVK(ac)FISR 160 ± 27b 11.5 ± 0.6 14 ± 2 
LARP1 Translation LGK(ac)FRR 653 ± 99 70 ± 10 9 ± 2 
CAD Protein Pyrimidine biosynthesis LSK(ac)FLR 660 ± 27 11 ± 1 60 ± 6 
MYH1 (CAD_LARP) Muscle contraction LSK(ac)FRR 2400 ± 100 10.6 ± 0.3 226 ± 11 
LARP_CAD Synthetic LGK(ac)FLR 2900 ± 700 19 ± 4 153 ± 49 
p53 Cell cycle RHK(ac)K(ac)-AMC 950 ± 96 26 ± 3 37 ± 6 
p53 Cell cycle RHKK(ac)-AMC 1030 ± 200 8 ± 3 129 ± 54 
 
                                               
a Values for kcat/KM were obtained by fitting the Michaelis-Menten equation (Equation II.1) to the dependence of the 
initial rates of deacetylation on the substrate concentration catalyzed by Zn(II)-constituted S39E and wild-type 
HDAC8. The p53 fluorogenic peptide substrates were measured using the Fluor de Lys assay (FdL) and all other 
peptides were measured using the acetate assay. Enzyme concentration was 1 µM and substrate concentration was 
varied from 10-1200 µM. Error was calculated from the linear fit of the initial rates (n0). 
b Values reported previously.68 Control reactions were performed with 1 µM wild-type HDAC8 and 100 µM H3K9 
and CSR2BP peptides parallel with the S39E reactions to verify that wild-type activity with peptide agreed with 
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Figure II.3 Deacetylation of LARP1 peptide by S39E and wild-type HDAC8 
Representative peptide assay data. Dependence of the initial rates of deacetylation of the LARP1 
peptide (LGK(ac)FRR) on the substrate concentration catalyzed by Zn(II)-constituted (A) S39E 
(closed blue circles) and (B) wild-type HDAC8 (open blue circles) measured using the acetate 
assay40. Enzyme concentration was 1 µM and substrate concentration was 10-800 µM. The data 
are a combination of two experiments (Zn(II)-S39E), or one experiment (Zn(II)-WT), and the 
Michaelis-Menten equation (Equation II.1) was fit to the data using global regression analysis 
(GraphPad Prism). 
 
A          B     C   
                
Figure II.4 Comparison of S39E and wild-type HDAC8 deacetylation of peptides 
A. Catalytic efficiencies, kcat/KM, of wild-type HDAC8-catalyzed deacetyation of peptides listed 
in Table II.2 as measured by the Fluor de Lys assay (FdL-HDAC8 and FdL-Sirt1 peptides) and 
the acetate assay (remaining peptides). B. Catalytic efficiencies of S39E HDAC8 and C. fold 
change in catalytic efficiency of S39E HDAC8 compared to wild type for peptides. For all three 
graphs, peptides are ordered from most to least active with wild-type. Error bars are shown in 
same colors as columns. Substrate names on X-axis correspond to peptides listed in Table II.2.  



























































































































































































S39E mutation increases metal dissociation rates and decreases metal-activation for iron(II) 
and zinc(II) 
Additionally, we investigated the impact of phosphorylation on metal-selectivity. 
HDAC8 is activated by different metals, most notably iron(II) and the canonical catalytic ion 
zinc(II), and substrate selectivity changes based on the identity of the active site metal.69 S39E 
HDAC8 activity was measured using the Fluor-de-Lys assay with Zn(II) and Fe(II) bound at the 
active site and the catalytic efficiencies were compared to those of Zn(II)- and Fe(II)-constituted 
wild-type HDAC8 (Table II.3, Figure II.5) Fe(II)- and Zn(II)-dependent catalytic efficiency 
(kcat/KM) was 6-fold and 34-fold lower, respectively, for the S39E mutant compared to wild type. 
Comparing the KM and kcat values for the Fe(II)-constituted enzymes revealed that the decrease in 
kcat/KM is due to both a 2-fold increase in KM and a 3-fold reduction in kcat. This suggests that the 
serine to glutamate mutation affects both substrate recognition and hydrolysis. As further 
evidence, the Zn(II) and Fe(II) metal dissociation rates were measured for the phosphomimetic 
and compared to those of wild type HDAC8 reported previously.70 For both Zn(II) and Fe(II), 
the metal-dissociation rates of S39E increased approximately 15-fold compared to wild type 
(Figure II.6) providing further evidence of structural changes at the active site. Taken together, 
altering S39 enhances metal dissociation, decreases catalytic activity and alters substrate 
selectivity. These results indicate that HDAC8 phosphorylation may be an important modulator 






Table II.3 Kinetics of Fe(II)- and Zn(II)-S39E and wild-type HDAC8a 
HDAC8 kcat/KM (M-1s-1) KM (µM) kcat (s-1) 
kcat/KM Ratio 
(WT/S39E) koff (min
-1) koff Ratio (S39E/WT) 
Fe(II)-S39E 440 ± 60 170 ± 30 0.077 ± 0.005 
6 ± 2 
0.48 ± 0.05 
16 ± 3 
Fe(II)-WT 2800 ± 700 90 ± 30 0.25 ± 0.02 0.030 ± 0.004b 
Zn(II)-S39E 28 ± 3 > 400c > 0.05c 
34 ± 5 
0.57 ± 0.07 
14 ± 2 
Zn(II)-WT 950 ± 96 1200 ± 300 1.1 ± 0.3 0.040 ± 0.003b 
 
              A               B 
        
Figure II.5 Zinc(II)- and iron(II)-constituted S39E and wild-type HDAC8 catalyzed 
deacetylation of fluorescently-labeled Fluor de Lys HDAC8 test substrate 
Dependence of the initial rates of deacetylation of the Fluor-de-Lys HDAC8 peptide substrate on 
substrate concentration catalyzed by A. Zn(II)-constituted S39E HDAC8 (closed blue circles) 
and Zn(II)-constituted WT HDAC8 (open blue circles) and B. Fe(II)-constituted S39E HDAC8 
(closed red circles) and Fe(II)-constituted WT HDAC8 (open red circles). Enzyme concentration 
was 0.5-1 µM and substrate concentration was 10-1000 µM. The data are a combination of four 
experiments (Zn(II)-S39E), or one experiment (Zn(II)-WT, Fe(II)-S39E, Fe(II)-WT), and the 
Michaelis-Menten equation (Equation II.1) was fit to the data using global regression analysis 
(GraphPad Prism). 
  
                                               
a Reactions consisting of 0.5 to 1 µM HDAC8 and 10 to 1000 µM substrate in 25 mM HEPES, pH 8.0, 137 mM 
NaCl, 3 mM KCl at 30°C. 
b Little curvature was observed in the dependence of activity on substrate concentration so that KM and kcat are 
poorly defined by this data set. The necessity for excessively high enzyme and substrate concentrations preclude the 
accurate determination of these parameters. 
c Values reported previously in Kim, et al. 70 





























Figure II.6 Metal ion dissociation rates for zinc(II) and iron(II)-constituted S39E HDAC8 
Initial rates for Zn(II)-constituted S39E HDAC8 (filled blue circles) and Fe(II)-constituted S39E 
HDAC8 (filled red circles) deacetylation activity as a function of time as measured using the 
Fluor-de-Lys assay after addition of 1 mM EDTA. The fraction activity is determined by 
dividing this activity by the activity of HDAC8 incubated in the absence of EDTA. The koff 
values were calculated by fitting an exponential decay equation to data from replicates on 
different days using global regression analysis (GraphPad Prism). 
 
Molecular dynamics simulations suggest phospho-HDAC8 structural changes 
The crystal structure provides a snapshot of inhibitor-bound S39E HDAC8. To 
investigate the effects of phosphorylation on substrate-HDAC8 interactions, molecular dynamics 
simulations were performed, starting with an HDAC8-peptide substrate complex crystal structure 
(PDB ID: 2V5W).26 We compared the substrate binding dynamics of phosphorylated HDAC8 
(pS39-HDAC8, modeled), S39E HDAC8 (with substrate, modeled), and wild-type HDAC8. By 
simulating phosphorylation on the wild-type HDAC8 structure, we were able to predict the 
structure and dynamics of residues in the L1 loop that were not resolved in the S39E crystal 
structure and validate the S39E mutation as a mimic of phosphorylated HDAC8. While the 
mutant was crystalized in complex with an inhibitor, the simulations predict the structure of 
pS39-HDAC8 with and without peptide substrate bound. First, wild-type HDAC8 was modeled 
with and without the Fluor-de-Lys p53-based peptide substrate, to identify key residues in 
substrate binding. Relevant residue conformations surrounding S39 are highlighted in Figure 
II.7, with the most important being those of the substrate, Y306, and K33. Figure II.7 shows a 
comparison of wild-type, pS39- and S39E HDAC8 snapshots during substrate binding. The 








































simulations demonstrate that the pS39-HDAC8 structural behavior is comparable to that of the 
S39E-HDAC8 mutant, which validates use of the S39E-HDAC8 mutant for prediction of pS39-
HDAC8 behavior in vitro. Importantly, the simulations also illustrate differences between wild-
type and pS39/S39E-HDAC8 substrate binding conformations. Based on the simulations, 
modification of S39 leads to a disruption of the interaction between Y306 and K33, which 
perturbs substrate binding. In wild-type HDAC8, the interaction between S39-D29-K36 tethers 
the L1 loop and maintains the orientation of K36. This is distinct from the S39E-HDAC8 mutant 
dynamic simulation, in which there is no interaction between E39 and D29 (Figure II.8). The 
interaction between S39 and D29 is disrupted by the addition of negative charge at position 39. 
Instead, D29 interacts directly with K36 (Figure II.8). The strength of these interactions, and the 
disruption of interaction between residue 39 and D29 in the S39E mutant, is evident in the 
distance versus time plots in Figure II.8B. The K36-D29 interaction and altered Y306-K33 
interaction preclude binding of substrate at the wild-type position. Instead, the peptide binds in a 
channel between K33 and Y306 where it is not optimally positioned for deacetylation by the 
active site metal-water nucleophile. These simulations provide insight into the basis for 
decreased pS39 and S39E HDAC8 activity and altered substrate selectivity, and although the 
D29-K36 contact is not noticeable in the S39E crystal structure, the altered orientation of D29 is 






Figure II.7 Simulations of wild-type HDAC8 binding to substrate 
Top panel (red box): The orientation of key residues in wild-type HDAC8 at A. the start, B. 51 
ns, and C. 70 ns of the substrate binding simulation. S39 is solvent-exposed. Y306 bends at 90° 
toward K33, and the Hε of Y306 forms a hydrogen bond with the carbonyl of K33 (B). This 
opens the tunnel for substrate interaction with the active site, which is otherwise blocked by 
Y306. Yellow and purple spheres represent Zn2+ and K+ ions respectively. Center and bottom 
panels: Simulations of pS39 (blue box) and S39E (green box) bound to substrate. In the center 
panel (pS39 modeled on wild-type HDAC8), two snapshots (D. start and E. 400 ns) during the 
simulation demonstrate that the substrate is shifted in the active site between K33 and Y306 
compared to wild-type HDAC8 (Figure II.7A-C). Y306 interacts with substrate but does not 
interact with K33. The bottom panel (S39E HDAC8 with modeled substrate) is a representation 
at F. the start and G. 400 ns of the simulation of key residues in S39E HDAC8 and demonstrates 
that the enzyme behaves similarly to pS39-HDAC8. The L1 loop is altered, Y306 and K33 do 
not interact (unlike in wild-type HDAC8 (Figure II.7B) where Y306 forms a hydrogen bond with 
the carbonyl oxygen of K33), and Y306 does not interact with substrate in this simulation. 
Substrate access to the active site is altered. Yellow and purple spheres represent Zn2+ and K+ 
ions respectively.  
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Figure II.8 Interaction between K36-D29-S39 
A. The wild-type (blue) and mutant HDAC8 (yellow) is illustrated. The S39-D29 interaction 
tethers loop 1 and maintains the orientation of K33 in the wild-type protein. S39E can interact 
with K36 but not with D29 and therefore K33 orientation is not maintained in the mutant. B-C. 
Distance plot showing the interaction between D29, K36 and S39 in (B) wild-type and (C) S39E 
mutant HDAC8. In wild type, S39 can interact with D29 directly while in S39E, mutant residue 













The mechanistic and functional roles of phosphorylation on HDAC8 are important facets 
of HDAC8 regulation that have not been well studied up to this point. To examine the effect of 
addition of a bulky negative charge at S39, S39E HDAC8 was used as a phosphomimetic. The 
validity of the mimic was bolstered by the fact that S39E HDAC8 and phospho-HDAC8 behave 
similarly in assays and in molecular simulations, while S39A HDAC8 behaves like the wild-type 
enzyme.4 Previously, crystal structures of the S39D HDAC8 have been solved, and the structure 
of this mutant is reported to be essentially the same as the wild type.26, 33 The S39E mutant, 
however, is a more appropriate mimic of phosphorylation4 and the S39E-HDAC8-Droxinostat 
structure exhibits noticeable differences from the structure of the wild-type enzyme. The 
structure of the S39E HDAC8-Droxinostat complex reveals that the L1 loop undergoes a 
conformational change and the interaction between S39 and D29 is disrupted by the glutamate 
substitution. Loop L1 is important for HDAC8 substrate and inhibitor interactions, so this 
structural perturbation likely contributes to decreased catalytic efficiency.33 It is important to 
note that a structure of wild-type HDAC8 complexed with Droxinostat has not been solved and 
comparing S39E HDAC8-Droxinostat directly to wild-type-HDAC8-Droxinostat would be 
useful to eliminate the possibility of structural changes induced by the identity of the inhibitor. 
However, structural comparisons indicate the capping group of the two inhibitors bound to the 
wild-type and S39E structures compared in this study is responsible for the selectivity seen with 
Droxinostat, and is thus less likely to affect active site orientation and structure, especially 
considering similar coordination of the hydroxamate moiety with the zinc(II) ion (Figure II.9). 
 



















Interestingly, contrary to previous hypotheses, the position of R37 is not altered in either 
the inhibitor-bound crystal structure or the phosphorylation simulation. As mentioned earlier, 
since R37 is in close proximity to S39E, conformational change of this important residue would 
not have been surprising.31 Additionally, an electrostatic interaction between K36 and E39 had 
been anticipated but was not evident in the structure. Instead, the relevant structural changes 
observed were the perturbed interactions between Y306, substrate, and K33, the loss of a 
hydrogen bond between the hydroxyl of S39 and the carboxylate of D29 (which bridges the α1 
and α2 helices), and the gain of an interaction between D29 and K36. Regarding the lost D29-
S39 hydrogen bond, the inhibitor-bound structure shows that this change is correlated with a 
conformational change of the L1 loop. The pS39 HDAC8 simulation reveals that this lost 
interaction alters the position of the bound substrate. The substrate does not fully interact with 
the canonical substrate binding surface and instead is shifted into a channel between K33 and 
Y306. In this simulation, K36 interacts with D29 and the location of the side chain of the L1 loop 
residue, K33, is altered. 
Substrate binding is typically oriented in part by Y306 and K33. However, in the absence 
of the hydrogen bond interaction between Y306 and the K33 backbone carbonyl, the substrate is 
shifted in the active site between these residues. This was the most significant difference 
observed in the simulations. The inhibitor-bound crystal structure does not show this altered 
Y306/K33 interaction and the inhibitor is positioned in the typical Zn(II)-bound orientation such 
that the carbonyl forms a hydrogen bond with Y306 (Figure II.2B). The fact that the crystal 
structure and the simulation provide somewhat different visualizations of ligand-bound S39E 
HDAC8 may be due to several factors. Mainly, the inhibitor is small and interacts primarily with 
the active site, limiting interactions with the HDAC8 peptide binding groove outside of the 
active site tunnel. Additionally, some residues (e.g. K33) cannot be directly compared to the 
simulated structure because they were not resolved in the crystal structure determination, 
suggesting significant mobility. Finally, while the crystal structure of S39E HDAC8 
demonstrates structural difference and mimics phosphorylation, glutamate is not identical to 
phosphoserine and thus some differences between E39 and pS39 are expected.  
S39E HDAC8 exhibits a 9- to 230-fold decrease in catalytic efficiency toward peptide 
substrates compared to wild type, consistent with previous data indicating phosphorylation 





phosphomimetic mutant suggests that phosphorylation also regulates the targeting of specific 
cellular substrates for deacetylation by HDAC8. Phosphorylation could potentially lead to the 
alteration in acyl-group selectivity, as a number of the other HDACs have been observed to 
catalyze deacylation of other modified lysine residues including crotonyl-lysine, myristoyl-
lysine, succinyl-lysine, and malonyl-lysine, among others.71 However, this remains to be tested 
and no other reaction outside of deacetylation has been observed for HDAC8. The simulations 
and crystal structure suggest that the decrease in catalytic activity and change in substrate 
selectivity that accompanies perturbation of S39 arise from the consequent reordering of and/or 
disorder in the L1 loop flanking the active site cleft and changes to the ligand binding surface. 
Structural differences in this loop presumably influence its affinity for substrates and inhibitors 
binding to the active site. Assuming that the mutation does not change the kinetic mechanism of 
this enzyme, KM is proposed to reflect the substrate binding affinity and kcat reflects the rate of 
hydrolysis of the acetyl-lysine decreases.36 Therefore, the increase in KM observed for Fe(II)-
constituted S39E HDAC8 compared to wild-type HDAC8 is consistent with the perturbation in 
the L1 loop affecting substrate affinity.36 Furthermore, the decrease in kcat indicates that the 
mutation also decreases catalysis of the hydrolytic step. This may be due to a direct effect on the 
reactivity of the metal-water nucleophile via structural changes propagated by the altered D29-
S39 interaction, which could also explain the increase in the metal dissociation rates of Zn(II) 
and Fe(II) observed for S39E HDAC8. Additionally, as the substrate selectivity between the two 
metals was altered, the change in kcat could also be linked to the alteration in the site of the bound 
peptide that leads to differential positioning of the acetyl-lysine amide bond relative to the 
nucleophilic metal-bound water molecule. However, the kcat value was only accurately 
determined for the Fe(II)-constituted enzyme while the structure and simulations used Zn(II)-
HDAC8, and activity data demonstrate that S39E HDAC8 and wild-type HDAC8 are activated 
to different extents depending on the identity of the catalytic metal ion.36, 69 
Taken together, these data provide insight into the residue interactions (i.e. S39/D29) that 
lead to perturbation of the kinetic properties by S39 phosphorylation. Further study is needed to 
parse how the phosphorylation, substrate specificity, and metal-dependence of HDAC8 are 
interconnected. The role and regulation of phosphorylated HDAC8 in the cell is unclear, 
however, the peptide selectivity data suggest that phosphorylation both decreases catalytic 





phosphorylation will provide insight into the regulation of deacetylation and inform drug 
discovery, as phosphorylation-dependent protein-protein interactions may present targeting 
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Histone deacetylases (HDACs) catalyze deacetylation of acetyl-lysine residues within 
proteins. To date, HDAC substrate specificity and selectivity have been largely estimated using 
peptide substrates. However, it is unclear whether peptide substrates accurately reflect the 
substrate selectivity of HDAC8 toward full-length proteins. Here, we compare HDAC8 substrate 
selectivity in the context of peptides, full-length proteins, and protein-nucleic acid complexes. 
We demonstrate that HDAC8 catalyzes deacetylation of tetrameric histone (H3/H4) substrates 
with catalytic efficiencies that are 40- to 300-fold higher than those for corresponding peptide 
substrates. Thus, we conclude that additional contacts with protein substrates enhance catalytic 
efficiency. However, the catalytic efficiency decreases for larger multi-protein complexes. These 
differences in HDAC8 substrate selectivity for peptides and full-length proteins suggest that 
HDAC8 substrate preference is based on a combination of short- and long-range interactions. In 
summary, this work presents detailed kinetics for HDAC8-catalyzed deacetylation of singly-
acetylated, full-length protein substrates, revealing that HDAC8 substrate selectivity is 
determined by multiple factors. These insights provide a foundation for understanding 
recognition of full-length proteins by HDACs.  
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CHAPTER III                                                                                                                      
HDAC8 Substrate Selectivity is Determined by Long- & Short-Range Interactions Leading 






The histone deacetylase (HDAC) family of enzymes comprises 18 proteins that catalyze 
the hydrolysis of the acetyl moiety from acetyl-lysine residues within substrate proteins.1-2 
Protein acetylation, catalyzed by lysine acetyltransferases (KATs), alters various properties of 
the modified protein (e.g. protein-protein interactions).3 These alterations can in turn affect 
downstream cellular events.4-5 As a result, regulation of acetylation by the respective activities of 
KATs and HDACs is important for effective cellular signaling and homeostasis; aberrant 
acetylation/deacetylation is implicated in pathologies ranging from neurological diseases6-7 to 
cancers.8-9 HDAC inhibitors have been approved by the FDA for the treatment of T-cell 
lymphomas and multiple myeloma.10-12 Identifying the specific substrate set for each HDAC 
isozyme is important for understanding the role of HDACs in disease progression and 
therapeutic development. 
To date, testing HDAC substrate specificity has remained a challenge, due in part to 
HDAC isozyme interchangeability and promiscuity, and the inherent difficulty in measuring the 
disappearance of signal from a previously modified substrate. To mitigate these difficulties, the 
HDAC field has sought to identify sequence motifs that define the substrate selectivity of each 
isozyme.13-16 Most of these studies have used peptide substrates to determine HDAC recognition 
motifs. However, the use of peptides to mimic recognition of protein substrates has not been 
sufficiently validated. Gurard-Levin and colleagues proposed an exocite model, in which 
HDAC8 contains one or more substrate binding surfaces away from the active site, after 
observing HDAC8 sequence selectivity distal to the acetyl lysine in H4-based peptides longer 
than 20 amino acids.15 However, outside of qualitative experiments,17-18 there has been no kinetic 
characterization of HDAC-catalyzed deacetylation of protein substrates. HDAC8 is the best-
characterized HDAC, with numerous crystal structures,19-27 kinetic studies,28-30 and peptide 
substrate specificity measurements,13-16 providing an important background for the investigation 
of HDAC activity with protein substrates. While several putative HDAC8 substrates have been 
identified by cellular studies, including overexpression (e.g. ERRα),31 genetic mutation (e.g. 
SMC3),32-33 and proteomic studies (e.g. ARID1A),34 the complete protein substrate set for 
HDAC8 is largely undefined.31-32, 35-40 
Histones are putative substrates for HDAC8.  In HEK293 cells, H3 and H4 acetylation 





specific SAHA-PIP derivative inhibitor Jδ increased acetylated H3 levels and expression of 
HDAC8-regulated transcription factors in mouse embryonic fibroblasts (MEF).42 Furthermore, 
HDAC8 catalyzes deacetylation of core histones and H3-based peptides in vitro43-44, however 
detailed kinetics have not previously been determined.  
Recently, substrate specificity for the S. cerevisiae lysine acetyltransferase piccolo NuA4 
has been measured using histone protein substrates, demonstrating acetylation of multiple lysine 
residues.45 However, HDAC substrate specificity studies to date have utilized acetylated 
peptides,13-15, 46-50 predicated on the assumption that HDAC8 uses similar interactions to 
recognize peptide and full-length protein substrates. To test the validity of this assumption, we 
determined the deacetylation kinetics of peptides corresponding to three biologically relevant 
acetylation sites on the putative HDAC8 substrate histone H3 (H3 K9, K14, and K56)51-52 and 
compared the values to HDAC8-catalyzed deacetylation of full-length histone substrates. 
To elucidate HDAC8 substrate specificity and recognition of protein substrates, we 
present the first detailed kinetic study of HDAC-catalyzed deacetylation of singly-acetylated, 
full-length protein substrates. Single acetyl-lysine side chains are inserted into H3 using non-
natural amino acid incorporation.53-54 We directly compare HDAC8 activity toward peptide 
substrates and toward protein substrates with the same local primary sequences. Furthermore, we 
analyze the effect of large histone complexes (histone core octamer and mononucleosome) on 
HDAC8-catalyzed deacetylation of acetylated H3. We demonstrate that deacetylation of 
acetylated full-length H3 tetramer and octamer complexes catalyzed by HDAC8 is significantly 
faster (> 8-fold) than that of acetylated peptides. However, the addition of DNA to form 
mononucleosomes decreases reactivity with HDAC8. These results demonstrate that HDAC8 
specificity for H3 peptide tetramer substrates is not determined solely based on the six amino 
acids proximal to the acetyl-lysine; substrate specificity of HDAC8 is modulated by both long-
range and short-range contacts for H3 substrates.  
Results 
Local sequence governs HDAC8 peptide specificity 
We focused on the activity of HDAC8 with three acetylated lysine sites within histone 
H3, a histone known to be amenable to non-natural acetyl-lysine incorporation.54 Two H3 





terminal tail and share an unfolded secondary structure. Because these sites differ only in amino 
acid sequence, the role of primary sequence in HDAC8 substrate specificity can be probed. A 
third site (H3K56ac), located on an α-helix within the globular structure of H3 (Figure III.1), 
allows the role of secondary structure in HDAC8 substrate recognition to be probed. 
 
Figure III.1 Structure of histone H3/H4 tetramer with highlighted acetylation sites 
Structure of histone H3/H4 tetramer55 with boxes around the sites which were acetylated. H3 is 
shown in blue and H4 in yellow. H3 residues 1 to 20 are shown in an extended conformation as 
they have no discrete fold within the crystal structure. The structure was generated from PDB ID 
1AOI using VMD. 
The rates of HDAC8-catalyzed deacetylation of 7-mer peptides representing the 3 amino 
acids upstream and downstream of the H3K9ac, H3K14ac, and H3K56ac acetylation sites were 
measured under multiple turnover (MTO) conditions, using an assay coupling acetyl-lysine 
deacetylation to the formation of NADH56 (Table III.1). The initial rates were linearly dependent 
on peptide concentration, indicating that the KM values are higher than the peptide concentrations 
used in this assay (> 100 µM). The specificity constant (kcat/KM) is the best parameter to use for 
comparing the activity of HDAC8 toward multiple substrates.57-59 HDAC8 has the highest 
catalytic efficiency for catalyzing hydrolysis of the H3K56ac peptide (kcat/KM = 78 ± 8.0 M-1s-1), 
followed by the H3K9ac (56 ± 6.0 M-1s-1) and H3K14ac (8.0 ± 0.70 M-1s-1) peptides (Table 
III.2). 
To probe the importance of amino acids at further distances from the acetyl-lysine in 
determining substrate selectivity, longer peptides (13 and 17 amino acids) were assayed (Table 
III.2). Increasing the length of the peptides from 7 to 13 amino acids had little to no effect on 
catalytic efficiency (1- to 3-fold change) and did not affect the substrate selectivity trend of 





than a three-fold increase in kcat/KM compared to the 7-amino acid peptide (56 ± 6.0 M-1s-1 vs. 
120 ± 11 M-1s-1; (Table III.2). The modest differences in activity toward the longer peptides 
indicate that the primary sequence surrounding the acetylated lysine residue (+/- 3 of the acetyl-
lysine) is the largest determinant of selectivity in peptide substrates, consistent with previously 
published data.13-16 
 
Table III.1 Sequences of peptides used in this studya 
Peptide  7-mer peptide sequence 13-mer peptide sequence 17-mer peptide sequence 
H3K9ac TARKacSTG TKQTARKacSTGGKA ARTKQTARKacSTGGKAPR 
H3K14ac TGGKacAPR RKSTGGKacAPRKQL  
H3K56ac RYQKacSTE EIRRYQKacSTELLI 
HDAC8 catalyzes deacetylation of H3/H4 tetramers more efficiently than corresponding 
peptides 
To investigate the importance of long-range HDAC8-substrate interactions in substrate 
recognition, we compared the rates of HDAC8-catalyzed deacetylation of peptide and the 
corresponding full-length protein. A major challenge in identifying HDAC substrates is 
determining the rates of deacetylation for individual acetyl-lysine sites, since HDAC substrates, 
such as histones, may have multiple acetylated lysine residues. We prepared proteins with single 
acetyl-lysine sites using the method of recombinant, non-natural amino acid incorporation 
developed by Jason Chin’s group.53-54 In each case, Q-TOF LC/MS of modified histone H3 
demonstrated a mass change corresponding to an added acetylated lysine (data not shown). To 
stabilize H3, H3 was assembled into an H3/H4 tetramer. We measured HDAC8 activity toward 
the singly-acetylated H3 proteins acetylated at the H3K9, H3K14, and H3K56 sites under single 
turnover (STO) conditions (3-15 µM HDAC8 and 0.5 µM acetylated H3/H4 tetramer) and 
assayed deacetylation by MS analysis. STO experiments were used to minimize the amount of 
singly-acetylated H3/H4 tetramer needed. An exponential decay was fit to the reaction progress 
curves to determine the observed rate constants, kobs (Figure III.2A). The observed rate of 
deacetylation of the H3K9ac/H4 tetramer was independent of the HDAC8 concentrations used in 
                                               
a The amino acid sequences of the peptides assayed are listed above. Kac represents the acetyl-lysine residue. All 





these assays indicating that the enzyme concentration is above the K1/2 for the reaction, even at 
the lowest concentration (3 µM). In contrast, the H3K14ac/H4 and H3K56ac/H4 tetramers show 
hyperbolic and nearly linear dependence, respectively, on the HDAC8 concentration. Assuming 
rapid equilibration of the HDAC8-H3/H4 complex, a hyperbolic fit to these data yields values of 
kmax/K1/2 equal to >17,000 M-1s-1, 2,500 ± 70 M-1s-1, and 4,000 ± 600 M-1s-1 for the H3K9ac, 
H3K14ac, and H3K56ac tetramers, respectively (Figure III.2B-D and Table III.2). H3K9ac 
tetramer deacetylation is an order of magnitude faster than H3K56ac, followed by H3K14ac 
deacetylation. Each of these catalytic efficiencies is 40- to 300-fold faster than the corresponding 
peptide kcat/KM values. 
The specificity constants indicate that substrate selectivity of HDAC8 for these H3 sites 
varies for the peptide (K56ac~K9ac>K14ac) and protein (K9ac>>K56ac>K14ac) substrates. The 
values of kmax/K1/2 (measures binding through deacetylation) and kcat/KM (measures binding 
through dissociation) can be directly compared if product release is not rate limiting under 
multiple turnover conditions. Previous data suggest that the deacetylation step is likely the rate-
limiting step (see discussion), also suggesting that K1/2 and KM reflect KD.28, 44 To validate our 
assumption in comparing the STO and MTO data, we assayed the 13-mer H3K9ac peptide under 
both STO and MTO conditions. MALDI-MS was used to measure HDAC8-catalyzed 
deacetylation of the peptide, due to the high enzyme concentration and sample size constraints in 
the enzyme-coupled peptide deacetylation assay. Using this method, the rate constant, kmax/K1/2, 
is 153 M-1s-1 (data not shown). This rate constant is within three-fold of the value of the kcat/KM 
of 51 ± 3 M-1s-1 measured by the fluorescence-based peptide deacetylation assay.  These data 
suggest that the STO measurements for the peptide substrates could be increased modestly 
compared to the MTO data but not enough to explain the increased reactivity of the protein 
substrates. 
Comparison of the multiple turnover data for peptides and the single turnover data 
measured for full-length proteins demonstrates that interactions outside of short peptide 
sequences are important for directing HDAC8 substrate selectivity and enhancing catalytic 
efficiency. Further analysis demonstrates that the H3 peptides have KM values higher than 100 
µM (data not shown) while the H3K9ac/H4, H3K14ac/H4, and H3K56/H4 tetramers have K1/2 
values of < 1.5 µM, 19 ± 1 µM, and > 11 µM, respectively. Therefore, one factor leading to the 





KM for the peptides, suggesting enhanced binding affinity of the protein substrates. These 
differences suggest that long-range interactions enhance activity of HDAC8 toward full-length 
substrates. 
The catalytic efficiency of HDAC8 towards its substrates is enhanced for all three H3Kac 
sites tested in the context of the tetramer compared to the corresponding peptides. However, 
relative HDAC8 activity for the tetramer sites compared to the peptides is different. The largest 
observed enhancement in catalytic efficiency is for the H3K9ac substrates (140- to 300-fold 
increase with the tetramer substrate), followed by H3K14ac (120- to 300-fold) and then 
H3K56ac (40- to 50-fold). In particular, the modest selectivity of HDAC8-catalyzed 
deacetylation of H3K56ac peptide compared to H3K9ac peptides is not maintained in the 
tetramer substrates, as would be expected if local sequence was the only determinant of substrate 






Figure III.2 Single turnover deacetylation of singly-acetylated H3/H4 tetramers 
A. Sample data from a deacetylation reaction (7 µM HDAC8 and 0.5 µM H3K9ac/H4 tetramer 
(1 µM acetyl-lysine)) measured using mass spectrometry. The time-dependent decrease in 
acetylated protein is best described by a single exponential. B. Dependence of apparent 
deacetylation rate constant of H3K9ac/H4 on the concentration of HDAC8. The kobs average of 
0.021 ± 0.001 s-1 shows little dependence on the [HDAC8]. Three separate hyperbolic fits are 
shown that bracket potential K1/2 values: K1/2 = 0.5 µM (dotted line); K1/2 = 1.0 µM (dashed line); 
K1/2 = 1.5 µM (solid line). These fits demonstrate that the K1/2 is < 1.5 µM and kmax/K1/2 is > 
17,000 M-1s-1. The data points are from multiple measurements in a single reaction at each 
HDAC8 concentration. C. Dependence of the deacetylation rate constant for H3K14ac/H4 on the 
concentration of HDAC8. The data points are from multiple measurements in a single reaction at 
each HDAC8 concentration. A hyperbolic fit indicates that the kmax/K1/2 is 2,500 ± 70 M-1s-1 with 
an estimated value for kmax of 0.06 s-1. D. Dependence of the deacetylation rate constant for 
H3K56ac/H4 on the concentration of HDAC8. The data points are from multiple measurements 
in a single reaction at each HDAC8 concentration. A linear fit indicates that the kmax/K1/2 is 4,000 















Tetramer Octamer Nucleosome 
 kcat/KM (M-1 s-1) kmax/K1/2 (M-1 s-1) 
H3K9ac 56 ± 6 51 ± 3 120 ± 11 >17,000 3,700 ± 100 28 ± 3 
H3K14ac 8.0 ± 0.7 21 ± 4 - 2,500 ± 70 1,000 ± 200 - 
H3K56ac 78 ± 8 100 ± 10 - 4,000 ± 600 - - 
  
                                               
a HDAC8 activity was measured and catalytic efficiencies were determined as described in the Experimental 





Octamer substrates less reactive than tetramers 
To further examine full-length substrate selectivity, we measured the deacetylase activity 
of HDAC8 toward histone octamer complexes containing single acetylation sites. We compared 
the local sequence of the best and worst tetramer substrates, H3K9ac and H3K14ac, in the 
context of the complete histone octamer. Histone octamers were reconstituted with two copies of 
each core histone (H2A, H2B, singly-acetylated H3, and H4). The deacetylation rate catalyzed 
by HDAC8 was measured under single turnover conditions and analyzed as described for the 
tetramer. The resulting kobs values for H3K9ac octamer are linearly dependent on the HDAC8 
concentration (Figure III.3), yielding a kmax/K1/2 value of 3,700 ± 100 M-1s-1. Deacetylation of the 
H3K14ac octamer has a hyperbolic dependence on HDAC8 concentration leading to a value of 
kmax/K1/2 of 1,000 ± 200 M-1s-1. This catalytic efficiency is decreased three-fold compared to the 
H3K14ac/H4 tetramer and is 40-120 fold faster than the deacetylation of H3K14ac peptides. The 
catalytic efficiency for the H3K9ac octamer site is decreased four-fold compared to that of 
H3K9ac tetramer.  
 
Figure III.3 Single turnover deacetylation of singly-acetylated H3 octamers 
A. Dependence of the apparent deacetylation rate constant of H3K9ac octamer on the 
concentration of HDAC8. Data points are from multiple measurements in a single reaction at 
each HDAC8 concentration, and error bars on kobs values represent errors calculated from the 
exponential fits. A linear fit of the data indicates that the kmax/K1/2 is 3700 ± 100 M-1s-1. C. 
Dependence of the apparent deacetylation rate constant of H3K14ac octamer on the 
concentration of HDAC8. The data points are from multiple measurements in a single reaction at 
each HDAC8 concentration. A hyperbolic fit indicates that the kmax/K1/2 is 1,000 ± 200 M-1s-1 







HDAC8-catalyzed deacetylation of acetylated nucleosome is slow 
HDACs involved in transcriptional regulation are likely to encounter nucleic acid-bound 
substrate proteins. To test the selectivity of HDAC-catalyzed deacetylation for a substrate 
complex containing nucleic acids, we incorporated H3K9ac into recombinant mononucleosomes. 
Deacetylation of these complexes was assayed in the same manner as the tetramer and octamer 
substrates (Figure III.4). The addition of nucleic acids to the octamer to assemble nucleosomal 
substrates significantly decreased HDAC8 catalytic efficiency at the H3K9ac site, kmax/K1/2 = 28 
± 3 M-1s-1. This is two-fold slower than the kcat/KM for the H3K9ac 7-mer peptide and 600-fold 
slower than deacetylation of this site in the H3/H4 tetramer. Adding the nucleosomal DNA to a 
Fluor-de-Lys peptide deacetylation assay resulted in an initial rate that is decreased only 25% 
compared to that of HDAC8 and peptide alone (data not shown); thus, the 130-fold decrease in 
HDAC8 activity observed between octamer and nucleosome substrates is not explained by DNA 
inhibition of the enzyme. 
  
Figure III.4 Single turnover deacetylation of singly-acetylated H3 nucleosome 
The initial rate of progress curves for deacetylation of H3K9ac nucleosome catalyzed by 0 – 7.5 
µM HDAC8 were fit linearly and the rate constant calculated assuming 100% deacetylated 
product. The data points are from multiple measurements in a single reaction at each HDAC8 
concentration, and error bars represent errors calculated from the initial rate fits. A linear fit of 
the data indicates that kmax/K1/2 is 28 ± 3 M-1s-1.  
















To understand the role of HDACs in cellular regulation, it is important to determine the 
substrate specificity and the molecular determinants of substrate recognition for each isozyme. 
Until now, HDAC recognition of protein substrates has largely been tackled by studying activity 
toward peptide substrates, which typically interact with less than an 8 x 20 Å2 area of an 
approximately 2025 Å2 binding surface.22 Within this larger binding interface, there may be 
many more HDAC8-protein substrate contacts, including potential recognition hotspots and 
negative interaction sites. With a peptide, a single interaction of 0.5 - 2 kcal/mol can alter the 
catalytic efficiency by 50-fold.56 With a protein substrate, the increased number of interaction 
sites could overcome the several kcal/mol interaction energy obtained from local contacts. 
Previously, distal HDAC8-substrate interactions have been observed using long peptide 
substrates; an upstream KRHR motif (based on histone H4) increases HDAC8-catalyzed 
deacetylation of an acetylated peptide.15 To elucidate the role of long-range interactions on 
HDAC8 substrate recognition, we measured HDAC8-catalyzed deacetylation of substrates of 
increasing size and complexity, from peptide to full-length protein and protein-nucleic acid 
complex.  
To analyze HDAC8-catalyzed deacetylation of peptide and protein substrates, we 
compared multiple turnover reactions (kcat/KM) of peptide substrates to single turnover (kmax/K1/2) 
reactions of the protein substrates. This comparison of kcat/KM to kmax/K1/2 was due mainly to the 
challenge of preparing sufficient quantities of singly-acetylated protein substrates to measure 
under MTO conditions. A variety of data suggest that the kinetic mechanism for deacetylation of 
most peptide substrates under MTO conditions is rapid equilibrium binding followed by a slow 
hydrolytic step. For example, our peptide assay demonstrated comparable deacetylation rate 
constants (within three-fold) under MTO and STO conditions. Additionally, HDAC8 catalyzes 
deacetylation of trifluoroacetate peptide substrates faster than non-fluorinated peptides (kcat), 
indicating that product release is not the main rate-limiting step.44 Furthermore, the kcat/KM 
values for peptides are significantly slower than diffusion control (102-103 M-1s-1 vs 107-108 M-
1s-1) and the KM values are large (> 100 µM), suggesting that a step other than substrate 
association, such as hydrolysis, is the rate-limiting step.  Similarly, the values of kmax/K1/2 are 
significantly lower than diffusion-controlled values suggesting that a step after association and at 





assume that the apparent second order rate constants determined under MTO and STO conditions 
characterize the same hydrolytic step. 
HDAC8 has remarkably enhanced catalytic efficiency for protein substrates in 
comparison to corresponding peptides. The varied HDAC8 catalytic efficiencies likely reflect the 
interactions between HDAC8 and substrate residues surrounding the acetyl-lysine, as previously 
demonstrated,15 differences in accessibility of the acetyl-lysine to the active site, and distal 
interactions between HDAC8 and protein substrates.  Previous analysis of activity toward 
acetylated peptide substrates has shown that HDAC8 prefers substrates with aromatic amino 
acids on the C-terminal side of the acetyl-lysine (+1 position).13-14 Based on these empirical data, 
the mediocre catalytic efficiency of the histone H3-based peptides (10 to 102 M-1s-1) (Table III.2) 
was predictable due to the lack of aromatic residues. The interactions between the 7-mer peptides 
and HDAC8 occur within an approximately 10 Å radius of the active site. HDAC8-catalyzed 
hydrolysis of the acetylated H3/H4 tetramers, which still lack an aromatic residue in the +1 
position, is 40 - 400 times faster than the corresponding peptides. Thus, HDAC8-tetramer 
interactions that are absent with the peptide substrates enhance HDAC8 substrate recognition. 
The increased catalytic efficiency for deacetylation of the acetylated H3/H4 tetramer compared 
to peptides corresponds to a Gibbs free energy increase of 2-4 kcal/mol, indicating a lower 
activation energy (Equation III.1) and demonstrating the importance of long-range interactions 
for HDAC8 substrate recognition.  






The Mrksich group previously demonstrated that distal HDAC8-peptide interactions can 
enhance deacetylation and proposed an exosite model which involves binding at the active site 
and at a second location elsewhere on the HDAC8 surface.15 Structures of peptides bound to 
HDAC8 are in an extended conformation.19, 22, 30 Consistent with this, H3K9ac and H3K14ac 
sites are both located on the unstructured histone tail. The H3K9ac/H4 tetramer has both the 
highest value of kmax/K1/2 and the largest increase in reactivity compared to the corresponding 9-
mer peptide (300-fold), which could be attributed to one or a few strong interactions or several 
weak interactions. H3K14ac/H4 is the slowest of the singly-acetylated tetramers tested, but the 
fold difference between H3K14ac/H4 tetramer and 9-mer peptide (300-fold) is similar to that of 





surprising disparity in HDAC8 activity toward these sites suggests the important role of local 
sequence on HDAC8 selectivity, even within the context of a full-length protein. Moreover, 
H3K56ac is located on an α-helix which may significantly hinder interaction with HDAC8. 
Consistent with this, while H3K56ac/H4 tetramer demonstrates the second fastest reactivity, the 
fold difference compared to the 9-mer peptide is the smallest (50-fold). This could reflect either 
weak affinity with the α-helix structure or a requirement for unfolding of the helix. 
The crystal structure of HDAC8 is useful in visualizing potential protein-protein 
interactions involved in full-length substrate recognition. In many crystal structures, HDAC8 
forms a dimer at the substrate binding interface, as part of the fundamental crystal unit. This 
potential protein substrate binding interface is a flexible 45 x 45 Å2 surface containing multiple 
interaction sites, including 10 van der Waals interactions and 6 hydrogen bonds between the 
HDAC8 dimers.21, 23 The interactions observed between these two HDAC8 units provide a 
framework for exploring the differences in catalytic efficiency observed for peptide and full-
length substrates. The 2-4 kcal/mol difference in Gibbs free energy between the peptide and 
tetramer deacetylation could be explained by the van der Waals interactions and/or hydrogen 
bonds that are observed in the dimeric crystal structures. The dimer also displays repulsive 
charge-charge interactions. The attractive and repulsive protein-protein interactions likely work 
in concert to determine HDAC8 substrate specificity. The HDAC8 substrate binding interface is 
mainly composed of flexible loops. Recent crystal structures have shown conformational 
changes in HDAC8 loops L1 and L2 upon binding of largazole analogs, as well as different L1 
and L2 loop conformations between two monomers of the same crystal structure, demonstrating 
the adaptability and importance of these loops in HDAC8 inhibitor and substrate binding.26  
Catalytic efficiency is not enhanced by increasing the size and complexity of the protein 
substrate from a tetramer to the histone octamer. The H3K14ac histone octamer was deacetylated 
with a similar catalytic efficiency to the corresponding tetrameric substrate, suggesting that 
interactions with the tetramer are sufficient to explain HDAC8 substrate interactions in that case. 
In contrast, the H3K9ac octamer was deacetylated at least 4-fold slower than the tetrameric 
substrate. This is likely due to decreased accessibility of the acetyl-lysine to the HDAC8 active 
site, although other effects including protein-protein interactions and allosteric effects could be 
involved in the recognition of these proteins. This suggests that HDAC8 substrate recognition is 





conditions (HDAC8 assay buffer and less than 240 mM NaCl) is that the octamer would 
disassemble into H3/H4 tetramer and H2A/H2B dimers. However, the sensitivity of HDAC8 
toward NaCl precluded higher salt concentrations.29 HDAC8 activity is salt and pH sensitive, 
and the selected assay buffer conditions were optimal for HDAC8 activity.29 The observed 
kinetics for the tetramer and octamer substrates are significantly different and suggest that the 
octamers, once assembled, remain intact during our assays.  
Addition of nucleic acid to form a nucleosome converted the most efficient protein 
substrate, the H3K9ac/H4 tetramer, to a substrate that is deacetylated by HDAC8 less efficiently 
than the corresponding peptide. The drastic decrease in kmax/K1/2 for nucleosomal H3K9ac likely 
reflects decreased substrate accessibility to the acetyl-lysine on the H3 tail by the nucleosome. 
One possibility is that the positively charged histone H3 tail interacts with the negatively charged 
DNA in the nucleosome and is no longer accessible to HDAC8. These data are consistent with 
proteomic studies suggesting that histones are not physiological substrates for HDAC8.34 
However, the low reactivity observed for nucleosomal H3K9ac does not completely preclude 
deacetylation by HDAC8 under all conditions. The chromatin structure can be altered by 
transcription factors, DNA binding proteins, chromatin remodeling factors and other proteins, 
possibly complexed with HDAC, to alter the accessibility of acetylated lysines in the tail of H3.  
This work presents the first report of detailed kinetics for HDAC8-catalyzed deacetylation of 
singly-acetylated, full-length protein substrates and adds integral information to the field of 
HDAC substrate specificity. The direct comparison of peptides and protein substrates reveals 
that additional factors alter activity of HDAC8 with protein substrates, including both increased 
activity due to distal protein-protein interactions and decreased activity due to decreased 
accessibility of the acetyl-lysine side chain. HDAC8 catalyzes deacetylation of tetrameric protein 
substrates with catalytic efficiencies more than 40-fold greater than corresponding peptide 
substrates due to enhanced protein-protein interactions. However, further increasing the protein 
complex size decreases catalytic efficiency, likely due to decreased side chain accessibility. 
These differences in catalytic efficiency represent the effects of HDAC8-protein substrate 
interactions that are absent in HDAC8-peptide interactions. This work provides a foundation for 








Adenosine triphosphate (ATP), coenzyme A, nicotinamide adenine dinucleotide (NAD+), 
L-malic acid, citrate synthase, malate dehydrogenase, and propionic anhydride were purchased 
from Sigma. Peptides were purchased from Peptide 2.0 Inc. Zinc(II) used to reconstitute HDAC8 
was purchased as an ICP standard (GFS Chemicals) or atomic spectroscopy standard (Fluka) and 
the acetic acid standard was purchased from Ricca Chemical Company. Chelex 100 resin was 
purchased from Bio-Rad. Acetyl-lysine was purchased from Chem-Impex Chemical 
International Inc. Alpha-cyano-4-hydroxy-cinnamic acid (CHCA) MALDI matrix was purchased 
from Thermo Scientific. All other materials were purchased from Fisher or Sigma Aldrich and 
were of a purity >95 % unless otherwise noted. 
HDAC8 expression and purification 
HDAC8 was expressed and purified using the method described previously28, 56 with the 
following modifications. BL21(DE3) E. coli cells transformed with the plasmid pHD4-HDAC8-
TEV-His6 were used to express HDAC8 in modified autoinduction-TB medium (12 g/L tryptone, 
24 g/L yeast extract, 8.3g/L Tris-HCl, 4 g/L lactose, 1 g/L glucose, 1% (v/v) glycerol, pH 7.4) 
supplemented with 100 µg/mL ampicillin and 200 μM ZnSO4. The cells were grown overnight at 
30°C and harvested 20 - 24 hours post inoculation (9,000 x g, 10 min, 4°C). The cell pellet was 
resuspended either in low salt DEAE buffer (50 mM HEPES, 200 μM ZnSO4, 1 mM TCEP, 50 
mM NaCl, 5 mM KCl, 1 µg/mL tert-amyl methyl ether (TAME), 10 µg/mL 
phenylmethylsulfonyl fluoride (PMSF), pH 7.8) and lysed using a microfluidizer (Microfluidics). 
Nucleic acids were then precipitated by addition of 0.1% polyethylenimine (pH 7.9) followed by 
centrifugation (39,000 x g, 45 min, 4°C). HDAC8 was fractionated on a DEAE Sepharose 
column with a stepwise salt elution (50 mM HEPES, 200 μM ZnSO4, 1 mM TCEP, 5 - 500 mM 
NaCl, 5 mM KCl, pH 7.8) and dialyzed against Buffer A (50 mM HEPES, 100 mM NaCl, 25 
mM imidazole, pH 7.8). The eluate was dialyzed against 50 mM HEPES, 50 mM NaCl, 25 mM 
imidazole, pH 7.8 for 1 hour at 4°C then incubated with Ni(II)-charged chelating sepharose fast 
flow resin (GE) for 30 minutes, stirring on ice. HDAC8 was eluted from the metal affinity 
chromatography column by a stepwise (50 mM - 250 mM) imidazole gradient. HDAC8, together 





against Buffer A without imidazole at 4˚C. Following the overnight TEV cleavage, HDAC8 was 
separated from TEV protease on a second Ni(II) column. The protein was further purified by size 
exclusion chromatography using a HiPrep 16/60 Sephacryl S200 HR column (GE) using size 
exclusion buffer (30 mM HEPES pH 8, 150 mM NaCl, 1 mM TCEP). HDAC8 was then 
dialyzed against metal-free chelation buffer (25 mM MOPS pH 7.5, 1 mM EDTA, 1 mM TCEP, 
5 mM KCl) overnight, followed by metal-free buffer (25 mM MOPS pH 7.5, 1 mM TCEP, 5 
mM KCl). Finally, residual EDTA was removed with a PD-10 column (GE) eluting with storage 
buffer (25 mM HEPES pH 8, 127 mM NaCl, 3 mM KCl, and 1 mM TCEP). HDAC8 was 
concentrated, aliquoted, and stored at -80°C. HDAC8 activity was confirmed using the Fluor de 
Lys assay as described previously.28, 60-61 
Peptide deacetylation assay 
HDAC8-catalyzed deacetylation of acetylated peptides was characterized using an 
enzyme-coupled assay, performed as previously described with a few modifications.56 To 
prepare peptide stocks, lyophilized peptides were dissolved in water, 50% acetonitrile, or 10% 
DMSO, depending on their solubility. Peptide solutions were chelated by incubation with Chelex 
resin at 4°C for at least three hours. Peptide concentrations were measured using the 
fluorescamine assay or absorbance at 280 nm, as previously described.56, 62 Peptides (0-100 µM) 
were incubated in HDAC8 assay buffer (50 mM HEPES, 137 mM NaCl, 3.7 mM KCl, pH 7.8) 
for 10 minutes at 30°C before initiating reactions with the addition of 0.5 µM Zn(II)-HDAC8. 
Acetate formation was coupled to NADH formation measured by an increase in fluorescence (ex 
= 340 nm, em = 460 nm).56 Initial rates were fit to the linear portion of the product versus time 
curve. 
Histone expression and purification 
Recombinant His6-tagged histone H3 variants containing a single acetyl-lysine were 
expressed and purified as previously described with a few modifications.54 The acetyl-lysine was 
incorporated into expressed proteins at an amber codon site (TAG) using a tRNA-cognate tRNA 
synthetase pair encoded on the pAcKRS-3 plasmid.54 Amber codons were substituted for the K9, 
K14, and K56 codons in the His6-tagged Xenopus histone H3 in the PCDF PyLT-1 plasmid, a 
generous gift from Jason Chin53-54 using QuikChange Site-Directed Mutagenesis (Agilent). 





plasmids for His6-tagged H3 expression. Expression plasmids for preparation of recombinant 
H2A, H2B, and H4 Xenopus histones were generous gifts from Geeta Narlikar. BL21(DE3) cells 
were transformed with the respective H2A, H2B, and H4 plasmids and grown in LB or 2xYT 
supplemented with antibiotic (kanamycin and streptomycin for H3, or ampicillin for H2A, H2B, 
and H4) at 37°C until reaching an OD600 of 0.7. To express full-length histone H3 proteins with a 
single acetyl-lysine residue, 20 mM nicotinamide and 10 mM acetyl-lysine were added to the 
medium; 30 minutes later 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to 
induce protein expression. For expression of the other histones, the cells were induced with 0.5 
mM IPTG. The cultures were harvested 3 - 4 hours after induction (9,000 x g, 10-15 min, 4°C). 
The cell pellets were stored at -80°C. 
Histones were purified using established protocols,54-55, 63 with H3 Ni(II) column buffers 
modified to include 7 M urea and 1 mM TCEP. Tetramer, octamer, and nucleosome were 
assembled as previously described, and nucleosomes contained a 147-base pair DNA fragment 
containing the 601 octamer positioning sequence prepared as described.54-55, 63-64 The 601 
plasmid was a generous gift from Yali Dou. Tetramer and octamer were purified by size 
exclusion chromatography, selecting a single peak in each case. Tetramer assembly was tested 
using IM-MS (data not shown). Native PAGE was used to verify nucleosome consisted of DNA-
bound histone protein. EDTA dialysis was used to remove any contaminating metal from histone 
protein complexes. Octamer and nucleosome were subsequently treated with Chelex resin for at 
least 1 hour at 4°C to ensure metal removal. Inductively coupled plasma mass spectrometry 
(ICP-MS) was used to verify less than 10% metal contamination. Nucleosome was stored in 20% 
glycerol, 20 mM HEPES pH 7.5 – 7.8, 1 mM TCEP.  
Protein deacetylation assays 
Apo-HDAC8 was reconstituted with stoichiometric Zn(II) for 1 hour on ice in HDAC8 
assay buffer (50 mM HEPES, 137 mM NaCl, 3.7 mM KCl, pH 7.8) 28. Histone complexes were 
incubated in HDAC8 assay buffer for 10 minutes at 30°C before initiating reactions by addition 
of 0 - 15 μM Zn(II)-HDAC8. The final concentration of NaCl in the assays with octamer was 
137 or 239 mM NaCl. This salt concentration is lower than typical histone octamer storage 
buffer (2 M NaCl),65 but allows for measurement of HDAC8 activity uninhibited by salt. 
Reactions were quenched by addition of 25% trichloroacetic acid at each time point, incubated 





washed in cold acetone twice. Acetone-washed pellets were resuspended in 2 µL propionic 
anhydride and 6 µL ammonium hydroxide (NH4OH) and incubated at 51°C for 1 hour. 30 µL of 
50 mM NH4HCO3 was added to each tube, and the pH of each sample was adjusted to 7 – 9 
using NH4OH. Then 0.2 μg trypsin (Promega) was added for overnight digest at 37°C. The pH 
was then reduced for mass spectrometry (MS) by addition of 3.5 µL of 10% formic acid. Tryptic 
peptides were analyzed by MS/MS analysis in the lab of Andrew Andrews (Fox Chase Cancer 
Center) as previously described 45, 66. Graphical analysis was done using Prism (GraphPad 
Software, Inc.). For each single turnover reaction, the kobs was determined by fitting a single 
exponential decay (Equation III.2) to the fraction substrate over time determined from the 
MS/MS analysis. The kmax/K1/2 values were determined by fitting hyperbola (Equation III.3E) or 
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MALDI-TOF-MS Deacetylation Assay 
HDAC8-catalyzed deacetylation of the H3K9ac 13-mer peptide was measured under 
single turnover (STO, [E]>>[S]) and multiple turnover (MTO, [S]>>[E]) conditions using 
MALDI-TOF-MS. Apo-HDAC8 was reconstituted with stoichiometric zinc(II) for 1 hour on ice 
in HDAC8 assay buffer. The H3K9ac 13-mer peptide was incubated in HDAC8 assay buffer for 
10 minutes at 30°C, and the deacetylation reaction was initiated with Zn(II)-HDAC8.  MTO 
control reactions contained either 1 μM enzyme and 50 μM peptide or 150 μM enzyme and 750 
μM peptide, and STO reactions contained 20 μM peptide and 0, 50, 100 and 150 μM enzyme 





μL of 10% HCl. Samples were stored at -80°C prior to MS analysis. The samples were prepared 
by mixing the quenched reactions 1:1 with alpha-cyano-4-hydroxy-cinnamic acid (CHCA) 
MALDI matrix followed by spotting on a Bruker MALDI-TOF-MS plate. Spectra were collected 
using a Bruker AutoFlex Speed MALDI-TOF mass spectrometer calibrated with a series of five 
peptide standards. Three random measurements from each spot were averaged, and the fraction 
of product formed was calculated from the area under the curve of the product and substrate 
peaks. The kcat/KM for the multiple turnover reaction was determined by fitting a line to the initial 
rate of the reaction progress curve. The kmax/K1/2 for the single turnover reaction was determined 
by fitting a hyperbola to the dependence of kobs on HDAC8 concentration (Equation 2). The 
values for kobs at each HDAC8 concentration were determined by fitting a single exponential to 
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The abbreviations used are: ARID1A, AT-rich interaction domain 1A; CHCA, alpha-cyano-4-
hydroxy-cinnamic acid; ERRα, estrogen related receptor alpha; H3/H4, tetrameric histone 
H3/H4; HDAC, histone deacetylase; ICP-MS, inductively coupled plasma mass spectrometry; 
IPTG, isopropyl β-D-1-thiogalactopyranoside; KAT, acetyltransferase; MTO, multiple turnover; 
PIP, pyrrole-imidazole polyamide; SAHA, suberanilohydroxamic acid; SMC3, structural 
maintenance of chromosomes 3;  STO, single turnover; TAME, Nα-p-Tosyl-L-arginine methyl 
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 Histone deacetylases (HDACs) catalyze the hydrolysis of acetyl-lysine amino acids of 
certain proteins.1 The acetyl-lysine post-translational modification (PTM) is an important 
regulatory feature that modulates vastly varied processes within all compartments of the cell.2 
This PTM is conserved from bacteria to humans and plays an integral role in modulating 
chromosomal architecture where acetylation of histone tails and interactions with transcription 
factors control the activation and silencing of specific genes.3 In addition to histones and other 
transcriptional-related machinery within the nucleus, acetylation occurs on lysine residues in a 
wide variety of non-nuclear proteins.4 Mass spectrometry-based proteomics has been used to 
identify thousands of acetylation sites in mammalian proteins, and the number continues to rise.5 
These acetylation events regulate proteins involved in most, if not all, cellular processes 
including cell-cycle regulation, cell signaling, metabolism, stress-response, cell integrity and 
mobility, and chromatin remodeling.2, 6 Additionally, the regulatory functions of acetylation vary 
widely and include protein-protein interactions, protein-nucleic acid interactions, protein 
structure and stability, enzyme activity, and signaling.6  
In the cytoplasm, well-known acetylation events include acetylation of a-tubulin at K40 
that regulates cytoskeletal dynamics and acetylation of Hsp90 that modulates complex formation 
and stress response, among others.7-8 Aberrant acetylation has been linked to devastating human 
diseases including cancer, neurodegeneration, and autoimmune disorders.9 Many of these 
diseases are linked to deacetylation dysregulation where differential expression of HDACs 
correlate with poor disease prognoses.9 The histone deacetylases, including the metal-dependent 
                                               
a Protein purification and enzyme assays were performed by Katherine Welker Leng, study design and analysis was 
completed by Katherine Welker Leng and Carol A. Fierke, and computer-based modeling and analysis were carried 
out by Ora Schueler-Furman and Julia Varga (University of Jerusalem). 
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HDACs 1-11 and the NAD+-dependent sirtuins SIRT1-7, are grouped into four classes based on 
homology, with class I HDACs, HDAC1, -2, -3, and -8, performing predominantly nuclear 
functions including transcriptional regulation and class II HDACs, HDAC4-7, and -9, 
performing predominantly cytoplasmic functions.1 The other classes include class III HDACs, 
SIRT1-7, and class IV HDAC11.1 The most notable of the class II HDACs is HDAC6, a 
particularly unique HDAC with regards to its structure and function.10 Abnormal HDAC6 
expression and/or activity has been implicated in cancer, neurodegeneration, and autoimmune 
disorders,11-14 and recently the crystal structure of HDAC6 was solved spurring a greater 
emphasis on the discovery of HDAC6 small molecule modulators.15-16 Between 2013-2017, over 
two-thirds of patents submitted for HDAC-specific small molecule inhibitors targeted HDAC6,17 
and several HDAC6-specific inhibitors are currently undergoing clinical trials, including the first 
clinically tested HDAC6-specific inhibitor ricolinostat.18 
HDAC6 contains unique structural features including two tandem catalytic domains, a 
ubiquitin binding zinc-finger domain, and a dynein motor binding domain (Figure IV.1).10, 16 The 
notable and well-conserved differences between HDAC6 and the other HDACs support 
significant and non-redundant functions for HDAC6 in the cell.19 Indeed, HDAC6 plays 
important roles in the cytoplasm where it regulates cytoskeletal dynamics and stress-response 
through deacetylation of target substrates a-tubulin and Hsp90, among others.20-22 Interestingly, 
global deletion of HDAC6 in mice is non-fatal and is the only HDAC global deletion to lack a 
pronounced phenotype,23 suggesting that inhibition of this isozyme might have low cellular 
toxicity. Due to its association with numerous disease-types, developing HDAC6-specific 
inhibitors has been a priority yielding several clinical candidates and numerous others currently 
under investigation.17-18, 24 Understanding HDAC6 function through its control of substrate 
acetylation levels and subsequent impact on the regulation of specific biological pathways is 
crucial for identifying where HDAC6 modulation would be most effective and developing 
targeted approaches to treating disease. Unfortunately, although there are thousands of 
acetylation events regulated by HDACs, relatively few HDAC-substrate pairs have been reported 







Figure IV.1 Diagram of HDAC6 structural features 
Human HDAC6 (blue) is composed of 1,215 amino acid residues organized into several key 
domains: N-terminal nuclear localization signal and C-terminal serine-glutamate 
tetradecapeptide repeat cytoplasmic retention domain (L and SE14, respectively in yellow), N- 
and C-terminal nuclear export signals (E in teal), catalytic domains 1 and 2 (CD1 and CD2 in 
orange), and finally the dynein motor binding domain and ubiquitin binding zinc finger domain 
(DM and BUZ, respectively in red).  
 
Identifying HDAC substrates is challenging due to the complexity of biological 
processes, a poor understanding of the cellular dynamics regulating these reactions, differences 
between experimental methodology and model systems, overlapping action and redundancy of 
the activity of multiple isozymes, and the insufficiency and inconsistency in the tools currently 
available. Efforts to streamline HDAC substrate specificity characterization and identify HDAC 
substrates include using peptide and protein library screens and computational- and proteomics-
based approaches.25-29 One method pairs readily available tools and information with powerful 
computational technology. Using the crystal structure of HDAC8, a computational model was 
developed to predict HDAC8 activity.25 Using a library of acetylated peptide substrates, an 
algorithm was developed for HDAC8 using Rosetta FlexPepBind that shows a significant 
correlation between a computational activity score and HDAC8 catalysis measured in vitro.25 
This powerful tool is able to rapidly score thousands of additional peptide sequences as HDAC 
substrates in a fraction of the time and cost required for traditional assay methods.25 The 
correlation between activity and sequence observed in developing this model provides evidence 
that the sequence directly flanking the acetyl-lysine is significant in determining HDAC substrate 
selectivity30. 
Here we report the use of a similar approach to model HDAC6 substrate selectivity in 
efforts to identify novel and therapeutically significant HDAC6 substrates. This is the first 
computational model to predict HDAC6 activity and selectivity. Recombinantly purified 
HDAC6 exhibits significantly greater activity in vitro than recombinantly purified HDAC8, thus 
there was speculation as to the extent of substrate selectivity by HDAC6 activity. However, our 
data demonstrate that the increased reactivity results in a greater dynamic range of HDAC6 





selectivity. HDAC6-catalyzed deacetylation of singly-acetylated peptides in vitro demonstrated 
up to 20,000-fold differences in reactivity, depending on the peptide sequence. While no simple 
sequence patterns were observed, the Rosetta FlexPepBind computational software using docked 
peptide substrates into the HDAC6 crystal structure led to a computational model able to identify 
good HDAC6 substrates. Test substrates demonstrating rapid turnover included peptides 
corresponding to putative HDAC6 substrate Hsp90 as well as novel substrates prelamin A, 
VDAC1, a-actinin, CRIP1, and MSH2. These results provide insight into the biological function 
of HDAC6, including its physiological substrates, and its participation in biological pathways 
and disease pathologies.  This information will help predict how HDAC6 inhibition will impact 
disease pathology and identify which diseases are amenable to treatment with HDAC6 inhibitors.  
Materials and Methods 
Reagents 
High flow amylose resin was purchased from New England Biolabs and Ni-NTA agarose 
was purchased from Qiagen. Adenosine triphosphate (ATP), coenzyme A (CoA), NAD+, NADH, 
L-malic acid, malate dehydrogenase (MDH), citrate synthase (CS), and mouse monoclonal anti-
polyhistidine-alkaline phosphatase antibody were purchased from Sigma. Rabbit monoclonal 
anti-HDAC6 antibody was purchased from Cell Signaling Technology. N-terminally acetylated 
and C-terminally carboxylated, singly-acetylated peptides were purchased from Peptide 2.0 or 
Synthetic Biomolecules at >85% purity. 3% (v/v) acetic acid standard was purchased from 
RICCA Chemical. All other materials were purchased from Fisher at >95% purity unless noted 
otherwise. 
HDAC6 Expression and Purification 
The plasmid and protocol for the expression and purification of zebrafish catalytic 
domain 2 (zCD2) was generously provided by David Christianson (University of Pennsylvania). 
The MBP-His6x-TEV-HDAC6 expression constructs were prepared previously by the 
Christianson lab by cloning the HDAC6 gene (gift from E. Verdin, University of California, San 
Francisco; Addgene plasmid #13823) into a modified pET28a(+) vector (gift from S. Gradia, 
University of California, Berkely; Addgene plasmid #29656) to encode HDAC6 with a Tev-
protease cleavable N-terminal maltose binding protein/His6x tag.16 HDAC6 was expressed and 





competent BL21(DE3) E. coli cells (Novagen 69450-3) were transformed with plasmid 
according to the protocol and plated on LB-media agarose supplemented with 50 µg/mL 
kanamycin. Plates were incubated overnight at 37°C (16-18 hours), and one colony was added to 
an overnight LB/kanamycin starter culture and incubated with shaking at 37°C for 16-18 hours. 
This overnight starter culture was diluted (1:200) into 2x-YT media supplemented with 50 
µg/mL kanamycin and incubated at 37°C with shaking until the cell density reached an OD600=1. 
The cultures were then cooled to 18°C for one hour and supplemented with 500 µM isopropyl β-
D-1-thiogalactopyranoside (IPTG) to induce expression and 100 µM ZnSO4. The cultures were 
grown for an additional 16-18 hours with shaking at 18°C and harvested by centrifugation at 
6,000 x g for 15 min at 4°C. Cell pellets were stored at -80°C. 1-mL pre- and post-induction 
samples were taken and tested for HDAC6 expression by polyhistidine and HDAC6 western blot 
analysis and activity measurements using the commercial Fluor de Lys assay (Enzo Life 
Sciences). 
Cell pellets were resuspended in running buffer (50 mM HEPES, pH 7.5, 300 mM KCl, 
10% (v/v) glycerol and 1 mM TCEP) supplemented with protease inhibitor tablets (Pierce) at 2 
mL/g cell pellet. The cells were lysed by three passages through a chilled microfluidizer 
(Microfluidics) and centrifuged for 1 h at 26,000 x g at 4°C. Using an AKTA Pure FPLC (GE) 
running at 2 mL/min, the cleared lysate was loaded onto a 10-mL packed Ni-NTA column 
equilibrated with running buffer. The column was washed with 10 column volumes (CVs) of 
running buffer and 10 CVs of running buffer containing 30 mM imidazole, and the protein was 
eluted with 5 CVs elution buffer containing 500 mM imidazole. 8 mL fractions were collected 
and analyzed by SDS-PAGE and western blot, and fractions containing His-tagged HDAC6 were 
combined and loaded onto a 30-mL amylose column equilibrated with running buffer running at 
1 mL/min. The column was washed with 2 CVs running buffer and the protein was eluted with 5 
CVs of running buffer supplemented with 20 mM maltose. Fractions containing HDAC6 were 
combined with His6x-Tev S219V protease (0.5 mg Tev protease/L culture) purified in-house31 
using a commercially purchased plasmid (Addgene plasmid pRK739) and dialyzed in 15-30 mL 
20K molecular weight cut-off (MWCO) dialysis cassettes against 200-fold running buffer 
containing 20 mM imidazole overnight at 4°C. After dialysis, the sample was loaded onto a 10-
mL Ni-NTA column running at 2 mL/min. The column was washed with 5 CVs of 50 mM 





protease were eluted with 20 CVs of a 50-500 mM linear imidazole gradient. Fractions 
containing cleaved HDAC6 were combined, concentrated to <2 mL, and loaded onto a 26/60 
sephacryl S200 size exclusion chromatography (SEC) column (GE) equilibrated with 
SEC/storage buffer (50 mM HEPES, pH 7.5, 100 mM KCl, 5% glycerol, and 1 mM TCEP) 
running at 0.5 mL/min. Eluted peaks were tested for deacetylase activity, and active fractions 
were concentrated, aliquoted, flash frozen with liquid N2, and stored at -80°C. A western blot 
analysis using an HDAC6 monoclonal antibody (Abcam 1:5,000) was performed to verify the 
identity of the protein. 
ACS Expression and Purification 
The expression plasmid was prepared previously. The chitin-tagged acetyl-CoA 
synthetase plasmid Acs/pTYB1 was a generous gift from Andrew Gulick (Hauptman-Woodward 
Institute). The pHD4-ACS-TEV-His6x was prepared previously by inserting the ACS gene into a 
pET vector containing a His6x tag to increase expression.27, 32 The pHD4-ACS-TEV-His6x 
construct was expressed and purified as previously described.27  
Coupled Acetate Detection Assay 
The coupled acetate detection assay or simply the acetate assay was performed as 
previously described with a few alterations.27 Briefly, lyophilized peptides were re-suspended in 
water when possible or with up 25% dimethylsulfoxide (DMSO). Peptide concentration was 
determined, depending on the peptide sequence, by: measuring A280 using the extinction 
coefficients for tryptophan or tyrosine absorbance if the peptide contained a tryptophan or 
tyrosine, using the fluorescamine assay if the peptide contained a free lysine,33 or performing the 
bicinchoninic (BCA) assay using bovine serum albumin (BSA) as a standard if the peptide had 
no aromatic or lysine residues. HDAC6 and singly-acetylated peptides (10-2000 µM) were pre-
incubated in 1X HDAC6 assay buffer (50 mM HEPES, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 
mM MgCl2) at 30°C for at least five minutes prior to initiation of the reaction by addition of 0.1-
1 µM HDAC6. Reactions were allowed to proceed at 30°C, and 60 µL were removed at selected 
timepoints (<2 minutes for fast reactions and up to 90 minutes for slow reactions) and quenched 
into separate tubes containing 5 µL of 10% hydrochloric acid. Each timepoint was briefly 
centrifuged and incubated on ice until assay completion (no more than 90 minutes) prior to flash 





Coupled solution (50 mM HEPES, pH 8, 400 µM ATP, 10 µM NAD+, 30 µM CoA, 0.07 
U/µL CS, 0.04 U/µL MDH, 50 µM ACS, 100 mM NaCl, 3 mM KCl, 50 mM MgCl2, and 2.5 
mM L-malic acid) and standards (acetate and NADH equal to 0-10% of highest peptide 
concentration) were prepared the day of the work-up and the coupled solution was incubated at 
room temperature for at least 20 minutes. NADH standards and coupled solution were protected 
from light. Timepoints were quickly thawed and neutralized with 10 µL of freshly prepared and 
filtered 6% sodium bicarbonate. Neutralized samples were vortexed and spun down, and 60 µL 
of each sample and each standard were added to 10 µL coupled solution (or 1X assay buffer for 
NADH standards) in a black, flat-bottomed, half-area, non-binding, 96-well plate (Corning No. 
3686). The NADH fluorescence (Ex=340 nm, Em=460 nm) of standards and samples was read 
on a fluorescence plate reader at 1-3-minute increments until the signal reached equilibrium 
(usually 30-60 min, depending on acetate concentration). The slopes of the acetate and NADH 
standard curves were compared to verify that the coupled mixture was working. When possible, 
a positive control reaction for enzyme activity was included. Using the acetate standard curve, 
the fluorescence of each timepoint was converted to µM product, and the slopes of the linear 
portion of the reaction (<10%) were plotted against substrate concentration. Using GraphPad 
Prism, the Michaelis-Menten equation (Equation IV.1) was fit to the resulting dependence of the 
initial velocity on substrate concentration to determine the kinetic parameters kcat/KM, kcat, and 









Modeling Peptide-Enzyme Complexes Using Rosetta FlexPepBind 
The Rosetta FlexPepBind protocol used to model HDAC8 peptide-enzyme complexes 
and predict substrate specificity was followed as previously described, with modifications.25, 34-35 
Briefly, the human HDAC6 CD2 in complex with trichostatin A (TSA) (PDB ID 5EDU) and 
zebrafish HDAC6 H574A CD2 in complex with histone H4K6 tripeptide substrate (PDB ID 
5EFN) crystal structures were used as the template ligand-receptor complexes to provide 
approximate starting models. Structural constraints (Table IV.1) were put in place to conserve 
key enzyme-substrate interactions such that the acetyl-lysine side-chain was locked into a 





constraints include the conserved His/Asp/Asp metal coordinating ligand contact to the acetyl-
lysine and several other residue/side-chain interactions. Using the algorithm to generate 1000 
models, the top scoring model, according to the most energetically favorable interface score (the 
total energy of the complex minus the energy of the individual partners when separated), was 
selected. The selected peptide sequences were then threaded into the peptide binding groove of 
the starting model using Rosetta fixed backbone design,36 and the peptide orientation and binding 
conformation were optimized using Rosetta FlexPepDock.  
The Rosetta default scoring function37 was used to rank the peptides in order of relative 
binding ability/strength, and the correlation between different subsets of the total score versus the 
logarithm of peptide activity (log[kcat/KM]) was determined. The model was then calibrated 
through adjusting the sampling protocol (e.g. refinement versus minimization) and analyzing the 
Rosetta score to determine the most correlative subset to provide a correlation R value (from -1 
to 1 with 0 indicating no correlation and 1 or -1 indicating perfect correlation) less than -0.3 with 
a probability p value of below 0.05. To validate and/or further optimize the model, 6-mer peptide 
sequences selected from our in-house library were then scored using the computational model to 
distinguish between binders and non-binders (i.e. substrates and non-substrates) and provide 
reactivity predictions for a second test group. These calibration steps were repeated with HDAC6 
activity data measured using the acetate assay to further optimize the model prior to screening 
the entire database of available acetylated sequences from PhosphoSitePlus.38  
Table IV.1 Residue constraints for human HDAC6 CD2 complexed with TSA (5EDU) 
Constraint type AA1 Position AA2 
Zn coordinating D 649 K-Ac 
Zn coordinating H 651 K-Ac 
Zn coordinating D 742 K-Ac 
Lock side chain of K-Ac H 610 K-Ac 
Lock side chain of K-Ac F 679 K-Ac 
Lock side chain of K-Ac F 620 K-Ac 
Lock side chain of K-Ac G 619 K-Ac 
Enforce H-bond  S 568 K-Ac 
cis-bind K-Ac - res4 peptide 
Lock side chain of K-Ac H 611 K-Ac 







Optimization of HDAC6 Expression and Purification 
After receiving plasmids from David Christianson for recombinant expression of HDAC6 
for human (didomain, hCD12) and zebrafish (didomain and single catalytic domains 1 and 2, 
zCD12, zCD1, and zCD2, respectively), I optimized expression and purification. To increase the 
transformation efficiency, I used a commercial stock of competent BL(21)-DE3 cells (Novagen). 
To increase the yield of purified protein from the recombinant expressions, I modified the 
purification protocol by swapping the first nickel and amylose columns, streamlining the buffer 
system, and moving to an overnight cleavage of the His6x-MBP tag catalyzed by Tev-protease in 
place of the less efficient on-column cleavage step in the original protocol. Total purified protein 
yield improved to 10 mg/L culture for zCD2. 
 As previously presented, HDAC6 contains two catalytic domains where domain 2 is 
considered the canonical domain with 23%-81% similarity between CD2 and the catalytic 
domain of the other Class II isozymes.1 HDAC6 is most similar to the other class IIb enzyme, 
HDAC10, sharing 55% overall identity.1 The CD2 domain has previously been shown to 
catalyze deacetylation of a small panel of fluorogenic and non-fluorogenic substrates with no 
obvious sequence selectivity.16 In contrast, the CD1 domain shows selectivity for hydrolysis of 
C-terminal acetyl-lysine substrates.16 Therefore, a systematic approach to identifying HDAC6 
substrates is warranted and here we began by measuring and modeling the behavior of the 
canonical domain CD2.  
The CD2 domains of HDAC6 are highly conserved in sequence and structure between 
zebrafish and human, with sequence identity of 59% and sequence similarity of 75%, particularly 
at the active site where only two side chains at the outer rim of the active site are not conserved 
(N530/N645 in zCD2 and D567/M682 in hCD2).16 Comparisons of the crystal structures of 
hCD2 and zCD2 demonstrate structural similarity, with an r.m.s. deviation of 0.43 Å for 314 Cα 
(Figure IV.2).16 These similarities demonstrate that zebrafish CD2 makes a valid surrogate for 
human CD2. Unfortunately, the human CD2 domain yields a protein that is ill-behaved in vitro; 
hCD2 is unstable in solution when cleaved from MBP and loses activity after a single freeze-
thaw cycle. In contrast, Zebrafish CD2 (zCD2) is well-behaved and stable in the absence of the 
MBP tag and retains activity comparable to an enzyme containing both domains (CD12).16 The 





zebrafish protein facilitates research towards a better understanding of human HDAC6 function. 
For these reasons, the zebrafish catalytic domain 2 was selected for in vitro testing and structure-
based identification of HDAC6 substrates.  
 
Figure IV.2 Catalytic domain 2 is conserved between humans and zebrafish 
Overlay of zebrafish and human HDAC6 catalytic domain 2 (PDB IDs 5EEK and 5EDU, 
respectively) complexed with TSA. Human CD2 (raspberry) and zebrafish CD2 (light cyan) 
closely align indicating strong structural homology. Only two residue pairs differ between the 
two structures: hCD2 N530 and zCD2 D567 and hCD2 N645 and zCD2 M682. In hCD2, the 
Zn2+ ion, TSA, and residues D567 and M682 are shown in ruby. In zCD2, the Zn2+ ion, TSA, and 
residues N530 and N645 are shown in dark teal. Figure modeled as previously published.16  
 
To test activity, zCD2-catalyzed deacetylation of four 6-mer, singly-acetylated peptides 
was measured using the acetate assay (Table IV.2) The four peptides selected correspond to 
acetyl-lysine residues in putative HDAC6 substrate Hsp90 and proteins involved in HDAC6-
regulated processes including cytoskeletal dynamics (actinin 1 and 2) and stress response 
(endoplasmin). The sequences were selected from available peptides in our in-house library. 
Although the acetate assay had not been tested with HDAC6 previously, the assay was designed 
to function with any metal-dependent deacetylase. As expected, HDAC6 catalyzed deacetylation 
of all four peptides. Unexpectedly, HDAC6 showed a 90-fold variation in activity even with this 
small selection of peptides. These results demonstrated that HDAC6 activity depends on the 
peptide sequence and validated the search for a substrate model based on the sequences 
immediately flanking the acetyl-lysine. The fastest peptide tested, corresponding to a well-





determine the steady state kinetic parameters:  kcat/KM = 85,000 ± 35,000 M-1s-1, kcat = 1.8 ± 0.6 s-
1, and KM = 21 ± 9 µM (Figure IV.3, Table IV.3). The kcat/KM for the peptide is higher than the 
kcat/KM, app since the peptide concentration selected for the initial test (50 µM) is above the KM for 
this peptide. 
 
Table IV.2 Approximate Activity for zCD2-Catalyzed Deacetylation of Four Peptides 
Protein Kac Function (Localization) Peptide Sequence kcat/KM, app, M-1s-1a 
HSP90A K436 stress response (Cy) YKKacFYE 19,000 ± 3,000 
ACTN1 K195  alpha actinin, actin binding (Pm, Cs) YGKacLRK 9,500 ± 700 
HSP90B1 K682 endoplasmin, stress response (Er) SQKacKTF 390 ± 190 
ACTN2 K181 alpha actinin, actin binding (Cs) SWKacDGL 210 ± 90 
aActivity was measured at a single concentration of substrate (50 µM) and the value of kcat/KM, app 
was determined from v0/[E][S]. Abbreviations: Cy = cytoplasm; Pm = plasma membrane; Cs = 
cytoskeleton; Er = endoplasmic reticulum. 
 
A       B 
    
Figure IV.3 Dependence of HDAC6-catalyzed deacetylation on the concentration of Hsp90 
K436ac Peptide 
HDAC6 zCD2-catalyzed deacetylation of the Hsp90 peptide YKKacFYE was measured using 
the acetate assay with [HDAC6]=100 nM and [Peptide] ranging from 0-300 µM. The initial 
velocity, n0, was determined from the first 10% of the reaction at each peptide concentration (up 
to 90 seconds) (A), and the steady-state kinetic parameters kcat/KM, kcat, and KM were determined 
by fitting the Michaelis-Menten equation (Equation IV.1) to the dependence of the initial 
velocity on the substrate concentration (B). Open blue circle denotes value for n0/[E] from the 
initial test. Analysis was performed, and standard errors were determined, using GraphPad 
Prism. 
  



































Peptide Screen Demonstrates Up to 20,000-fold Changes in Activity Depending on Sequence 
To obtain further insight into the selectivity of HDAC6 CD2, the peptide reactivity for 
additional sequences was measured using the acetate assay. zCD2-catalyzed deacetylation of a 
library of 28 peptides was assayed at one concentration per peptide with two timepoints per 
reaction. The resulting values for kcat/KM, apparent (assuming that the selected peptide 
concentrations are below the KM) follow a similar trend as the initial four test peptides and 
demonstrate that some peptides are excellent HDAC6 substrates (>103 M-1s-1) while other 
peptides are poor substrates (<100 M-1s-1) (Table IV.3). The peptides were selected from an in-
house peptide library used for HDAC8 substrate specificity determination and included peptides 
from a diverse set of proteins. The peptides were chosen from a library containing over 250 
peptides, and the selection was based principally on amount of peptide available, solubility, and 
varied sequence and subsequently on diverse corresponding protein function (localization, 
cellular role, etc.) with special attention to proteins with known functions, proteins involved in 
HDAC6-related pathways (e.g. stress response, cytoskeletal dynamics) and proteins with clinical 
significance (e.g. LMNA, MSH2, PTEN). All peptides correspond to known acetyl-lysine 





Table IV.3 Initial Peptide Screen and Model Training Seta 
Protein K(ac) Function (Localization)b Peptide Sequence kcat/KM, app M 1s-1 
CRIP1 K22 zinc finger, zinc transport (Cy,Nu,Cn) SLGKacDWHR 6500 
LMNA K450 nuclear assembly, dynamics (Nm) EGKacFVR 5200 
VDAC1 K61 membrane channel (Pm, Mi) ETKacYRW 3200 
ACTN1 K195 alpha actinin, actin binding (Pm, Cs) YGKacLRK 3000 
ACLY K540 acetyl-CoA synthesis (Cy, Pm, Nu) DHKQKacFYWGHK 3000 
TRIM28 K770 nuclear co-repressor (Nu) RMFKacQFNK 2700 
MSH2 K635 DNA mismatch repair (Nu) RIILKacASRH 2600 
MCM6 K599 helicase (Nu) EQYKacHLR 2600 
SFPQ K314 splicing factor (Nu) EFKacRLF 2200 
RDH16 K221 oxidoreductase, lipid metabolism (Er) ERFLKacSFLE 2000 
PTEN K125 phosphatase, tumor suppressor (Nu, Cy) HCKacAGK 1800 
HNRL2 K570 transcriptional regulation (Nu) DWKacKRL 1500 
UPF1 K386 helicase, mRNA catabolism (Nu) RYKGDLAPLWKacGIGHVIKVPD 1400 
ITGB1 K134 receptor, cell signaling/adhesion (Pm) TLKacFKR 1100 
NPEPPS K48 aminopeptidase (Nu,Cy) PEKacKRP 1100 
HS71 K146 chaperone, stress response (Nu, Cs) EFKacRKH 910 
HSPA1L K321 chaperone, stress response (Nu, Cy) VEKacALR 830 
HSP90B1 K682 chaperone, stress response (Er) SQKacKTF 820 
QARS K628 ligase, tRNA aminoacylation (Cy) EPEPGFKacRLAWGQ 820 
H4K16 K16 histone H4, chromatin (Nu) KGGAKacRHR 490 
RL3 K393 ribosomal protein, translation (Nu, Cy) PLKacKDR 450 
LMNA K260 nuclear assembly, dynamics (Nm) QYKacKEL 380 
S10A8 K84 metal binding, immunity (Pm, Ec, Cy) AHKacKSH 370 
PARP1 K505 ribosyltransferase, DNA repair (Nu) LSKacKSK 360 
PTEN K128 phosphatase, tumor suppressor (Nu, Cy) AGKacGRT 260 
PTEN K6 phosphatase, tumor suppressor (Nu, Cy) IIKacEIVSR 100 
DPP3 K294 aminopeptidase (Cy) AHKacRGS 80 
AKR1C2 K246 oxidoreductase, lipid metabolism (Cy) LAKacKHK 12 
 
                                               
a Values for kcat/KM, app  were determined from a reaction of 100 nM HDAC6 and 100 µM peptide. Two timepoints 
were taken (15 and 600 seconds) per reaction. The values may be an underestimate of the value of kcat/KM  if the 
peptide concentration is above the KM value. Abbreviations: Cs=Cytoskeleton, Cy=Cytosol, Cn=Centrosome, 
Pm=Plasma membrane, Mi=Mitochondria, Nu=Nucleus, Nm=Nuclear Membrane, ER=endoplasmic reticulum, Ec-
extracellular region).  





 This initial screen provides a qualitative analysis of the catalytic activity of HDAC6 with 
these peptides, demonstrating selectivity for 6 amino acid peptide substrates of >400-fold.  
However, the values for kcat/KM,app may underestimate the actual value for two reasons. First, 
since only two time points were taken in these assays, the reactions may have progressed beyond 
the initial 10% by the 10 min timepoint. Second, the peptide concentration (100 µM) used in the 
screen, may have been above the KM and thus invalidated the approximation used in the 
calculation of kcat/KM, app. Both of these inaccuracies should have the largest effect for the best 
substrates. Therefore, the initial rate at multiple substrate concentrations was tested to calculate 
the steady-state kinetic parameters kcat/KM, kcat, and KM for several of the most reactive peptides 
including cysteine-rich protein 1 (CRIP1) Kac22, prelamin A (LMNA) Kac450, voltage-
dependent anion-selective channel protein 1 (VDAC1) Kac61, a-actinin (ACTN1) Kac195, 
transcription intermediary factor 1-b (TRIM28) Kac770 , and DNA mismatch repair protein 
Msh2 (MSH2) Kac635, as well as one of the least reactive peptides dipeptidyl-peptidase 3 
(DPP3) Kac294 as was done with Hsp90 K436ac (Table IV.4, Figure IV.4).  
The results showed that, indeed, the kcat/KM, app values from the initial screen 
underestimated the values for peptides at the upper range of activity, but the peptides on the 
lower range of activity were more accurately estimated (Figure IV.4, Table IV.4). These more 
accurate values demonstrated HDAC6 selectivity for 6 amino acid acetylated peptides of nearly 
20,000-fold using the AKR1C2 peptide as the lower limit. Surprisingly, for the most reactive 
peptides, the kcat/KM values approach the estimated 106-108 M-1s-1 diffusion-controlled limits for 
catalytic turnover.41 The selectivity ratios and kcat/KM values are significantly larger than 
previously reported for domain 2 of zebrafish HDAC6.16 
Table IV.4 Training set steady-state kinetic parameters for HDAC6-catalyzed 
deacetylation of short peptides 
Protein K(ac) Peptide Sequence kcat/KM, M-1s-1 KM, µM kcat, s-1 
LMNA K450 EGKacFVR 220,000 ± 35,000 19 ± 4 4.2 ± 0.7 
HSP90A K436 YKKacFYE 85,000 ± 29,000 21 ± 9 1.8 ± 0.6 
VDAC1 K61 ETKacYRW 42,000 ± 9,500 160 ± 110 6.8 ± 1.5 
ACTN1 K195 YGKacLRK 31,000 ± 3,500 200 ± 80 6.0 ± 0.7 
CRIP1 K22 SLGKacDWHR 31,000 ± 4,900 320 ± 150 9.9 ± 1.5 
TRIM28 K770 RMFKacQFNK 21,000 ± 1,300 >100 >2 
MSH2 K635 RIILKacASRH 19,000 ± 3,000 210 ± 120 4.1 ± 0.6 






                 
                 
                 
                 
Figure IV.4 Dependence of HDAC6-Catalyzed Deacetylation on Peptides Concentration 
HDAC6 zCD2 activity with short peptides, including LMNA peptide EGKacFVR, HSP90 
peptide YKKacFYE, VDAC1 peptide ETKacYRW, ACTN peptide YGKacLRK, CRIP1 peptide 
SLGKacDWHR, TRIM28 peptide RMFKacQFNK, MSH2 peptide RIILKacASRH, and DPP3 
peptide AHKacRGS was measured using the acetate assay. [HDAC6]=100 nM. [Peptide]=0-200 
µM. The initial velocity, n0, was determined from product formation for the first 10% of each 
reaction, and the steady-state kinetic parameters kcat/KM, kcat, and KM were determined by fitting 
the Michaelis-Menten equation (Equation IV.1) to the dependence of n0 on the substrate 





















































































































Development of Structure-Based Protocol for HDAC6 Using Initial Peptide Screen as 
Training Set 
Using the first set of peptides and kinetic parameters (Table IV.3 and Table IV.4), an 
initial model of HDAC6 substrate binding was developed using the Rosetta framework and 
FlepPepDock and FlexPepBind protocols described previously.25, 34-35 The milestones for model 
development include: 1) developing a model of HDAC6 binding capable of distinguishing 
between 6-mer peptide binders and non-binders (i.e. substrates and non-substrates), 2) 
optimizing the model to rank peptides in order of relative binding strength, and 3) screening 
acetylome databases to identify putative HDAC6 structures. This research encompasses efforts 
towards achieving the 1st milestone.  
To create an initial receptor-ligand template structure, two HDAC6 structures were 
modeled using Rosetta FlexPepDock. The two crystal structures implemented were zebrafish 
HDAC6 CD2 bound to a 3-mer H3K6ac peptide (PDB ID 5EFN) and human HDAC6 CD2 
bound to TSA (PDB ID 5EDU). Human and zebrafish structures were used to compare and 
identify differences, if any, between models. In order to maintain the acetyl side-chain in a 
favorable binding orientation for catalysis yet allow for flexibility within the flanking peptide 
sequence, key residues were identified and constrained such that the substrate was locked into 
the active site. This way, the protocol had access to only relevant conformations with enough 
flexibility to sample numerous possible structures. The residues selected for constraint include 
the conserved catalytic Zn(II) ligands D649, H651, and D742 for the human CD2-TSA structure 
(Table IV.1) and D612, H614, and D705 for the zebrafish CD2-H4Kac6 peptide structure to 
tether the acetyl-group to the Zn(II) binding site and to several residues with hydrogen-bond 
interactions along the peptide backbone of the acetyl-lysine.  
With these constraints in place, the Rosetta protocol FlexPepDock was adapted to 
HDAC6 by modeling the binding of HDAC6 to the peptide sequence corresponding to the best 
substrate prelamin A, EGKacFVR. An output of 1,000 structures of HDAC6-peptide binding 
were produced and of these, the most energetically favorable structures were further analyzed, 
and the best structure was selected as the template to model multiple peptide interactions. In 
order to test and optimize the starting structure, additional peptide sequences were threaded into 
the peptide binding groove using the Rosetta protocol FlexPepBind and scored. Peptide binding 





the logarithm of catalytic efficiency (log[kcat/KM]) was determined. Multiple subsets of the 
Rosetta default scoring function (total score) were analyzed to identify the best correlating 
parameter. Further changes were made to the protocol to optimize binding and correlation. These 
include increasing the amount of sampling (or the number of structural permutations analyzed by 
the program) and performing additional peptide minimization and structural refinement 
operations. For both zebrafish and human models, the interface score, the subset of the total 
score encompassing the sum of the interactions across the interface, yielded the best correlation. 
Correlation R values, which range from -1 to 1 with 0 indicating no correlation and 1 or -1 
indicating perfect correlation, and probability p values were determined using GraphPad prism 
analysis. For the zebrafish and human models, the best correlation between the logarithm of 
catalytic efficiency (kcat/KM) and corresponding interface score for the training set of peptides 
listed in Table IV.3 were -0.59 and -0.74, respectively. Due to better correlation for the human 
structure, this model was selected to test additional sequences and identify a set of peptides for 
validation. The protocol was run for an additional 60 peptide sequences selected from our in-
house peptide library of >250 peptides, and 8 peptides were chosen for validation. 
Optimization of Structure-Based Protocol for HDAC6 
In order to test the algorithm developed based on the data from the initial training set 
(Table IV.3, Table IV.4), a validation set of peptides was tested (Figure IV.5, Table IV.5) 
including peptides corresponding to TCOF1, PCBP1, KIF5B, CDK1, MATR3, LARP1, EIF3B, 
and GOT1. Six of the peptides were scored as good binders, while two of the peptides were 
scored as poor binders. HDAC6 zCD2 deacetylated all 8 peptides tested with catalytic 
efficiencies ranging from 16,000-44,000 M-1s-1. The kcat/KM values for TCOF1, PCBP1, KIF5B, 
and CDK1 peptides were reliably measured (Figure IV.5, Table IV.5). However, for the other 4 
peptides, MATR3, LARP1, EIF3B, and GOT1, the values for kcat/KM were difficult to calculate 
reliably due to either inhibition at high peptide concentrations or KM values below the detection 
level of the assay (<10 µM). For the peptides with inhibitory activity, an estimate of kcat/KM was 
calculated from the substrate concentration at the highest initial velocity. For LARP1, due to a 
low KM, (HDAC6 was already saturated at [LARP1] = 10 µM), an estimated value for catalytic 
efficiency was determined from the initial velocity at the lowest peptide concentration measured. 
However, in order for accurate representation of catalytic activity, the assay would have to be 





interference. The same estimation was performed for EIF5B, as HDAC6 was saturated at the 
lowest peptide concentration measured (50 µM). Moreover, peptide concentration will have to be 
carefully analyzed in order to verify stock concentration, as the concentration of certain peptides 
may not be accurately represented using measurements by BCA. This, however, has yet to be 
determined. Despite all of this, the resulting correlation for the peptides that were scored as good 
binders with interface scores > -26.5 was very good with R = -0.85 and p = 0.03. However, the 
two peptides that were scored as poor binders, PCBP1 and KIF5B, have values of kcat/KM and KM 
comparable to the good binders (Table IV.5) and inclusion of these data made the correlation 
insignificant with R = -0.57 and p = 0.1 (Figure IV.6A). Due to these two false negatives, the 
model was further calibrated to distinguish between HDAC6 substrates and non-substrates. With 
this modified model, the resulting correlation for all data (Table IV.6) was R = -0.62 and 
p<0.0001(Table IV.6, Figure IV.6B). 
 
Table IV.5 Validation peptide set kinetic parameters for HDAC6 structure-based modela 
Protein Kac Function (Localization)b Peptide Sequence kcat/KM, M-1s-1 KM, µM I-S 
TCOF1 
K450 
K296 RNA pol I regulation (Nu) SEKacILQ 44,000 ± 12,000 33 ± 11 -26.77 
PCBP1 K23  iron chaperone (Nu) HGKacEVG 39,000 ± 15,000 85 ± 51 -23.93 
KIF5B K346 kinesin, transport (Cs) YEKacEKE 27,000 ± 4,600 66 ± 14 -24.08 
CDK1 K33 kinase, cell cycle (Cs, Nu) AMKacKIR 16,000 ± 1,600 60 ± 11 -26.76 
MATR3c K473 transcription (Nu) SQKacYKR 99,000 20 -29.75 
LARP1de K1017 translation (Nu, Cy, Er) LGKacFRR 97,000 
 
ND -29.01 
EIF3Bde K364 translation (Nu, Cy) GEKacFKQ 28,800 ± 500  
 
ND -27.91 




                                               
a Values for kcat/KM and KM are from Figure IV.5. Abbreviations: Nu=nucleus, Cs=Cytoskeleton, I-S = interface score. 
b Function and localization information was taken from the UniProt protein database and the human atlas project.39-40 
c Values for kcat/KM, and KM were determined from 2 points at concentrations above the KM (Figure IV.5).from lowest 
concentration of peptide measured/largest initial velocity 
d Values for kcat/KM,app  were determined from lowest concentration of peptide measured (Figure IV.5). 





                 
                 
                 
                 
Figure IV.5 Validation set of peptides concentration dependence of HDAC6 deacetylation 
HDAC6 zCD2 activity with peptides SEKacILQ (TCOF1), HGKacEVG (PCBP1), YEKacEKE 
(KIF5B), AMKacKIR (CDK1), SQKacYKR (MATR3), LGKacFRR (LARP1), GEKacFKQ 
(EIF3B), and GFKacDIR (GOT1) was measured using the acetate assay. For CDK1 and LARP1, 
[HDAC6]=500 nM and [Peptide]=0-100 µM. For all other peptides, [HDAC6]=100 nM and 
[Peptide]=0-500 µM. The initial velocity, n0, was determined from the first 10% of the reaction 
at each peptide concentration, and the kinetic parameters kcat/KM, kcat, and KM were determined 
by fitting the Michaelis-Menten equation (Equation IV.1) to the initial velocity dependence on 
substrate concentration. Analysis was performed using GraphPad Prism and standard errors were 

















































































































Table IV.6 Peptide kinetic parameters and interface scores for current structure-based 
binding model used to determine correlationa 
Protein K(ac) Peptide Sequence kcat/KM, M 1s-1 
Interface 
Score Conclusion 
LMNA K450 EGKacFVR 220000 -29.704 G 
MATR3 K473 SQKacYKR 99000 -31.07 G 
LARP1 K1017 LGKacFRR 97000 -31.28 G 
HSP90 K436 YKKacFYE 85000 -29.784 G 
TCOF1 K296 SEKacILQ 44000 -30.69 G 
VDAC1 K61 ETKacYRW 42000 -29.54 G 
PCBP1 K23 HGKacEVG 39000 -27.59 G 
CRIP1 K22 SLGKacDWHR 31000 -27.941 G 
ACTN1 K195 YGKacLRK 31000 -29.478 G 
EIF3B K364 GEKacFKQ 28800 -30.15 G 
KIF5B K346 YEKacEKE 27000 -27.22 G 
GOT1 K154 GFKacDIR 27000 -29.78 G 
TRIM28 K770 RMFKacQFNK 21000 -28.147 G 
MSH2 K635 RIILKacASRH 19000 -28.035 G 
CDK1 K33 AMKacKIR 16000 -28.26 G 
ACLY K540 DHKQKacFYWGHK 3000 -29.533 M 
MCM6 K599 EQYKacHLR 2600 -31.064 M 
SFPQ K314 EFKacRLF 2200 -29.781 M 
RDH16 K221 ERFLKacSFLE 2000 -29.147 M 
PTEN K125 HCKacAGK 1800 -30.109 M 
HNRL2 K570 DWKacKRL 1500 -28.088 M 
UPF1 K386 RYKGDLAPLWKacGIGHVIKVPD 1400 -28.248 M 
ITGB1 K134 TLKacFKR 1100 -28.299 M 
NPEPPS K48 PEKacKRP 1100 -24.401 M 
HS71 K146 EFKacRKH 910 -26.041 M 
HSPA1L K321 VEKacALR 830 -28.811 M 
HSP90B1 K682 SQKacKTF 820 -25.666 M 
QARS K628 EPEPGFKacRLAWGQ 820 -29.62 M 
H4K16 K16 KGGAKacRHR 490 -27 P 
RL3 K393 PLKacKDR 450 -24.443 P 
LMNA K260 QYKacKEL 380 -25.99 P 
S10A8 K84 AHKacKSH 370 -24.893 P 
PARP1 K505 LSKacKSK 360 -25.614 P 
PTEN K128 AGKacGRT 260 -26.325 P 
ACTN2 K181 SWKacDGL 210 -27.073 P 
DPP3 K294 AHKacRGS 115 -25.531 P 
PTEN K6 IIKacEIVSR 100 -28.61 P 
AKR1C2 K246 LAKacKHK 12 -26.46 P 
  
                                               
a Compiled values for best kcat/KM measured for short peptides with HDAC6 zCD2. Interface scores are for current 
computational binding model and graphed in Figure IV.6. Abbreviations: K(ac) = acetyl-lysine, G = good 






A             B 
 
 
Figure IV.6 Correlation between modeled binding and HDAC6 activity for peptides 
The correlation between the interface score and the logarithm of catalytic activity (log[kcat/KM]) 
for the validation set (A) and the training and validation sets with the optimized model (B) 
(Table IV.6). The line indicates a linear fit, and the correlation R and p values (from -1 to 1 with 
0 indicating no correlation and 1 or -1 indicating perfect correlation) were calculated to be -0.57 
and 0.1375 for the validation set (A) and -0.62 and <0.0001 for all data with the optimized 
model, respectively. Blue open circles = validation set (Table IV.5, Figure IV.5) and previous 
model interface scores, blue closed circles = validation set with new model interface scores, 
green closed circles = training set good substrates/binders (>16,000 M-1s-1), purple closed circles 
= training set moderate substrate/binder (500—16,000 M-1s-1), and red closed circles = training 
set poor substrate/binder (<500 M-1s-1) (Table IV.6).  































Histone deacetylase 6 is an important regulator of cellular processes including 
cytoskeletal dynamics and stress response.13 Furthermore, aberrant HDAC6 activity has been 
linked to various types of human disease making HDAC6 an attractive target for drug 
discovery.11, 13-14 Although HDAC6 has been studied extensively over the last decade, few 
specific substrates have been identified. Given that there are only 18 human deacetylases and 
thousands of acetylation events observed in humans, it is unlikely that the current shortlist of 
HDAC6 substrates, with the majority of reports relating to Hsp90, a-tubulin, and cortactin, is 
complete.42 However, identifying which acetyl-lysines are HDAC6 substrates is a significant 
challenge. In order to provide a tool to virtually screen large numbers of potential substrates, we 
are developing a computational, structure-based model using the Rosetta FlexPepBind platform, 
optimized specifically to HDAC6. Previously, a similar model was developed for the class I 
deacetylase HDAC8, and after optimization, this algorithm successfully predicted HDAC8 
peptide substrates.25  
Our results demonstrate a wide range of HDAC6 catalytic activities, varying from 10-106 
M-1s-1. Compared to HDAC8, HDAC6 displays more robust catalysis in vitro, deacetylating 
peptide substrates over 20 times more efficiently than the best HDAC8 in vitro substrate,25 with 
larger values for kcat and smaller values for KM, suggesting both tighter binding and faster 
chemistry/product dissociation. Unfortunately, a comparison of the sequences of the slowest and 
fastest HDAC6 peptides reveals no obvious trend in sequence preference, as is the case for other 
HDACs. For example, although peptide screens identified favorable residues for HDAC2, 
HDAC3, and HDAC8, such as an arginine residue at the -1 position and an aromatic residue at 
the +1 position to the acetyl-lysine, this information is not sufficient to identify HDAC 
substrates.29  
Our current model successfully predicts good peptide substrates for HDAC6, however 
further optimization is needed for the model to accurately predict which peptides are poor 
HDAC6 substrates and thus allow discrimination between good and bad binders/substrates. Part 
of the difficulty associated with predicting poor substrates is the high HDAC6 activity observed 
thus far and the relatively few examples of poor peptide substrates. Additionally, the distinction 
between a good substrate and a bad substrate is relative. Since HDAC6 catalyzes deacetylation 





the value of kcat/KM and the substrate concentration as reflected by the ratios of (kcat/KM)[Si]. 
Expanding the study to include more peptides predicted to be poor binders will be critical for 
identifying additional sequences exhibiting low reactivity with HDAC6 and therefore improving 
model calibration. 
The high in vitro activity observed for HDAC6 may also indicate that the deacetylase 
domain 2 has lower substrate selectivity than the previously modeled HDAC8. However, the 
initial data (Table IV.2, Table IV.3, and Table IV.4) showing large variations in reactivity argue 
against a lack of substrate selectivity. Furthermore, the divergent structure and localization of 
HDAC6 compared to other HDACs argue against complete redundancy, although substrate 
overlap is common and structural accommodations including flexible surface architecture, such 
the dynamic loops flanking the active site of HDAC8, allow for accommodation of multiple 
substrates.1, 43  
A caveat to the use of such a model is that it only analyzes the interface between the 
peptide substrate with the assumption that substrate selectivity can be deduced from local 
sequence interactions and does not take into account contribution of contacts apart from those 
directly adjacent to the active site. Distal contacts between enzyme and substrate may play a 
more prominent role in substrate selectivity, and the overall structure of the substrate and the 
location of the acetyl-lysine residue within structured or unstructured regions of the protein must 
be considered. Furthermore, our model is limited to catalytic domain 2, and CD1 and other 
HDAC6 domains likely play a part in substrate recognition. However, recent data comparing 
HDAC8 with peptide and protein substrates (Chapter III), does provide a precedent for substrate 
selectivity dependence on local sequence, even with short 6-mer segments as used in this study. 
This has not yet been tested with HDAC6, but a similar study could be adapted to test HDAC6 
activity with peptide and protein substrates, and as HDAC6 is proposed to catalyze deacetylation 
of numerous cytoplasmic substrates, these proteins may be more amenable to in vitro study than 
other nuclear or membrane-bound proteins or protein complexes. Other regulatory functions 
including post-translational modifications, protein-protein interactions, cellular localization, and 
environmental conditions are likely to impact HDAC6 substrate selectivity and may play a 
significant role in regulating HDAC6 substrate selectivity and activity. 
The fastest peptide substrate measured for HDAC6 corresponds to prelamin A (LMNA) 





structural component of the nuclear lamina responsible for supporting numerous nuclear 
functions.44 Prelamin A is highly post-translationally modified by prenylation, phosphorylation, 
and acetylation, which assist in prelamin maturation and function, and many of these PTMs have 
been linked to disease. For example, a prelamin A variant K39E, prevents acetylation at that site, 
which leads to altered ventricular dilation and systolic function resulting in congestive heart 
failure, arrhythmia, and increased risk of premature death.45 Moreover, lamin A has been shown 
to interact with other HDACs, including Sirt1, HDAC1/2, and HDAC3.46 Although lamin A is 
nuclear and HDAC6 is considered predominantly cytoplasmic, HDAC6 is able to shuttle into the 
nucleus and has been implicated in non-cytoplasmic processes, and direct interactions with 
prelamin A, and other nuclear proteins, cannot be ruled out.47 This is the first evidence for 
HDAC6 involvement in nuclear lamina regulation, and prelamin A may represent a novel 
HDAC6 substrate suggesting HDAC6 inhibition could be a therapeutic avenue in slowing the 
progress of LMNA-related diseases.  
The peptide corresponding to K437ac of matrin 3 (MATR3), another internal nuclear 
matrix protein, was one of the fastest HDAC6 substrates. Matrin 3 associates with lamin A and is 
implicated in similar muscular impairment diseases, including amyotrophic lateral sclerosis 
(ALS), a fatal disorder caused by degeneration of motor neurons.48 HDAC6i has been shown to 
ameliorate transport defects in ALS motor neurons, presumably through increased alpha-tubulin 
acetylation.49 The potential interactions between HDAC6 and these nuclear matrix proteins 
warrants a closer investigation, as HDAC6-catalyzed deacetylation of these and other nuclear 
proteins may be important in disease progression. 
Hsp90 (HSP90), kinesin (KIF5B), and CDK1 were three substrates with evidence of 
HDAC6 interactions in the literature. HDAC6 immunoprecipitates with Hsp90 in mouse 
fibroblasts, and HDAC6 genetic knockout and inhibition with tubacin and tubastatin lead to 
Hsp90 hyperacetylation and support a model for HDAC6-mediated Hsp90 activation whereby 
deacetylation of Hsp90 results in Hsp90 repressive complex disassociation and increased 
chaperone activity.50 Our data support HDAC6-catalyzed deacetylation of Hsp90. Kinesin, like 
dynein, is a molecular motor responsible for intercellular trafficking along microtubules, and 
HDAC6 promotes kinesin association with microtubules, thus facilitating cargo transport.51 
While this is thought to be due to HDAC6 a-tubulin deacetylation and/or an activity-independent 





function. Another putative substrate, cyclin-dependent kinase 1 (CDK1), has previously been 
reported in association with HDAC6 and both have implications in breast cancer.52-53 Our data 
suggests CDK1 K33ac may be an HDAC6 substrate thus connecting HDAC6 with CDK1-
regulation and by association with CDK1-directed diseases. Testing other known acetyl-lysine 
sites within these substrates may provide additional evidence for HDAC6 function with these 
proteins and processes.  
Measuring HDAC6-catalyed deacetylation of additional peptides will be necessary to 
expand our knowledge of HDAC6 substrates and further develop the computational model. Key 
residues to test include peptides corresponding to putative substrates a-tubulin K40ac, cortactin, 
as well as additional Kac residues from Hsp90 such as K294ac, a residue important for 
chaperone function and hyperacetylated upon HDACi treatment.54 Testing of an additional set of 
peptides predicted to be poor HDAC6 substrates using the current structure-based model will 
also be necessary to further calibrate the model. These peptides include additional TCOF1 
(treacle protein) residues K146ac, K379ac, and K1414ac and proteins EIF5 (eukaryotic 
translation initiation factor 5) residue K28ac, COPA (coatomer subunit alpha) residue K74ac, 
RL4 (60S ribosomal protein L4) residue K162ac, and UBA1 (ubiquitin-like modifier-activating 
enzyme 1) residue K1024ac. 
Taken together, the data described above provide evidence that HDAC6 recognizes 
sequence-specific determinants in substrates adjacent to the acetyl-lysine reside that contribute to 
the substrate selectivity of this enzyme. After further optimization of the model, we plan to use 
this algorithm to screen the PhosphoSitePlus database38 of known human protein acetyl-lysines 
to identify additional putative HDAC6 substrates. Cross referencing identified substrates with 
known HDAC6 interactions and HDAC6-regulated processes will help identify important 
connections between HDAC6 substrates and cell homeostasis. Use of orthogonal in vitro and in 
vivo approaches, similar to studies previously described, will be important for further validating 
this computational model, determining the impact of substrate structure on HDAC6 selectivity, 
and comparing in vitro activity to cellular function. Screening tools, such as this HDAC6 
structure-based identification model, will facilitate progress in defining the function and 
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The research summarized in this dissertation is part of an on-going effort in the field of 
protein post-translational acetylation to better understand the intricacies of this important PTM, 
its function in biological systems, and the enzymes responsible for its regulation. The focus of 
this research has centered on the family of metal-dependent human deacetylases, the HDACs. 
Specifically, HDAC8 and HDAC6 are the targets of this research, which not only seeks to 
investigate and characterize their function and regulation, but also to develop tools and establish 
paradigms for HDAC research. HDAC8 and HDAC6 share commonalities and divergencies that 
serve to enlighten the field about shared functionality among HDACs and key differences in their 
regulation. Both HDAC8 and HDAC6 share canonical deacetylase domains with conserved 
active sites and divalent metal ion coordination.1-4 Both have proposed functions in the 
cytoplasm and the nucleus of the cell, some of which, like cytoskeletal dynamics regulation, are 
shared, and the two enzymes even display overlap in putative substrates and/or interacting 
partners including Arid1A5-6, Hsp907-8, and a-tubulin.9 Additionally, HDAC8 and HDAC6 
appear to play a role in some of the same disease pathologies, such as invasive breast cancer.10-12 
However, the two enzymes exhibit many differences. HDAC8 is a class I enzyme, sharing 
structural homology with yeast Rpd3, and the second smallest isozyme, with short C- and N-
terminal sequences flanking its deacetylase domain.13-15 On the other hand, HDAC6 is a class II 
enzyme, with homology to yeast Hda1, and the largest deacetylase, containing multiple domains 
including a second catalytic domain with different substrate specificity.13-15 These structural 
differences allude to significantly different cellular roles. Indeed, HDAC8 and HDAC6 do not 
share many protein substrates, and are involved in numerous different physiological and disease 
pathologies.16-17 Understanding the shared and unique functions of HDAC8 and HDAC6 is a 
priority in the field and will help us obtain a clearer picture of their specific roles and, more 
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importantly, inform us about key aspects of their function and regulation that may be used to our 
advantage to improve the quality of life for those afflicted with disorders caused or exacerbated 
by HDAC misregulation and dysfunction. 
This dissertation discusses research into aspects of HDAC function and regulation 
concerning the impact of post-translational modifications and substrate structure and sequence 
on the activity of HDAC8 and HDAC6. Here, I have described new details regarding HDAC8 
post-translational phosphorylation and how it may regulate substrate binding and activity 
through slight shifts in structure. I also share the results of a study to investigate differences 
between peptide and full-length protein substrates and reported a methodology for doing so that 
can be adapted to other HDACs and protein substrates. And finally, I have revealed the 
development of a new structure-based computational tool to screen and identify novel HDAC6 
substrates. This chapter summarizes key findings and conclusions from each chapter and 
discusses their implications in the field and future approaches for furthering the study on these 
topics. 
The Impact of HDAC8 Post-Translational Phosphorylation on Structure and Function  
In chapter II, we share a study on HDAC8 phosphorylation and its impact on HDAC8 
substrate selectivity. We use HDAC8 S39E as a phosphomimetic, where the serine residue 
targeted for phosphorylation is replaced with a bulky and negatively charged glutamate residue, 
to model the effect of the PTM in in vitro activity and structure. We also implement molecular 
dynamics simulations to compare and contrast the structures of native HDAC8, phosphorylated 
HDAC8 and the phosphomimetic HDAC8 mutant. Previously, PKA was identified as the kinase 
responsible for the unique phosphorylation of HDAC8 at position 39.18 However, less is known 
about the impact of phosphorylation on HDAC8 function other than apparent downregulation for 
a few substrates. Several studies have reported on changes due to HDAC8 phosphorylation, such 
as increasing HDAC8 affinity for the protein human ever- shorter telomeres 1B (hEST1B), but 
no prior in-depth analyses have been performed on HDAC8 phosphorylation.8  
Here, we have reported that the phosphomimetic mutant both decreases deacetylase 
activity and alters substrate selectivity, suggesting that phosphorylation at S39 serves as a means 
of regulating targets of HDAC8-catalyzed deacetylation. Crystallographic analyses of the 
phosphomimetic mutant provide an explanation for the decreased activity and altered selectivity. 





interactions, increased loop dynamics at the peptide binding interface, and structural differences 
at the active site, thus altering both the substrate binding interface and the active site. Molecular 
dynamics simulations demonstrated that similar changes were observed for the peptide binding 
interface in both the phosphomimetic mutant and the modeled phosphorylated enzyme that result 
in less favorable binding interactions and less efficient deacetylation. In summary, these data 
suggest that phosphorylation causes slight shifts in the structure that subtly alters the peptide 
binding groove and the active site. These changes affect peptide substrates differentially, thus 
altering HDAC8 substrate selectivity and potentially altering both HDAC8 activity and the 
regulation of HDAC8-specific cellular substrates. These results further our understanding of 
HDAC8 phosphorylation by providing evidence that HDAC8 phosphorylation may be used as a 
means of altering HDAC8 substrate selectivity in the cell and thus warranting further study to 
tease out specific cellular changes due to HDAC8 phosphorylation.  
Firstly, although molecular dynamics simulations provide support for the similarities 
between the phosphomimetic mutant and phosphorylated wild-type enzyme and support the use 
of the S39E mutant as a viable surrogate, the analysis of phospho-HDAC8 would be ideal. 
Obtaining sufficient quantities of fully phosphorylated HDAC8 to crystallize and perform 
enzymatic activities has not been achieved thus far. However, several approaches may prove to 
yield the desired results. The first includes enzymatically phosphorylating HDAC8 through 
incubation with PKA followed by a phospho-enrichment step, most often used in phospho-
proteomics studies.19 It has yet to be determined if this will provide sufficient quantities and 
purity of phospho-HDAC8 rapidly enough to maintain HDAC8 structure and activity; however, 
an anti-phosphotyrosine antibody immobilized agarose resin was used to successfully separate 
phospho-calmodulin from non-phosphorylated calmodulin.20 Another technique recently 
reported by Jason Chin, is the use of a similar method to what was described in Chapter III to 
incorporate a phosphoserine residue during protein expression by means of non-natural amino 
acid incorporation.21 Although non-natural amino acid incorporation often decreases protein 
expression, this would yield HDAC8 with the desired modification. Additionally, this technique 
could be used to express phospho-HDAC8 in mammalian cells thus allowing for analysis under 
more physiological relevant conditions. 
Secondly, profiling additional substrates, both peptides and proteins as in Chapter III, 





changes in substrate selectivity. Developing a model of peptide binding to phospho-HDAC8, 
facilitated by the available crystal structure of S39E, may accelerate this process by identifying 
peptides that might bind more favorably to phospho-HDAC8 than to wild type. Future crystal 
structures using the same ligand for both wild-type and phospho-/S39E HDAC8 would enhance 
the development of the structural model. Additionally, analysis of activity changes with 
acetylated protein substrates are needed to further clarify the functional role of phosphorylation 
of HDAC8. 
Lastly, to establish relevant connections between the altered activity observed with 
peptides in vitro and changes to HDAC8 cellular function, recently reported approaches and 
methods currently under development may be implemented to study HDAC8 phosphorylation in 
a cellular context. One method is the use of active-site directed chemical covalent capture to 
identify HDAC8 substrates by genetically incorporating a photocrosslinker, such as p-benzoyl-L-
phenylalanine (Bpa), into the structure of phospho- or S39E HDAC8 to capture transient 
interactions in cell lysates and live cells.22 This method was used to identify 119 putative 
substrates of wild-type HDAC8 in HEK293 cell lysates.22 Briefly, HDAC8 harboring an amber 
codon mutation at a selected location adjacent to the active site is co-expressed with an 
orthogonal p-benzoyl-L-phenylalanyl-tRNA synthetase (BpaRS)-tRNATyrCUA pair in E. coli 
supplemented with Bpa. When combined with cell lysates and exposed to light, HDAC8 
photocrosslinks with interactors near the photocrosslinker site, and these interactors can be 
detected and identified using mass spectrometry. A similar approach adapted for use in live cells 
is currently under development. Comparing the photocrosslinking results of phospho- or S39E 
HDAC8 with that of wild-type could provide deeper insight into the regulatory role of HDAC8 
phosphorylation. 
A second method is to use mass spectrometry to measure changes in acetylated proteins 
in cells upon perturbation of HDAC8.6 This method was used to identify multiple HDAC8 
putative substrates, including SMC3, in MCF-7 cells treated with HDAC8-specific inhibitor PCI-
34051.6 Briefly, HDAC8 was expressed in MCF-7 cells grown in different media types 
containing normal, heavy, or light arginine and lysine and treated with the inhibitor PCI-34051 
and with a structurally similar non-inhibitor BRD3811 and DMSO as negative controls. Using 
SILAC(stable isotope labeling of amino acids in cell culture)-based mass spectrometry, relative 





identify putative HDAC8 substrates demonstrating hyperacetylation in the inhibitor treatment 
group. This approach could be adapted to look for changes due to phospho- or S39E HDAC8 by 
comparing the results from wild-type HDAC8 to results obtained with cells expressing phospho- 
or S29E HDAC8 or cells treated with a PKA activator. In place of SILAC-based mass 
spectrometry, an alternative approach is to use a proximity ligation assay (described in the next 
section) to identify putative substrates and quantify changes in acetylation.23  
These methods may be used to determine whether phosphorylation of HDAC8 affects 
sister chromatid cohesion through SMC3 hyperacetylation, since the S39E mutation nearly 
abolished HDAC8 activity with an SMC3 peptide. Phosphorylation is often used by the cell to 
regulate protein function and is common among the HDACs.24 However, phosphorylation within 
the deacetylase domain as a negative regulator of activity is unique to HDAC8 and serves as an 
opportunity to better understand HDAC8-specific function and cellular regulation and also to 
highlight potential approaches for HDAC8-specific targeting with small molecule modulators.18 
Comparing Protein and Peptide Substrates and the Impact of Structure on HDAC8 
In chapter III, HDAC8 deacetylase activity for three acetyl-lysine residues located on the 
N-terminal tail of Histone H3, H3K9ac, H3K14ac, and H3K56ac, in several different contexts 
was measured and compared. Using the acetate assay, HDAC8-catalyzed deacetylation of 
histone H3 was measured for 7-mer, 13-mer, and 17-mer sequences, and a mass spectrometry 
assay optimized for quantification of specific post-translationally modified histone residues was 
used to measure full-length tetrameric, octameric, and nucleosomal histone H3. Comparison of 
the catalytic efficiencies measured for peptides compared to proteins revealed that changing the 
size and structure of the substrate enhanced activity, with 30-300-fold enhanced catalytic 
efficiency and activities up to 104 M-1 s-1 for tetrameric H3K9ac compared to its corresponding 
peptides. Although the reactivity trends differed slightly, K9ac was a better substrate than K14ac 
for both peptides and full-length substrates. K9 is located only 4 residues away from K14 and 
both are within the unstructured region of the H3 tail. This differential reactivity provides 
compelling evidence that the local sequence affects HDAC8 substrate selectivity even in the 
context of a protein and supports the use of peptides to determine substrate selectivity.  
Although the reactivity of HDAC8 with the peptide containing K56ac is similar to that of 
K9ac (within 2-fold), in the context of the tetrameric H3/H4 protein, K56ac reactivity did not 





lies within a more structured region of the first a-helix in histone H3 thus suggesting that the 
structural context of the acetylated lysine also plays a pronounced role in determining HDAC8 
substrate selectivity. Finally, introducing DNA into the octameric H3K9ac structure drastically 
reduced the catalytic efficiency compared to tetrameric and octameric H3K9ac, possibly due to 
the altered electrostatic charge or any changes in the structure or dynamics of the complex due to 
DNA incorporation. In contrast to the DNA-free protein complexes, HDAC8 catalytic efficiency 
for the nucleosome H3K9ac substrate was within the same order of magnitude as the acetylated 
peptide substrates thus underscoring the importance of local enzyme-substrate interactions in 
determining substrate selectivity. These results also suggest that for efficient HDAC8-catalyzed 
deacetylation of histones, remodeling factors may be necessary to alter chromatin reorganization 
and enhance DNA-histone dissociation.  
This is the first time HDAC activity has been directly measured for full-length substrates 
and the first time the validity of using peptide substrates to draw conclusions about HDAC 
activity with proteins has been tested. This study marks an important milestone in HDAC 
research, allowing for in-depth analysis of HDAC activity with full-length substrates. However, 
several challenges remain. First, this method has been optimized for the analysis of single 
histone protein post-translational modifications, and while this approach can be easily adapted 
for use with any HDAC isozyme and any histone acetyl-lysine, expanding beyond single histone 
modifications will take further optimization. Since histones are often modified in more than one 
location, one question that remains to be answered is how multiple PTMs affect the substrate 
recognition of HDACs. Comparing HDAC-catalyzed deacetylation of substrates with two or 
more genetically incorporated acetyl-lysines (or other modification) could provide answers to 
these questions. Second, the methods for preparing full-length, singly acetylated substrates using 
non-natural amino acid incorporation is currently limited mainly to proteins that can be 
expressed and purified from E. coli. This limits analysis of many putative HDAC substrates due 
to large sizes, insolubility, and poor stability. Finally, as this study is designed to look 
specifically at a single interaction in isolation, important factors may be missed, such as protein 
concentration, substrate PTMs including multiple acetylation sites, cell status, and the presence 
of binding partners, that would otherwise be present in a normal functioning cell. 
While some of these challenges are inherent in this type of research, this does highlight 





cellular substrates that can be easily adapted to a wide variety of substrates. One such method 
that is currently under development is the proximity ligation assay.23, 25 This assay is performed 
in living cells, allowing for the study of multiple cell lines and therefore different contexts of 
HDAC activity, and utilizes HDAC-specific inhibition (small molecules), knock-down (RNAi), 
or knock-out (gene deletion/silencing) to measure changes in the acetylation levels of HDAC-
specific substrates. The method for studying these changes in acetylation levels combines 
specific targeting of a given substrate and acetyl-lysine PTM using two antibodies, one against 
the substrate of interest and one against acetyl-lysine, with sensitive quantification of the 
acetylated substrate. In order to quantify the levels of the target acetylated protein, the two 
antibodies are modified with complementary segments of DNA such that when the two 
antibodies are within close proximity to each other, as would be the case when the antibodies 
targeting the protein and the acetyl-lysine are bound to the same molecule, the two 
complementary segments ligate together (method under development). These ligated segments 
can be sensitively quantified using real-time quantitative reverse transcription PCR (qRT-PCR) 
thus providing the acetylation status of a protein of interest that can be compared under different 
conditions, such as HDAC-specific inhibition.26  
However, this approach does not demonstrate direct activity, since the signal (increased 
acetylation) is merely the response to the cue (HDACi). Additional control experiments would be 
necessary to test direct HDAC deacetylation. Inhibition of the other HDACs, for example, can be 
used to verify that the observed response is due to the activity of one isozyme. Moreover, the 
photocrosslinking method described in the previous section can be implemented to provide 
evidence of direct interactions between HDAC and substrate.22 There is still much to be done to 
fully develop these tools to be used in place of or as an orthogonal approach to study direct 
HDAC activity with cellular substrates. In the meantime, the data presented in chapter III 
supports the continued use of peptide surrogates to screen and test HDAC activity as well as the 
adaption of the mass spectrometry approaches described in this chapter to measure HDAC-
catalyzed deacetylation of other histone and non-histone substrates. 
Profiling HDAC6 Substrate Specificity 
In chapter IV, we report on the development of a structure-based approach to predict 
HDAC6 binding and activity using in vitro HDAC6 activity measurements and computer-based 





of short, 6-mer, singly-acetylated peptide substrates are used to calibrate and optimize 
computational calculations in order to develop a structural model of peptide binding capable of 
distinguishing between HDAC6 peptide binders and non-binders and therefore between excellent 
and poor peptide substrates. Using such a model, large volumes of sequences can be rapidly 
screened to identify candidate HDAC6 substrates. Such a model has been developed using 
HDAC8 capable of reliably predicting HDAC8 activity in vitro with peptides.27 Recently 
published crystal structures of HDAC6 have allowed for the development of a similar tool to 
study HDAC6 interactions thus accelerating the process of identifying relevant HDAC6 
substrates.14-15 Profiling HDAC6 activity with a library of peptides has revealed a wide array of 
catalytic efficiencies ranging from 12 to 220,000 M-1 s-1. This indicates that HDAC6 has strong 
local sequence structural determinants that alter reactivity. Comparing the sequences of the best 
substrates with those of the poorest substrates does not reveal any obvious patterns, so a 
computational model was developed to identify the most energetically favorable sequences for 
HDAC-peptide binding.  
Using the Rosetta framework and modules developed for modeling peptide binding, a 
starting template structure was identified of the best substrate docked into the catalytic pocket of 
HDAC6 using FlexPepDock. The screening module FlexPepBind was used to calibrate binding 
to identify the structure that yielded the best correlation between computational score and 
HDAC6 activity. The resulting model has successfully been able to identify good HDAC6 
substrates. However, since the median activity for tested sequences is 2,500 M-1 s-1 indicating 
that, depending on what in vitro activity correlates to HDAC6 activity in cells, there are more 
good substrates than bad substrates in our peptide library and HDAC6 may show more substrate 
promiscuity than other isozymes, the model is still being optimized to identify poor binders. 
However, with peptide substrates measured thus far, the correlation between the interface score 
and measured peptide reactivity is promising and statistically significant with a correlation of R= 
-0.62 and p = <0.0001. This study represents the first report of such a wide dynamic range for 
HDAC6 activity as well as the first computational structure-based binding model for HDAC6 to 
identify novel HDAC6 substrates. Once the model is optimized to the point of identifying 
sequences with favorable and unfavorable interactions, the model can be used to screen the 





Moving forward, the highest rated hits will be selected as putative substrates from the 
best-documented sequences with strong evidence for acetylation (i.e. >5 reports including 
references to both high and low throughput studies with independent validation) and special 
attention paid towards known disease-related residues, sequences, and/or modifications. With 
putative substrates in-hand, we will begin efforts towards validating our findings and providing 
further evidence for HDAC6 interaction as described in Chapter IV using in vitro analysis of 
acetylated peptides and proteins. HDAC6 activity with the putative substrates can be further 
investigated in cells using HDAC6-specific inhibition or genetic knockout cell lines to observe 
changes in target protein acetylation either through simpler and less-sensitive methods such as 
western blot analysis or more sensitive methods such as mass spectrometry or the chemical 
ligation assay described above.6, 23, 29-30 Additionally, the active-site directed covalent capture in 
cell lysates and live cells, as described above, could be implemented to identify HDAC6-specific 
interactions under physiological conditions. 
One challenge to these approaches is isolating the contribution of HDAC6 activity to the 
regulation of a specific protein or pathway from that of other deacetylases. As previously 
mentioned, overlapping activity between isozymes is common, and the regulation of HDAC6 
activity is not well documented.31 We do not yet understand how one HDAC may compensate 
for the loss of activity of another, whether multiple isozymes react interchangeably and to the 
same extent given isozyme availability, or whether HDAC-specific activity is tissue- or 
organelle-specific. This is an ongoing question in the field. Expanding tools such as 
computational modeling of HDAC activity to encompass the whole family of histone 
deacetylases may elucidate the extent of the overlap of substrate selectivity and identify the 
functional contributions of each enzyme. In tandem with the development of potent isozyme-
specific inhibitors, rational decisions can be made to identify which isozyme or isozymes would 
be most effective to target in a given disease pathology while maintaining the activity of the 
other isozymes and thus reducing toxicity from unnecessary loss of activity and expanding the 
therapeutic window of a treatment based on HDAC inhibition. 
Concluding Remarks 
Since the first mention of protein acetylation in the mid-20th century, we have sought to 
understand the purpose and regulation of this PTM, especially in light of the association of 





particular over the past decade, have allowed discovery of the broad impact of protein 
acetylation. Studying the regulatory enzymes behind this modification provides a window into 
the tightly regulated process and the complexity of the impact acetylation has in maintaining 
cellular homeostasis. The family of histone deacetylases has been a central focus in acetylation 
research. The field has solved their crystal structures, elucidated their mechanisms, developed 
potent inhibitors for them, and studied their function in normal and disordered cells, tissues, and 
animals. However, there is much left to do to complete our understanding of these enzymes and 
of acetylation as a whole. As is often the case in research, when one question is answered, many 
new questions arise, and the more we discover about acetylation, the enzymes that regulate it, 
and the processes it regulates, the more we realize how much we have left to understand. The 
drive to find the answers to these questions is what makes the field of acetylation so compelling, 
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